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Abstract 
Mutational activation of RAS is one of the most common molecular 
abnormalities associated with acute myeloid leukaemia (AML).  Normal human 
haematopoietic progenitor cells (HPC) expressing mutant RAS overproduce ROS due to 
NADPH oxidase (NOX) activation and this promotes the proliferation of these cells as 
well as AML blasts.  The mechanisms by which ROS promote proliferation is however 
unclear.  The current study investigated the effect of RAS-induced ROS production on 
gene expression in normal HPC using gene expression profiling (GEP) and assessed 
whether ROS-induced gene expression changes contributed to the pro-proliferative 
phenotype.  In order to determine the ROS-specific GEP, Affymetrix Human Exon 1.0ST 
arrays were used for the comparison of mutant RAS and control cells cultured in the 
presence or absence of the NOX inhibitor, DPI, which strongly suppressed the production 
of ROS.  This analysis showed that RAS changed the expression of 342 genes.  Of these, 
24 genes were specifically altered in response to ROS production by these cells and 
amongst these increased expressions of genes of the glycolytic pathway were prominent.  
To establish the functional significance of up-regulated expression of glycolytic enzymes, 
aldolase C (ALDOC) was investigated since it showed greatest induction with ROS.  
ALDOC was directly induced by physiological levels of ROS in both HPC and AML cell 
lines.  Further, overexpression of ALDOC demonstrated that its overexpression promoted 
the proliferation and serum-independent survival of leukaemic cell lines.  Conversely, anti-
proliferative effects were observed when ALDOC was knocked-down in cells known to 
have high levels of constitutive ROS production.  Given the high frequency of ROS 
production in AML, this study provides a plausible mechanism of enhanced glycolysis 
seen in this disease and suggests that agents restoring the redox environment could be used 
to correct metabolic imbalances which contribute to treatment resistance. 
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1 Introduction 
 
1.1 NORMAL HAEMATOPOIESIS 
1.1.1 OVERVIEW OF HAEMATOPOIESIS 
Haematopoiesis is the formation, development and maintenance of blood 
cellular components. Approximately 1 x 1012 mature blood cells are generated daily in a 
healthy human body (Ogawa, 1993). These cells have biochemical and structural 
properties which allow them to carry out their specialized roles in living organisms. Such 
roles include tissue repair, blood coagulation, immunity and oxygen transport. For instance 
erythrocytes consist of high levels of haemoglobin and are bi-concave in shape which 
allows them to pass through the fine blood capillaries. On the other hand neutrophils, 
eosinophils and basophils (granulocytes) destroy pathogens via expression of antimicrobial 
proteins and inflammatory mediators and possession of a hyper-segmented flexible nucleus 
allows trans-endothelial migration via the blood into the site of infection. In addition, 
neutrophils, monocytes and macrophages produce reactive oxygen species (ROS) 
generating oxidases which contribute to the killing of pathogens.  
The sites of haematopoiesis include, the yolk sac, liver and spleen (for foetus) 
vertebrae, ribs, sternum, skull, sacrum, pelvis and proximal ends of femur (for adults) 
(Hoffbrand and Moss, 2011). Most importantly, the bone marrow is the main source of 
new blood cells in normal healthy children and adults. 
Haematopoiesis has been extensively studied and a considerable amount of 
evidence exists suggesting the hierarchical organisation of the haematopoietic system and 
the origin of all functionally diverse mature haematopoietic cells are attributed to the 
pluripotent haematopoietic stem cells (HSCs) (Figure 1.1) which are regulated by a 
1
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complex array of growth factors. According to Smithgall (1998), haematopoietic growth 
factors influence the proliferation, differentiation and survival of progenitor cells as well as 
the functional activities of the end-stage cells. Transcription factors also play an important 
role in lineage commitment and development and these together with growth factors 
govern the output of the haematopoietic system (section 1.1.2.2 and 1.1.2.3).  
1.1.2 HAEMATOPOIESIS AND THE MICROENVIRONMENT 
1.1.2.1 The HSC niche 
HSCs are currently classified in to long term HSC (LT-HSC) and short term 
HSC (ST-HSC). It is important to note that LT-HSC are capable of reconstituting the 
whole haematopoietic system with the unique characteristic of long term self-renewal 
(Figure 1.1). Research on the HSC phenotype dates back to the 1960s and the broad 
immunophenotypic classification of human HSC was facilitated by studies in mice (Till 
and McCulloch 1961). Later studies defined a population of human haematopoietic cells 
which were able to repopulate sub-lethally irradiated non-obese diabetic-severe combined 
immunodeficient mice (NOD-SCID) and hence were termed human SCID-repopulating 
cells (SRC) (Dick, 1996; Larochelle et al., 1996; Bonnet and Dick, 1997) (also discussed 
in 1.2.1 and Figure 1.3). Using experiments such as these, human LT-HSC have been 
defined as lineage negative (Lin-) CD34+ CD38- and ST-HSC as Lin-CD34+ CD38+. 
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Figure 1.1 The hierarchical structure of the haematopoietic system 
Diagrammatic representation of the bone marrow pluripotent, self-renewal, HSC 
and the mature blood cells arising from it. These cells terminally differentiate with a 
functionally adapted structure. Several haematopoietic progenitor cells can be identified by 
the type of colony they form in culture; CFU = colony forming unit; BFU = burst forming 
unit; GEMM = granulocyte erythroid monocyte megakaryocyte; GM = granulocyte 
monocyte; NK = natural killer; LT = long term; ST = short term; HSC = haematopoietic 
stem cell; RBC = red blood cell. Adapted from Rad, (2009). 
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Studies have shown that stem cells occupy specialized places in the bone 
marrow termed niches which are close to the blood vessels and the endosteum of the 
trabecular bone (Zhang et al., 2003; Kopp et al., 2005; Kiel et al., 2005; Orkin and Zon 
2008).  HSCs are known to reside in two highly specialised types of bone marrow niches 
namely the osteoblastic (Zhang et al., 2003; Yoshihara et al., 2007) and vascular niches 
(Kiel and Morrison 2006) (Figure 1.2). Quiescent HSCs are able to migrate to these sites in 
the bone marrow which provide a suitable environment for stem cell self-renewal and 
development. The bone marrow microenvironment is composed of microvascular network 
and stromal cells such as fibroblasts (Figure 1.2). Stromal cells secrete several growth 
factors necessary for HSC survival. These cells also secrete extracellular molecules 
essential for the formation of the extracellular matrix.   
The homing of HSCs to the niche is made possible by several interactions and 
proteins found in the bone marrow microenvironment such as very late antigen-4 (VLA-4), 
very late antigen-5 (VLA-5), P-selectin and the well-studied chemokine; stromal derived 
factor-1 (SDF-1) (also known as CXCL12) and its receptor CXCR4 (also known as 
CD184) (Wilson and Trumpp, 2006; Petit et al., 2007). The pleiotropic chemokine, SDF-1 
and its receptor, CXCR4 are widely expressed by the haematopoietic and endothelial cells 
of the niche (Peled et al., 1999). SDF-CXCR4 pathway has been reported to have a crucial 
role in the modulation of the trafficking and proper engraftment of the HSCs and 
reconstitution of haematopoiesis (Ara et al., 2003). In addition CXCL12 has been shown to 
regulate the migration of HSCs to the vascular cells (Kiel and Morrison, 2006). In 
summary, it is believed that stem cells depend on their microenvironment, the niche for 
regulation of self-renewal and differentiation (discussed in 1.1.2.2). 
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Figure 1.2 HSC Niche in the bone marrow 
In the adult bone marrow, HSCs are found adjacent to osteoblasts (osteoblast 
niche) and blood vessels (vascular niche). HSCs in the osteoblast niche are believed to be 
under the regulation of bone morphogenetic protein (BMP) and CXCL12 regulates the 
migration of HSCs to the vascular cells in the bone marrow (reviewed by Orkin and Zon, 
2008). Stromal cells, also present in the bone marrow space, secrete cytokines (c-kit and 
others not indicated in the figure) which influence stem cell self-renewal and survival. 
Curved white arrow = self-renewal. Adapted from Orkin and Zon, (2008). 
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1.1.2.2 Growth factors/cytokines in haematopoiesis 
The stem cell niche in the adult bone marrow generates cytokines (Figure 1.2) 
that stimulate HSC and progenitors such as c-Kit and those that influence the progenitor 
survival and function; (e.g. thrombopoietin (TPO), erythropoietin (EPO) (Orkin and Zon 
2008). Growth factors greatly influence proliferation, survival and terminal maturation of 
HSCs. For instance FLT-3 ligand and stem cell factor (SCF) act mainly on pluripotent 
HSCs, common myeloid progenitors (CMP`s) and common lymphoid progenitors (CLP`s) 
to facilitate their proliferation (Hoffbrand and Moss 2011). Cytokines such as GM-CSF, 
CSF-1 and EPO act primarily on a particular lineage of cells, enhancing the expansion and 
differentiation of macrophages, granulocytes and erythrocytes respectively. Cytokines also 
act synergistically, for example the combination of GM-CSF with G-CSF greatly augments 
the production of neutrophils compared with either cytokine alone (Lowry, 1995).       
1.1.2.3 Transcription factors in haematopoiesis 
Cell fate is regulated by transcription factors that control lineage development 
programmes, for example, GATA-binding protein 1 (GATA1), GATA 2 and FOG 1 (also 
known as ZFPM1) are vital for megakaryocyte-erythrocyte-basophil or mast cell-
eosinophil development (Graf, 2002). The activities of transcription factors such as PU.1 
have been shown to drive or direct HSCs or progenitors away from the erythroid fate to a 
myeloid fate (Galloway et al., 2005). Several studies have shown that high levels of PU.1 
and GATA1 expression is necessary to generate neutrophils and monocytes (Dahl et al., 
2003) whilst low levels of the above transcription factors are essential to enable the 
development of B cells (DeKoter and Singh 2000). The expression of the myelomonocytic 
associated factor; CCAAT/enhancer binding protein (C/EBPα) directs megakaryocyte-
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erythroid progenitors to become macrophages and neutrophil-monocyte progenitors to 
become monocytes (Mukai et al., 2006). It is important to note that phosphorylation of 
transcription factors also play an important role in the determination of cell fate. For 
instance, phosphorylation of C/EBPα can inhibit its activity and can force neutrophil-
eosinophil progenitors to become eosinophils (Buitenhuis et al., 2008). These findings 
together with the findings of other studies have demonstrated that the enforced expression 
of transcription factors can direct development towards an alternative cell fate.  
Abnormal transcription factor activities are closely associated with leukaemia.  
Translocations frequently found in Acute Myeloid Leukaemia (AML) affect transcription 
factors previously shown to play vital roles in haematopoietic lineage development; for 
instance, the analysis of patients harbouring the most common abnormality associated with 
AML, the t (8; 21) translocation generating RUNX1-ETO oncogene, have shown that the 
expression of this oncogene leads to decreased expression of the critical granulocytic 
differentiation factor CEBP/α (Pabst et al., 2001). Researchers have therefore linked the 
alteration of the transcriptional machinery to the mechanisms leading to arrested 
differentiation (Tenen 2003). Single nucleotide polymorphisms (SNPs) can also influence 
transcription factor expression, for example, in AML a SNP within a highly conserved 
distal enhancer greatly decreases the expression of PU.1 via the blockage of chromatin-
remodelling transcriptional regulator SATB1 (Steidl et al., 2007).  
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1.1.3 MODELS USED TO STUDY HAEMATOPOIESIS 
Research models used to examine the haematopoietic system date back to the 
1960s when it was demonstrated that bone marrow cells injected into irradiated mice 
resulted in spleen colonies (Till and McCulloch et al., 1961). Since then, several models  
(both in vivo and in vitro) have been developed and employed in the study of 
haematopoiesis, including experimental culture systems that incorporate stromal cells to 
aid in the generation of lymphoid  (Whitlock and Witte, 1982) or myeloid cells (Dexter, 
1979). For instance, the most recent and relevant model for study of haematopoiesis in 
mammals was generated via in vitro studies of primary haematopoietic cells and 
haematopoietic cell lines along with the in vivo murine studies. The ability to culture 
normal haematopoietic cells in vitro overcomes the shortcomings associated with cell lines 
which have limited developmental potential and harbour abnormalities including 
chromosome translocations (Furukawa, 2002).  
1.2 ACUTE MYELOID LEUKAEMIA 
1.2.1 OVERVIEW AND PATHOPHYSIOLOGY OF AML 
AML is a heterogeneous malignancy of the HSC and haematopoietic progenitor 
cells (HPCs) characterized by a clonal expansion of immature white cells (blast cells). 
These are abnormal cells that have failed to differentiate into functional myeloid cells. 
Accumulation of leukaemic blasts results in the failure of normal haematopoiesis (Pollyea 
et al., 2011).  
AML has been described as a very challenging aggressive malignancy with a 
very poor clinical outcome (Löwenberg 1999). It has a very high morbidity and mortality 
rate worldwide with an incidence of 3.4 cases per 100 000 people in the UK (Milligan et 
al., 2006). Among other types of acute leukaemia, it is the most common one in adults and 
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elderly people are the most affected group with a median age at diagnosis of 67 years as 
reported in the National cancer institute 1975-2007 report (Kohler et al., 2011). Therefore 
it is clear that the risk of AML increases with age. Other risks associated with AML 
include exposure to radiation, smoking, previous chemotherapy and pre-existing blood 
disorders (Estey and Döhner, 2006).  
Advances in research have led to the identification of molecular and cytogenetic 
abnormalities in AML (discussed later 1.2.2 and 1.2.3). For instance, at least one 
chromosomal rearrangement was reported in over 80% of myeloid leukaemias (Pandolfi, 
2001). In another study by Gilland and Tallman (2002), more than 100 chromosomal 
translocations were cloned most of which were associated with genes encoding 
transcription factors that play crucial roles in haematopoietic lineage development. It was 
also suggested that changes of the transcriptional machinery pose a potential common 
mechanism leading to arrested differentiation (Tenen 2003).  
Despite the identification of several risk factors and abnormalities in AML, the 
specific cause of this disease is not clear; however the manifestation of acute leukaemia 
has been attributed to cooperation between the class I activating mutations such as FLT3, 
KIT and RAS family (1.3) and class II mutations which induce the termination of 
differentiation (Table 1.1), Gilland and Tallman (2002). Class I mutations confer 
proliferative and survival advantage to haematopoietic progenitors due to the activation of 
signal transduction pathways while class II mutations results in a halt in differentiation via 
interference with either transcription factors or co-activators. Evidence exists in support of 
this model. For example, it is believed that in AML, an initiating event such as 
chromosomal translocation (t (8; 21) which results in RUNX1-ETO fusion gene), occurs in 
primitive HSC and/or HPC. Such occurrence is not enough to cause leukaemia alone 
although it was shown to impair normal differentiation (Miyamoto et al., 2000; Downing, 
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2003) which confers the essential advantages needed to pre-dispose to subsequent 
transformation of the pre-malignant clone through the acquisition of class I mutations. 
There is also evidence supporting the fact that myeloid leukaemia cells known as 
leukaemia stem cells (LSC) exist in a hierarchy similar to that of normal haematopoiesis 
(Figure 1.3) (Bonnet and Dick, 1997). These authors used a strain of immunocompromised 
mice termed non-obese diabetic mice with severe combined immunodeficiency disease 
(NOD/SCID mice) which allowed engraftment of human AML cells. Only a subpopulation 
of AML blasts-termed SCID-leukaemia initiating cell (SL-IC) was found to efficiently 
engraft these mice. The SL-ICs from all subtypes of AML were analysed and found to be 
CD34+ CD38- (equivalent to the cell surface phenotype of normal HSC). Engraftment of 
just this subpopulation of phenotypically primitive cells subsequently recapitulated the 
heterogeneous phenotype of the original disease.  These findings also suggested that HSC 
rather than committed progenitor cells are the target for leukaemic transformation and gave 
rise to the concept of leukaemic stem cells. 
Despite these and other recent advances in the identification of recurrent 
mutations, the initiating mutations of AML are unknown because pre-leukaemic cells are 
clinically silent and are out-competed by their malignant descendants (Greaves et al., 
2010). However recent findings have revealed pre-leukaemic HSCs which might 
contribute to better understanding of AML and future therapy (see 1.2.4).  
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Figure 1.3 Acute myeloid leukaemia stem-cell hierarchy 
Leukaemia cells are believed to be derived from HSCs which are CD34+CD38- 
just like normal HSC. Normal HSC repopulating NOD/SCID mice (SCID-repopulating 
cells; SRC), are capable of self-renewal and production of all mature lineages through a 
succession of multipotent and committed progenitors. Leukaemia stem cells (LSC or SCID 
leukaemia-initiating cell (SL-IC)) that initiate AML express some shared surface 
phenotypic markers with HSC and have the capacity for producing both the clonogenic 
leukaemic progenitors and the non-clonogenic blast cells which make up the bulk of 
leukaemia. Curved arrow = self-renewal. Adapted from Bonnet and Dick, (1997). 
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1.2.2 MOLECULAR ABNORMALITIES IN AML 
There are several molecular abnormalities associated with AML some of which 
are listed in Table 1.1. Mutational activation of RAS (particularly N-RAS) (section 1.3) is 
common (for full details see section 1.3.3). The other abnormality that frequently occurs in 
AML is the internal tandem duplication in the FLT3 tyrosine kinase (FLT3-ITD) with a 
vital role in AML prognosis (section 1.2.3), cell proliferation, survival and differentiation. 
Activation of FLT3 receptor by FLT3 ligand result in receptor dimerization and 
phosphorylation and activation of downstream signalling pathways  such as Janas kinase 2 
(JAK2) signal transducer activator of transcription 5 (STAT5) and mitogen activator 
protein kinase (MAPK) pathways (Reindl et al., 2006; Grundler et al., 2005; Lee et al., 
2007). Mutations in the FLT3 genes, found in approximately 40% of AML patients are 
believed to promote its auto phosphorylation and constitutive activation resulting in ligand-
independent proliferation (Frankfurt et al., 2007). KIT mutations have also been linked to 
AML (Bachas et al., 2010). 
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Mutation 
class  
Gene involved Frequency Prognosis 
I RAS  15-30% Not prognostic 
FLT-3 25-45% bad 
c-KIT 6-10% bad 
II NPM1 25-35% good 
CEBPα 4-9% good 
Table 1.1  Common mutations in AML 
Mutations most frequently identified in AML include: class I (signal 
transduction) and II (transcriptional). Reviewed by Ravandi et al., 2007; Dohner and 
Dohner, 2008).  
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1.2.3 CLASSIFICATION, DIAGNOSIS AND PROGNOSIS 
The appearance of the blasts among patients with AML (Warner et al., 2004) 
gave rise to the French-American-British (FAB) classification (Table 1.2). This has been 
superseded by the World health organisation (WHO) classification which is based more 
heavily on the molecular characterisation of AML (Table 1.3). In the FAB classification 
system, AML is classified into nine FAB types according to the maturation stage of 
leukaemia based upon the examination of blast morphology and the expression of lineage 
differentiation markers (Bennet et al., 1976, 1982).  Under the WHO classification, there 
are four categories of AML (detailed in Table 1.3) based upon a combination of advanced 
immunophenotyping, morphology assessment, clinical features and genetic data and 
recurring chromosomal abnormalities (Vardiman et al., 2002; 2009).  This classification is 
more helpful in clinical decision making. Differences among patients that affect response 
to treatment are termed prognostic factors and these help in the decisions made by doctors 
concerning the amount of treatment required by people with certain types of leukaemia. 
The main prognostic factors in AML include cytogenetic status (the presence or absence of 
chromosome translocations, aneuploidy or deletions), age of the patient, white blood cell 
(WBC) count, prior blood disorders, active systemic blood infection and treatment-related 
AML (Estey and Dohner, 2006; Grimwade et al., 1998; Grimwade et al., 2001). 
Cytogenetic and molecular abnormalities (others discussed above) that have been 
identified in AML as of prognostic value include FLT3-ITD (Jan et al., 2012). This 
abnormality frequently occurs in AML and it indicates high risk (Schlenk et al., 2008).  
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FAB subtype Description/Name 
M0 Undifferentiated AML 
M1 Acute myeloblastic leukaemia with minimal 
maturation 
M2 Acute myeloblastic leukaemia with 
maturation 
M3 APL 
M4 Acute myelomonocytic leukaemia 
M4 eos 
 
Acute myelomonocytic leukaemia with 
eosinophilia 
M5 Acute monocytic leukaemia 
M6 Acute erythroid leukaemia 
M7 Acute megakaryoblastic leukaemia 
 
Table 1.2 The FAB classification of AML 
AML is divided into nine FAB subtypes based on the type of cell from which 
leukaemia developed and how mature the cells are. Abbreviations: FAB = French-
American-British; APL = Acute promyelocytic leukaemia. Adapted from: Tenen et al., 
(2003). 
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Category of AML Description 
AML with recurrent genetic 
abnormalities 
AML with t(8;21)(q22;q22), AML1/ETO 
AML with abnormal bone marrow 
eosinophils and inv(16)(p13q22) or 
t(16;16)(p13;q22),(CBFβ-MYH11) 
APL with t(15;17)(q22;q12), (PML-RARα) 
AML with t(9;11)(p22;q23), MLLT3-MLL 
AML with t(6;9)(p23;q34), DEK-NUP214 
AML with inv(3)(q21q26.2) or 
t(3;3)(q21;q26.2), RPN1-EVI1  
AML with multi-lineage dysplasia AML with  changes  associated with 
myelodysplasia or following MDS or 
MDS/MPD 
AML and therapy related 
myelodysplastic syndromes 
Alkylating agent/radiation- related type 
AML not otherwise categorized AML with minimal differentiation 
AML without maturation 
AML with maturation 
Acute myelomonocytic leukaemia 
Acute monocytic/monoblastic leukaemia 
Acute erythroid leukaemia (pure 
erythroleukaemia and erythroid/myeloid) 
Acute megakaryoblastic leukaemia 
Acute basophilic leukaemia 
Acute panmyelosis with myelofibrosis  
Myeloid sarcoma 
 
Table 1.3 The WHO classification of AML 
In the WHO classification, AML is divided into 4 subgroups/categories. 
Abbreviations: MDS = Myelodysplastic syndrome; APL = acute promyelocytic leukaemia 
Adapted from: Vardiman et al., (2002; 2009). 
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1.2.4 THERAPY 
The treatment of AML occurs in two main phases: the induction phase which is 
aimed at reduction of tumour burden AML and consolidation treatment geared towards 
preventing relapse. The induction phase is based on chemotherapy using drugs such as 
cytarabine (Bloomfield et al., 1994). Sometimes a combination of different drugs is used 
for high risk patients. Consolidation phase follows successful remission induction and this 
includes more chemotherapy, donor transplant or blood stem cell transplant. It is 
noteworthy that doctors take into account several factors when making decisions 
concerning consolidation therapy including remission, patient history of other cancers and 
treatments. The treatment of cancer includes several health care professionals which in turn 
facilitates best treatment decisions. Other factors influencing cancer treatments are AML 
type, age and general health of a patient. 
 There are several challenges faced with regards to AML therapy. LSC have 
been shown to impact therapy in AML patients. LSC has been reported to be present after 
chemotherapy, thus the failure of current AML treatments has been attributed to the 
insufficient eradication and survival of chemotherapy resistant LSC (Van Rhenen et al., 
2005; Ishikawa et al., 2007). For instance, a study by Terwijn et al., (2010) showed that 
high frequencies of CD34+ CD38- LSC at diagnosis and after treatment predicted relapse in 
AML suggesting that the LSC are indeed clinically important (Eppert et al., 2011) and 
prognostic. Eradication of LSC may therefore prevent relapse and lead to a better long-
term outcome in AML; however this presents enormous challenges.  The heterogeneity of 
LSC phenotype within the single AML patient (Taussig et al., 2010) together with the 
similarities of both normal HSC and LSC in the same cell compartment within the AML 
bone marrow requires careful consideration for the tailoring and application of therapies. 
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In support of this, Buggins et al., (2001) pointed out that the extent to which LSC and HSC 
differ is critical to the development of LSC-targeted therapies with low toxicity. A study 
by (Schuurhuis et al., 2013) has already formed the foundation for combined 
immunophenotypically and functionally based identification and purification of LSC and 
HSC within the bone marrow which is a step towards the development of highly specific 
anti-LSC therapy. In this study it was shown that normal CD34+, CD38- HSC found in 
AML bone marrow were distinct sub-population of cells with high aldehyde 
dehydrogenase (ALDH) activity in LSC. Therefore it was concluded that there are lower 
levels of ALDH activity in LSC than the normal CD34+CD38- HSC that co-exist with 
these LSC in the bone marrow across all AML cases.  
1.3 THE RAS FAMILY OF PROTEINS 
1.3.1 OVERVIEW OF THE RAS PROTEIN SUPERFAMILY 
The founding members of the RAS (rat sarcoma) protein superfamily includes Harvey-
RAS (H-RAS) located on human chromosome 11p15.5, neuroblastoma-RAS (N-RAS) 
located on human chromosome 1p13.2 and two isoforms of Kirsten-RAS (K-RAS4A, K-
RAS4B) located on human chromosome 12p12.1 (Malumbres and Barbacid, 2003; 
Wennerberg et al., 2005). Their structural similarities and differences are illustrated and 
discussed below (Figure 1.4). These proteins are membrane-bound GTPases that integrate 
signals from membrane-associated growth-factor receptors to a variety of effector 
molecules and have been previously shown to modulate different cellular processes 
(Beaupre and Kurzrock 1999; Hingorani and Tuvenson, 2003). For instance, H-RAS and 
K-RAS were shown to play a vital role in development (Schubbert et al., 2007). RAS 
proteins are activated when bound to guanosine triphosphate (GTP), and normally inactive 
when bound to guanosine diphosphate (GDP) (Mitin et al., 2005;Wennerberg et al., 2005) 
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which enable them to deliver an ‘on’ or ‘off’ signal,  acting as binary molecular switches 
(Figure 1.5). X-ray crystallographic research studies of RAS proteins bound to either GDP 
or GTP reported large conformational changes induced in the RAS protein upon an 
exchange of GDP to GTP and vice versa (Schlichting et al., 1990). The location of these 
conformational changes have been attributed to switch I and II (Figure 1.4) which are 
flexible loop regions of the RAS superfamily responsible for their protein signalling and 
regulation of downstream effectors(Figure 1.5 and Figure 1.6)(Karnoub and Weinberg, 
2008).  
It is important to note that activated RAS molecules have the capability to self-
limit their activation in an intrinsic manner via their weak intrinsic GTPase activity which 
enables them to hydrolyse bound GTP forming GDP and inorganic phosphate. GTPase 
activating proteins (GAPS) such as neurofibromin (NF1) act as negative regulators and 
have been shown to enhance accumulation of GDP-bound RAS (Ahmadian et al., 1997) by 
promoting efficient GTP hydrolysis (Figure 1.5). On the other hand RAS is activated via 
the preferential binding of GTP. This is because the positive regulators of RAS such as the 
guanine nucleotide exchange factors (GEFs) (Figure 1.5) link with inactive form of the 
GDP-bound RAS and induce conformational changes which in turn augment the release of 
GDP. Usually these result in binding of GTP which is at a 10X higher concentration in the 
cytosol than GDP (Karnoub and Weinberg 2008). 
In addition, post-translational modification is essential for RAS proteins to carry 
out their roles. This involves post-translational attachment of lipid molecules and  
prenylation of the post-translated RAS molecule in the cytosol by either farnesyl 
transferase (FT) or geranylgeranyl transferase which attach either farnesyl or 
geranylgeranyl groups to the cysteine (Cys) residue within the C-terminal motif of the 
RAS protein, CAAX (A = aliphatic amino acid; X = any amino acid). The farnesylated 
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CAAX motif then undergo palmitoylation step which involves the attachment of palmitic 
acid by palmitoyltransferase of the selected cysteine residues near the farnesylation site.  
Mutational activation of RAS proteins has been well studied. Activating 
mutations of RAS proteins are clustered in codons 12, 13 and 61 (Krengel et al., 1990). In 
addition, it is now known that the most common substitutions in human cancers replace 
glycine with valine or aspartate at these positions. This is because several studies have 
shown that those positions are crucial to intrinsic GTP hydrolysis by RAS since the 12th 
and 13th codons in each of the RAS isoforms encode glycine (the only amino acid without 
a side chain). Thus any mis-sense mutation at these positions results in the inclusion of an 
amino acid with a side chain and substitutions at codons 12 or 13 leading to an 
accumulation of GTP-bound RAS (activated form) due to impairment or radical decrease 
in GTPase activity (Schubbert et al., 2007). 
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Figure 1.4 Structure of RAS proteins 
The diagram illustrates the structures of the four isoforms of RAS proteins, N-
RAS, H-RAS, K-RAS4A and K-RAS4B with high homology throughout the amino acid 1-
165 (G-domain). The first 85 amino acids are identical in all proteins and specify binding 
to GDP and GTP. This includes the phosphate-binding loop (P- loop) (amino acids 10–16), 
which binds the γ-phosphate of GTP, and switch I (amino acids 32–38) and II (amino acids 
59–67) which regulate binding to RAS regulators and effectors. Amino acids 85–165 show 
sequence identity (~85–90%). The C-terminal hyper-variable domain (amino acids 165–
188/189) specifies membrane localization through post-translational modifications that 
include the farnesylation of each isoform on the C-terminal CAAX motif (CVLS, CVVM, 
CIIM and CVIM, respectively) and palmitoylation of key cysteines on HRAS, NRAS and 
KRAS4A; these cysteines are highlighted below each representation (C). Membrane 
localization of KRAS4B is facilitated by a stretch of lysines (KKKKKK) proximal to the 
CVIM motif. A box at the bottom of each isoform representation shows the conserved 
residues (bright pink) and the variable residues (pink) to indicate the degree of homology. 
Adapted from Schubbert et al., (2007). 
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Figure 1.5 The GDP-GTP cycle and regulation of RAS 
(A) An illustration of the GDP-GTP cycle of RAS. Inactive, GDP-bound RAS is 
activated by GEFs, which stimulates the release of GDP and permits GTP binding. GTP 
loading induces a marked conformational change in RAS allowing it to bind effector via 
their RBDs. The so called ‘on’ state of RAS is limited by its low intrinsic GTPase activity, 
which is accelerated by the binding of a GAP, allowing RAS to return to its inactive, GDP-
bound state.(B) An illustration of several families of GEFs, GAPs and effectors that have 
been reported to regulate RAS or transmit signals from RAS.GTP. Abbreviations: GEF = 
guanine nucleotide exchange factor; GAP = GTPase-activating protein; RBD = RAS-
binding domains; CAPRI = calcium-promoted RAS in-activator; GAP1IP4B  =  GAP1 InsP4 
–binding protein; NF1 = neurofibromin 1; P =  phosphate; PI3K = phosphoinositide 3-
kinase; RALGDS = RAL guanine nucleotide dissociation stimulator ; RASAL = 
RASGAP-activating-like; RASGRF = RAS-specific guanyl-nucleotide-releasing factor; 
RASGRP = RAS-specific-guanine-nucleotide-releasing protein; RASSF = RAS 
association domain-containing family; RIN1 = RAS and RAB interactor 1; SYNGAP = 
synaptic RASGAP; TIAM1  = T lymphoma invasion and metastasis-inducing 1. Adapted 
from Ahearn et al., (2011). 
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1.3.2 RAS SIGNALLING AND HAEMATOPOIESIS 
A sequence of events occur leading to the recruitment and activation of RAS 
GEFs which in turn results in the accumulation of the activated GTP-bound RAS (Figure 
1.6). SHP2 is recruited to the activated receptor complex along with molecules such as 
growth factor-receptor bound protein 2 (GRB2) linking the activated receptor to SOS 
family of proteins (RAS GEFs). Signalling is initiated by growth factor binding to cell 
surface receptors (tyrosine kinase) resulting in the activation of receptor complexes 
consisting of adapters such as SH2-containing protein (SHC), GRB2 and GRB2-associated 
binding (Gab) proteins. These proteins recruit SHP2 and SOS1, the latter increasing RAS-
GTP levels by catalysing nucleotide exchange on RAS. GAPs such as NF1 bind to RAS-
GTP and speed up the conversion of RAS GTP to RAS-GDP hence antagonising RAS 
activation resulting in the termination of its signalling. NF1 play an important role in the 
regulation of RAS signalling, with inactivating mutations implicated in neurofibromatosis, 
a congenital developmental disorder linked with the strong risk of Juvenile 
myelomonocytic leukaemia (JMML) development (Niemeyer et al., 1997; Schubbert et al., 
2007)  
Many RAS-GTP effector pathways have been described and the key ones are 
illustrated in Figure 1.6. The BRAF-mitogen-activated and extracellular-signal regulated 
kinase kinase (MEK)-extracellular signal-regulated kinase (ERK) cascade frequently 
governs proliferation and becomes deregulated in certain cancers and developmental 
disorders. In addition RAS activates other pathways such as the phosphatidylinositol 3-
kinase (PI3K)-3-phosphoinositide-dependent kinase 1 (PDK1)-Akt pathway that often 
determines cellular survival (Figure 1.6). RAS also binds and activates the enzyme 
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phospholipase Cε (PLCε), the hydrolytic products of which regulate calcium signalling and 
the protein kinase C (PKC) family.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.6 Summary of RAS activation and signalling pathways 
An illustration of the events leading to RAS activation, the key effector 
signalling pathways initiated by activated RAS and proteins affected by mutations in 
developmental disorders and cancer. Abbreviations: SHC = SH2-containing protein; GRB2 
= growth-factor-receptor bound protein 2; Gab = GRB2-associated binding proteins; RAS-
GTP = RAS-guanosine triphosphate; GAP = GTPase-activating protein; NF1 = 
neurofibromin; RAS-GDP = RAS-guanosine diphosphate; MEK = mitogen-activated 
extracellular-signal regulated kinase; ERK = extracellular signal-regulated kinase; PI3K = 
phosphatidylinositol 3-kinase; PDK1 = phosphoinositide-dependent protein kinase 1; RGL 
= RALGDS-like gene; PLD =  phospholipase D; PLCε =  enzyme phospholipase Cε; PKC 
=  protein kinase C; P =  phosphate; Y = receptor tyrosine. Adapted from Schubbert et al., 
(2007) 
Growth factor 
Receptor  
RAS effector pathways 
Plasma membrane 
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 RAS has long been linked to the haematopoietic system. H-RAS, N-RAS and 
K-RAS4B were all found to be expressed in mammalian haematopoietic cells with N-RAS 
being the most predominant according to Shen et al., (1987). RAS proteins play a crucial 
role in haematopoiesis as the downstream effectors growth factors receptors. Many 
haematopoietic cytokines known to influence the development of haematopoietic cells 
(Hoang 2004), such as IL-3, GM-CSF, FLT3-L, G-CSF and EPO act through RAS (De 
Koning et al., 1998; Itoh et al., 1996; Satoh et al., 1991) and consequently plays an 
important role in cell cycle progression and survival (Schubbert et al., 2007). Interestingly, 
PKC, which phosphorylates p47phox during activation and assembly of the NAPDH oxidase 
complex (section 1.4), was shown to mediate developmental dysregulation of human 
CD34+ haematopoietic cells through activated RAS (Pearn et al., 2007). RAS signalling is 
therefore important in the haematopoietic system and this is further demonstrated in its 
contribution to leukaemogenesis (section 1.3.3). 
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1.3.3 THE ROLE OF RAS MUTATIONS IN AML 
Activation of RAS via point mutations has long been reported to be among the 
most common molecular abnormalities in haematopoietic malignancy with an incidence of 
approximately 30% in both myeloid leukaemia and preleukaemia (Farr et al., 1988; 
Miyauchi et al., 1994; Niemeyer et al., 1997; Bos et al., 1989). The expression of mutant 
RAS including variants such as H-RASG12V and N-RASG12D has been reported in AML 
with the latter being the most common one (Bos et al., 1989). RAS mutations are among 
the pro-proliferative class I genes (Table 1.1) implicated in the two-hit hypothesis of 
leukaemogenesis (previously discussed in 1.2.1). This is because RAS oncogenes activate 
a variety of pathways that lead to proliferation of the haematopoietic cells (Figure 1.6) and 
cooperate with other gene mutations in the pathogenesis of AML (reviewed by Renneville 
et al.,2008). As highlighted previously (1.3.1), RAS mutations found in cancer cells 
introduce amino-acid substitutions at positions 12, 13 and 61. These changes impair the 
intrinsic GTPase activity and confer resistance to GAPs, thereby causing cancer-associated 
mutant RAS proteins to accumulate in the active, GTP-bound conformation (Trahey and 
McCormic, 1987). Therefore constitutively activated RAS leads to the activation of pro-
proliferative pathways including Raf-MEK-ERK and survival pathways such as PI3K-Akt 
(Figure 1.6). It is noteworthy that inappropriate activation of RAS can also arise as a 
consequent of activating mutations of the FLT3 gene and loss of negative regulator of 
RAS, NF1, and (Zhang et al., 1998).      
It has also been shown that mutational activation of RAS in human primary 
haematopoietic stem/progenitor cells give rise to deregulated development characteristic of 
preleukaemia (Darley et al., 1997; Darley et al., 2002; Pearn et al., 2007). Furthermore, H-
RASG12V expression has been shown to disrupt the differentiation of these normal 
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haematopoietic cells (Darley et al., 1999) (discussed below). The fact that activating RAS 
mutations are also common in preleukaemia highlights their contribution to 
leukaemogenesis. A study by Darley et al., (2002) has demonstrated that N-RAS can also 
subvert the normal developmental cues that regulate erythropoiesis via PKC activation. 
This was reported to have led to the phenotypic and functional abnormalities commonly 
found in pre-leukaemia (Darley et al., 2002) suggesting a direct association between RAS 
mutations and the pathogenesis of preleukaemia. Other studies have shown that activated 
RAS can drive human CD34+ cell development towards the myelomonocytic lineage at the 
expense of erythroid and granulocytic cells in a PKC dependent manner (Darley et al., 
1997). In another study by and Mavilio et al., (1989), activated RAS was shown to block 
terminal granulocytic differentiation of unipotent 32D subline, which was reported to have 
led to self-renewal of semi-differentiated myeloid cell population. The dysregulating 
influence of mutant RAS on the differentiation programme of neutrophil lineages has also 
been demonstrated in vitro (Darley et al., 1999). In another study, mutant RAS was shown 
to promote a myeloproliferative disorder in vivo and to inhibit erythropoiesis (MacKenzie 
et al., 1999) in agreement with the observations made in the in vitro studies. 
 Taken together the above findings demonstrate that mutant RAS has the ability 
to disrupt haematopoietic differentiation; however the mechanisms through which it 
contributes to leukaemogenesis are still not completely understood. One novel observation 
recently made in haematopoietic cells is that both mutant H-RAS and N-RAS promote the 
production of reactive oxygen species (ROS) (discussed in section1.4) in human CD34+ 
cells via increased NADPH oxidase (NOX) (section 1.4.1.1) activity (Hole et al., 2010) 
and this in turn promoted their proliferation (Hole et al., 2013) (discussed in 1.4.3). The 
mechanisms underlying this observation will be the subject of this thesis.  
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1.4 REACTIVE OXYGEN SPECIES 
ROS are a group of inorganic molecules and free radicals including superoxide, 
hydrogen peroxide (H2O2) and hydroxyl radicals (amongst others) which possess wide 
spectrum of reactivity (Figure 1.7). These molecules are heterogeneous in nature 
(Lambeth, 2004) and have been linked to a number of cellular processes; both normal (Ray 
et al., 2012) and abnormal (Hole et al., 2013; Hole et al., 2010; Trachootham et al., 2009). 
Their role in diseases such as cancer is demonstrated in several studies and is discussed in 
section 1.4.3.  
1.4.1 GENERATION OF ROS 
The main sources of cellular superoxide are mitochondrial electron transport 
chain (ETC) (1.4.1.2) and the members of the NOX protein family/enzymes (1.4.1.1) 
(Lambeth 2004; Lambeth and Neish, 2014). Fenton chemistry has been largely implicated 
in the formation of hydroxyl radicals (Figure 1.7) which are generated by Fe2+ and Fe3+ 
ions in the presence of endogenously generated H2O2 (Koppenol, 2001). Specifically, Fe2+ 
ions react with H2O2 giving rise to a hydroxyl radical, a hydroxide ion and a Fe3+ ion. 
Superoxide (generated by ETC, NOX oxidases or reaction of H2O2 with hydroxyl radicals) 
may also react with Fe3+ to regenerate Fe2+. It is therefore clear that iron play an important 
catalytic role in the generation of ROS.  
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Figure 1.7 Reactive oxygen species: generation and degradation/regulation 
NOX enzymes (for example Phox/NOX2) and the electron transport chain 
(ETC) generate ROS (superoxide) via the oxidation of molecular oxygen. Two molecules 
of superoxide can react to generate H2O2 in a reaction catalysed by superoxide dismutase 
(SOD). Superoxide and H2O2 react to generate hydroxyl radicals in the presence of iron 
(Fe3+) (Fenton reaction). Singlet oxygen and hypochlorous acid (HOCL) may be formed 
from oxygen and H2O2 in areas of inflammation through the action of Phox/NOX and 
myeloperoxidase (MPO)-catalysed oxidation of halide ions and ozone can also be 
generated from singlet oxygen. H2O2 may be reduced to H2O and O2 in reactions catalysed 
by glutathione peroxidase, catalase and peroxiredoxin (Prx). The reactivity of individual 
molecules is colour coded in the following manner: pink = relatively unreactive; yellow = 
limited reactivity; orange = moderate reactivity; red = high reactivity. Adapted from 
Lambeth, (2004). 
Molecular 
O2 
H2O + O2 
ETC 
Fenton reaction 
  Fe2+                      Fe3+
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1.4.1.1 Generation of ROS via NOX oxidases 
NOX enzymes form a part of a membrane bound complex (Figure 1.8) which 
generates superoxide via oxidation of molecular oxygen (Figure 1.7). Superoxide is a short 
lived radical but can dismutate into H2O2 either spontaneously or via an enzyme catalysed 
reaction involving superoxide dismutase (SOD) (Rahman et al., 2006) (Figure 1.7). The 
members of the NOX family include NOX1-5 and DUOX1-2 (Figure 1.8) and are widely 
distributed (Table 1.4). These enzymes catalyse the transfer of high energy electrons from 
NADPH to diatomic oxygen which yields superoxide and indirectly ROS such as H2O2. 
NOX2 (catalytic subunit of phagocyte NOX (Phox) is the founding member of the NOX 
family of proteins. Other sub-units of Phox include p22phox, p47phox, p40phox, p67phox and 
the small GTPase Rac (Figure 1.8) associate with NOX2 to form an active complex thus 
regulating its activity.  
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Figure 1.8 Human NOX enzymes 
This figure shows the NOX enzymes (NOX1-5 and DUOX1/2) and other sub-
units of the phox complex. O2- = superoxide. These enzymes catalyse the transfer of high 
energy electrons from NADPH to diatomic oxygen which yields superoxide. In order for 
these enzymes to perform their role, the corresponding regulatory subunits indicated above 
are required. Some of these subunits are common to several oxidases e.g. NOX1-4 are 
regulated by p22phox whilst some are specifically associated with a particular oxidase 
e.g.the p47 subunit is specific to NOX2. NOX5 and DUOX1/2 are regulated by calcium 
ions (Ca2+). Adapted from Lambeth, (2004). 
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Oxidase High-Level 
Expression  
Intermediate- to Low-Level Expression 
NOX1  Colon  Smooth muscle, endothelium, uterus, placenta, prostate, 
osteoclasts, retinal pericytes 
NOX2  Phagocytes  B lymphocytes, neurons, cardiomyocytes, skeletal 
muscle, hepatocytes, endothelium, hematopoietic stem 
cells, smooth muscle 
NOX3  Inner ear  Foetal kidney, foetal spleen, skull bone, brain 
NOX4  Kidney blood vessels Osteoclasts, endothelium, smooth muscle, 
hematopoietic stem cells, fibroblasts, keratinocytes, 
melanoma cells, neurons 
NOX5  Lymphoid tissue, 
testis 
Endothelium, smooth muscle, pancreas, foetal tissues 
DUOX1 Thyroid   Airway epithelia, tongue epithelium, 
cerebellum, testis 
DUOX2  Thyroid Salivary 
and rectal glands 
 Salivary and rectal glands, gastrointestinal 
epithelia, airway epithelia, uterus, gall 
bladder, pancreatic islets 
 
Table 1.4  Tissue distribution of NOX enzymes 
The distribution of NOX enzymes and their expression levels human tissue. 
Interestingly, NOX1, 2 and 4 are also expressed in the plasma membrane of human CD34+ 
HPCs (Piccoli et al., 2007). 
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1.4.1.2 Generation of ROS via Mitochondria 
The generation of ROS via mitochondrial ETC involves a number of redox-
coupled proteins and complexes such as nicotinamide adenine dinucleotide (NADH) 
dehydrogenase (complex I) which accepts high-energy electrons from NADH (formed 
from pyruvate and fatty acids in the mitochondrial matrix via citric acid cycle). Electrons 
are passed to complex I through flavin mononucleotide (FMN) cofactor, moved to 
ubiquinone (coenzyme Q), transferred to cytochrome c reductase (complex III), then 
moved to cytochrome oxidase (complex IV) where tetravalent reduction of diatomic 
oxygen to water molecules takes place indicating the end of the ETC. Several studies 
suggest that superoxide production takes place when electrons ‘leak’ from the ETC before 
reaching their destination (Murphy, 2009). In the same study which employed the use of 
mitochondria isolated from mammalian cells, it was suggested that electrons may escape 
from the ETC predominantly at complex I forming superoxide via univalent reduction of 
O2. Under similar experimental conditions, Chance and Hollunger (1961) estimated that 1-
2% of the oxygen consumed by isolated mammalian mitochondria is converted to 
superoxide. Therefore, complex I appear to be the most common site of ROS production in 
the mitochondria.  
1.4.1.3 Elimination of ROS  
While ROS may have physiological roles (1.4.2), it can also damage biological 
molecules including proteins, lipid and DNA. To limit the negative consequences of ROS 
production, a number of enzymes and other molecules are expressed in human cells for the 
purpose of eliminating ROS. These include SOD, catalase, peroxiredoxins (Prxs) and 
glutathione (GSH) (Figure 1.7). SOD catalyses the dismutation of superoxide and as a 
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result, H2O2 is formed which is converted to O2 and water by the action of catalase or the 
glutathione peroxidase (GSH) system (Lambeth, 2004). GSH, a tripeptide consisting of 
glutymyl, glycine and cysteine residues is the most predominant thiol in mammalian cells 
(Komatsu and Obata, 2003) and is used as an electron donor in the reduction of H2O2 to 
form O2 (Poole et al., 2004). This is one of the important mechanisms involved in the 
prevention of the oxidative stress (Ballatori et al., 2009). Hydrogen peroxide is also 
reduced through the action of Prxs (Rhee et al., 2005). Hydrogen peroxide reacts with the 
N-terminal cysteine residue (cys51 in mammalian Prxs) of the Prxs generating sulphenic 
acid (-SOH) which reacts with the sulphydryl group (-SH) of the cys172 (cysteine residue 
found in the members of the 2-cys Prxs family) forming an intermolecular disulphide bond 
(S-S). Oxidised 2-cys Prxs are then reduced by thioredoxin. Therefore Prxs, GSH and 
catalase are the main antioxidants systems promoting the reduction of H2O2. 
 
1.4.2 BIOLOGICAL AND PHYSIOLOGICAL FUNCTIONS OF ROS 
ROS has been shown to have a crucial role in the innate immune response. For 
instance, it has been implicated in microbial killing (Reeves et al., 2002). NOX2 has a key 
role in innate immunity as mutations or deletions NOX2 components result in inherited 
conditions such as chronic granulomatous disease (CGD) (Segal et al., 1996). This disease 
is characterized by the impaired ability of neutrophils to kill microorganisms giving rise to 
chronic infections. Therefore it is clear that ROS plays an important role in host defence.      
In addition to their expression in phagocytic cells, NOX family members have 
been shown to be expressed in human HPCs (CD34+ cells) (Piccoli et al., 2007) (Table 
1.4). NOX-derived H2O2 is well known to play crucial roles in haematopoiesis (Sardina et 
al., 2012) and haematopoietic growth factor signalling (Sattler et al., 1999 and Zhu et al., 
2006). There is accumulating evidence from murine and human HSC models that ROS 
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management is critical for primitive haematopoietic cells. For example elevated ROS 
appears to drive HSCs out of quiescence and reduces self-renewal capacity, resulting in 
rapid bone marrow failure if not remedied (Rizo et al., 2009; Tothova et al., 2007; Ito et 
al., 2004). In another study, an additional role of ROS in haematopoiesis was demonstrated 
where in vivo imaging technique showed that ROS-dependent expression of vascular cell 
adhesion protein 1 (VCAM-1) on the bone marrow endothelial cells is essential for the 
early stages of HSC bone marrow homing and localisation in the context of transplantation 
(Lewandowski et al., 2010). ROS signalling has also been associated with a variety of 
biological processes such as senescence and apoptosis (Burdon, 1995) and reviewed by 
Lambeth, (2004). In addition, ROS has also been shown to play an important biological 
role in proliferative signalling (Irani et al., 1997) and has been linked to diseases such as 
cancer (1.4.3). Excessive ROS production or a defect in antioxidant defence can lead to a 
state known as oxidative stress, characterized by oxidative damage to DNA and augmented 
ROS signalling (Block and Gorin, 2012). In addition, Hole et al., (2013) demonstrated that 
the overproduction of ROS in AML blasts showed depleted antioxidant defences but 
evaded the oxidative stress response through suppression of p38MAPK signalling (Hole et 
al., 2013). 
1.4.3 ROS IN LEUKAEMIA  
Though ROS have been increasingly implicated in several normal cellular 
processes (Ray et al., 2012), their overproduction have been reported in cancer cells, for 
example CML (Ciarcia et al., 2010; Ahmad et al., 2010), ALL ( Battisti et al.,2008) and 
AML (Sallmyr et al., 2008; Hole et al., 2010; 2013). Growing evidence suggests that ROS 
are at least partly responsible for the mutant RAS phenotype observed in several cancers 
cell models (Irani et al., 1997; Liu et al., 2001; Cho et al., 2002; Lee et al., 2007). The 
study by Hole et al., (2010) was the first to show that human haematopoietic CD34+ 
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progenitor cells transduced with N-RASG12D produce excessive ROS. Given that ROS have 
the potential to modulate cell signalling, the direct effects of ROS on gene transcription are 
also unknown. It is also noteworthy that transcriptional dysregulation is a key element in 
leukaemogenesis. The instability in the genome of blast cells in the pathogenesis of AML 
has been attributed to dysregulation of genes involved in cell maintenance and DNA repair 
and has been reported to lead to acquisition of molecular abnormalities that contribute to 
the progression of this disease (Suela et al., 2007; Alcalay et al., 2003). Therefore the 
current study was undertaken to determine the contribution of RAS-induced ROS 
production on gene expression and to identify the transcriptional targets of mutant RAS 
which could be related the proliferative responses of cells exposed to ROS. 
Additionally, in a more recent study in our group by Hole et al., (2013), NOX 
enzymes have been correlated with the increased levels of ROS in AML blasts. The 
authors of this study concluded that the over production of NOX-derived ROS in AML 
promotes proliferation and is associated with defective stress signalling (Hole et al., 2013). 
However the mechanism by which ROS or NOX family members acts is still poorly 
understood despite the growing literature surrounding them, warranting further research. 
1.5 GLYCOLYSIS 
1.5.1 OVERVIEW OF GLYCOLYSIS 
Glycolysis is a metabolic process that converts glucose into pyruvate and is a 
sequence of enzyme catalysed reactions which results in the release of free energy used to 
form the high energy compounds such as reduced nicotinamide adenine dinucleotide 
(NADH) and adenosine triphosphate (ATP) (Stryer, 1988; Munoz-Pinedo et al., 2012). It is 
an ancient metabolic pathway occurring in the cytosol of the cells of both aerobic and 
anaerobic organisms (Stryer, 1988). The net products of this pathway when one molecule 
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of glucose is catabolized are the formation of two molecules of ATP and NADH (Figure 
1.9).  
 
 
Figure 1.9 Overall process of glycolysis 
An equation showing the net reaction in the transformation of glucose into 
pyruvate. Abbreviations: Pi = Inorganic phosphate 
 
The reactions of glycolysis are summarized in Figure 1.10. As illustrated in both 
figures, in the first phase of glycolysis (priming phase), two molecules of ATP are used to 
convert glucose to fructose-1, 6-bisphosphate through sequential reactions catalysed by 
hexokinase (HK/HXK), phosphoglucose isomerase (PGI) and phosphofructokinase (PFK). 
The second phase (energy-yielding phase), involves the stepwise conversion of fructose-1, 
6-bisphosphate to pyruvate with the production of four molecules ATP and two molecules 
of NADH. Two ADP and two NAD+ molecules are used up and in the absence of oxygen; 
NAD+ is regenerated from NADH by reduction of pyruvate to lactic acid in a reaction 
catalysed by lactate dehydrogenase (LDH). It is important to note that, under aerobic 
conditions, pyruvate can be further oxidised to CO2 and H2O in the mitochondria via the 
tricarboxylic acid (TCA) cycle and the respiratory chain, yielding large amounts of ATP. 
As illustrated in Figure 1.10, each reaction in the glycolytic pathway is catalysed by a 
specific enzyme or enzyme complex detailed below. 
1.5.1.1 Hexokinase 
Hexokinases are tissue-specific isozymes that catalyse the first and rate-limiting 
reaction in glycolysis which involves the ATP-dependent phosphorylation of glucose to 
 
Glucose + 2 ADP + 2 Pi + 2 NAD+ → 2 Pyruvate + 2 ATP + 2 NADH+ 2 H+ + 2H2O 
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form glucose-6-phosphate (G-6-P) which serves as the starting point for the entry of sugar 
into the glycolytic pathway or the pentose phosphate pathway (PPP) (Figure 1.10) or for 
glycogen synthesis. Four mammalian isozymes of hexokinase (Types I-IV) exist with type 
IV (also known as glucokinase) being responsible for the storage of excess glucose in the 
liver (Pelicano et al., 2006). Various studies have demonstrated that type II isozyme of 
hexokinase (HK II) play a vital role in initiating and maintaining the high glucose catabolic 
rates of fast growing tumours. For instance increased expression of HK II has been 
reported in most immortalized and malignant cells and this has been linked to elevated 
glycolysis (Arora et al., 1990; Rempel et al., 1996). Hexokinases have also been shown to 
play part in the inhibition of the apoptotic pathway (Rathmell et al., 2003; Majewski et al., 
2004). Pelicano et al., (2006) pointed out that inhibition of these enzymes is likely to have 
profound effects on cellular energy metabolism and survival making them attractive targets 
for anticancer agents (Figure 1.15 and Table 1.5). 
1.5.1.2 Phosphoglucose isomerase  
Phosphoglucose isomerase (PGI) also known as glucose-6-phosphate isomerase 
(GPI) catalyse the inter-conversion of G-6-P and fructose-6-phosphate (Figure 1.10). 
Previous studies have shown that GPI can function as an autocrine motility factor (AMF), 
secreted from the tumour cells to promote cell proliferation (Niinaka et al., 1998; Sun et 
al., 1999). Interestingly, the presence of GPI in serum and urine is associated with cancer 
progression and indicates poor prognosis (Baumann and Brand, 1988; Baumann et al., 
1990; Filella et al., 1991). It is therefore clear that GPI does not only play a role in the 
glycolytic pathway but also functions as a cytokine extracellularly and is linked with 
malignant activities.   
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1.5.1.3 Phosphofructokinase 
PFK catalyses the second rate limiting step of glycolysis which involves the 
phosphorylation of fructose-6-phosphate to fructose-1,6-bisphophate using ATP as the 
source of energy (Figure 1.10). This enzyme is regulated by allosteric effectors and 
covalent modifications such as phosphorylation. It is activated by adenosine 
monophosphate (AMP) and fructose 2,6-bisphosphate. An abundance of ATP inhibits the 
activity of PFK. Nevertheless fructose 2,6-bisphosphate is capable of overriding the 
inhibitory effect of ATP and maintain continuous glycolytic flux. The up-regulation of 
fructose 2, 6-bisphosphate has been linked to cancer (Chesney et al., 2006). Three forms of 
PFK have been identified in humans namely; M (muscle), P (platelets) and L (liver), 
(Vora, 1983) and their involvement in cancer is unclear.  
1.5.1.4 Aldolase 
This enzyme catalyses the reversible conversion of fructose-1,6-bisphosphate to 
glyceraldehyde-3-phosphate (GLAP) and dihydroxyacetone phosphate (DHAP) (Penhoet 
et al., 1969) (Figure 1.10). There are three known distinct isozymes of aldolase namely; 
aldolase (ALDO) A (most highly expressed in muscle), B (highly expressed in the liver) 
(Penhoet et al., 1969; Mukai et al., 1986) and ALDOC which is most strongly expressed in 
neuronal tissues and brain (Penhoet and Rutter, 1971; Haimoto and Kato 1986; Lebherz 
and Rutter, 1969). These 3 mammalian aldolase isozymes have similar molecular masses 
but differ in structure and kinetics as well as tissue distribution. The differences in tissue 
and kinetics specificity among the human aldolase isozymes have been attributed to 
structural changes such as isozyme-specific residues (ISRs), those residues conserved 
among paralogs (Arakaki et al., 2004). The same study was the first to report the structure 
of human ALDOC via X-ray crystallography. In this study, a complete analysis of the ISRs 
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demonstrated that in several cases an amino acid residue that is conserved among ALDOC 
orthologs prevents an interaction that occurs in paralogs. Furthermore, the structure 
identified confirmed the clustering of ISRs into discrete patches on the surface and 
revealed the existence in ALDOC of a patch of electronegative residues localised near the 
C terminus. The authors of this study therefore concluded that these structural changes 
highlight the differences required for tissue and kinetic specificity among aldolases.     
ALDOC enzyme has been linked to cancer. For example, aldolase was shown to 
be elevated in the serum of patients with malignant tumours (Taguchi and Takagi, 2001). 
In addition, proteome analysis has demonstrated that this enzyme is overexpressed in 
human lung squamous carcinoma (Li et al., 2006). Elevated levels of ALDOC have been 
found in cancer cells (Schapira et al., 1970; Skala et al., 1987). For more detail on the 
aldolase involvement in cancer see chapter 5 discussion. 
Remarkably, aldolase not only plays a key role in glycolysis, but has also been 
demonstrated to bind macromolecules unrelated to glycolysis such as F-actin (Wang et 
al.,1996), vacuolar H+ -ATPase (Lu et al.,2001) and GLUT4 (Kao et al.,1999). These 
alternative non-glycolytic functions of aldolases have been described as “moonlighting 
functions” (Jeffery, 1999; Copley 2003) which may be specific to each isozyme.  
1.5.1.5 Glycealdehyde-3-phosphate dehydrogenase 
Gyceraldehyde-3-phosphate dehydrogenase (GAPDH) enzyme catalyses a redox 
reaction in the glycolytic pathway which involves the conversion of glyceraldehyde-3-
phosphate to 1, 3-bisphosphoglycerate coupled with the reduction of NAD+ to NADH. The 
role of this enzyme in cancer remains to be defined. 
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1.5.1.6 Phosphoglycerate kinase 
Phosphoglycerate kinase (PGK) catalyses the conversion of 1, 3-
bisphosphoglycerate to 3-phosphoglycerate coupled with the generation of ATP from 
ADP. This enzyme consist of two domains joined by a conserved hinge with the 
ADP/ATP-binding site located in the N-terminal domain and a conformational 
rearrangement involving bending of the hinge takes place upon binding of both substrates, 
bringing them in position for phosphate transfer. Two isozymes of this enzyme has been 
identified namely; PGK-1 and PGK-2. 
1.5.1.7 Phosphoglycerate mutase 
This enzyme catalyses the inter-conversion of glycerate-3-phosphate and 
glycerate-2-phosphate and also requires D-glycerate-2, 3-diphosphate for activation by 
donating one of its phosphoryl groups to form a covalently linked phosphoryl enzyme. 
Phosphoglycerate mutase has been shown to be differentially expressed in human lung 
squamous carcinoma (Li et al., 2006).  
1.5.1.8 Enolase 
The conversion of 2-phosphoglycerate to phosphoenolpyruvate is catalysed by 
enolase (Figure 1.10). There are three major isoforms of this enzyme in mammals: non-
neuronal enolase (NNE)/enolase 1/α enolase (found in a variety of tissues, including liver, 
brain, kidney, spleen, adipose and haematopoietic cells); muscle specific enolase 
(MSE)/enolase 3/ β enolase (largely restricted to muscle where it is present at very high 
levels); neuron-specific enolase (NSE)/enolase 2/ γ enolase (expressed at very high levels 
in neurons and neural tissues and at much lower levels in most mammalian cells). 
Proteome analysis showed that NNE is overexpressed in human lung squamous carcinoma 
(Li et al., 2006). 
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1.5.1.9 Pyruvate kinase 
Pyruvate kinase (PK) is the enzyme that catalyses the third irreversible step in 
glycolysis which involves the phosphoryl group transfer from phosphoenolpyruvate to 
ADP, yielding ATP and pyruvate; is a vital metabolic intermediate that channels into 
several metabolic pathways (Figure 1.10). Therefore this enzyme controls the outflow from 
the glycolytic pathway. Three forms/isozymes of PK have been found in mammals: the L 
type predominates in the liver, M type in muscle and brain and the A type in other tissues. 
These isozymes have the same architectural plan and catalytic mechanism but differ in 
how they are regulated. PK isozyme type M2 (PKM2 or M2-PK) is the predominant 
pyruvate kinase isoform in proliferating cells, such as fibroblasts, embryonic cells and 
adult stem cells and most human tissue, including lung, bladder, kidney and thymus. M2-
PK has been implicated in tumourigenesis (Mazurek et al., 2005; Reinacher and 
Eigenbrodt, 1981). Furthermore, Mazurek et al., (2005) pointed out that M2-PK interacts 
with oncoproteins which seem to cause its dimerization in tumour which is thought to 
allow the survival of tumour cells in environments with varying nutrients and oxygen.   
1.5.1.10 Lactate dehydrogenase  
Lactate dehydrogenase (LDH) catalyses the conversion of pyruvate to lactate 
coupled with an oxidation of NADH to NAD+. This reaction occurs in a variety of 
microorganisms and higher organisms when the amount of oxygen is limiting, for example 
in muscle during intense activity. Major isoforms of this enzyme, LDH-A and LDH-B 
have been identified with the former mostly implicated in cancer. Therefore LDH-A is 
used as a biomarker for many malignancies including lymphoma, renal carcinoma, 
melanoma and prostate cancer (Augoff and Grabowki., 2004; von Eyben, 2001; Kolev et 
al.,2008; Jovanovic et al.,2007; Porporato et al., 2011; Sola-Penna, 2008).  
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1.5.1.11 Pyruvate dehydrogenase 
Pyruvate dehydrogenase (PDH) catalyses the pyruvate decarboxylation process 
for the transformation of pyruvate to acetyl-CoA which is used in the TCA for cellular 
respiration. Therefore PDH links the glycolysis metabolic pathway to citric acid cycle. 
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Figure 1.10 Glycolytic pathway and its metabolic interconnections with PPP and TCA 
cycles. 
A diagrammatic representation of the glycolytic pathway. Reactions (red 
arrows), intermediates (black), enzymes (red), metabolic interconnection with the Pentose 
Phosphate Pathway (PPP) (Purple arrow), further metabolism of pyruvate downstream of 
glycolysis (orange arrows). Abbreviations: PDH = Pyruvate dehydrogenase; LDH = 
Lactate dehydrogenase; GLAP = Glycealdehyde-3-phosphate; DHAP = Dihydroxyacetone 
phosphate; G6PD = Glucose-6-phosphatase. Adapted from Biochem: online 
(http://biochem.co/2010/02/)
G6PD   
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1.5.2 REGULATION 
The regulation of glycolysis is based on the changes in the rate of particular 
steps in this pathway. This is achieved by the activation or inhibition of the enzymes that 
are involved in the process. There are several points of regulation in glycolysis which 
indicates that intermediates between these points enter and leave the glycolysis pathway by 
other processes as indicated in (Figure 1.10) and there are three key regulated enzymes in 
glycolysis namely phosphofructokinase (PFK), pyruvate kinase and hexokinase (HK) 
(discussed above).  
 
1.5.3 POST GLYCOLYSIS PROCESSES  
Glycolysis provides intermediates for other pathways which strongly rely on it 
as a source of metabolites. These metabolic pathways include; gluconeogenesis, lipid 
metabolism, pentose phosphate pathway and citric acid cycle (Figure 1.10) which leads to 
processes such as amino acid and nucleotide synthesis.  
1.5.4 GLYCOLYSIS IN CANCER  
Increased glycolysis is known to be linked to cancer and was originally 
described by Otto Warburg (Warburg, 1956). Normal cells obtain ATP primarily via 
oxidative phosphorylation (respiration) (described in section 1.5 and Figure 1.10). Cancer 
cells on the other hand exhibit the Warburg effect in which cancer cells exhibit increased 
glycolysis and use this metabolic pathway for generation of ATP as a main source of their 
energy supply even under aerobic conditions (Koppenol et al., 2011). Originally it was 
thought that this was driven by impairment or dysfunction in mitochondrial metabolism 
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(Warburg, 1956). Subsequent work suggests that the Warburg effect arises from changes in 
the signalling pathways that regulate glucose uptake and utilization as opposed to 
mitochondrial dysfunction (Jang et al., 2013). Furthermore, the genes of glycolysis are 
found to be ubiquitously overexpressed in cancers (Mikuriya et al., 2007; Altenberg et al., 
2004).  
In addition to solid cancers, a high level of glycolytic metabolism has also been 
demonstrated in AML blasts (Herst et al., 2011). In this study, in vitro dye reduction assay 
was used to determine the level of glycolytic metabolism in 26 bone marrow (BM) samples 
taken from adult patients with newly diagnosed or relapsed AML and the blasts were 
categorized into moderate and high levels of glycolytic metabolism. Highly glycolytic 
AML blasts were found to be more resistant to apoptosis induced by all-trans retinoic acid 
(ATRA) and/or arsenic trioxide (ATO) in vitro suggesting possible resistance to induction 
chemotherapy as for solid tumours (Herst et al., 2011). This study concluded that the 
extent of myeloblast glycolysis may be an effective and easily applied method for the 
determination of pre-treatment prognosis in AML.  
Furthermore the importance of glycolytic phenotype in cancer has been 
emphasized by studies which demonstrated that increased glucose uptake coincide with 
transition from pre-malignant lesions to invasive cancer (Younes et al., 1996) which in part 
could explain the significant prevalence of the glycolytic phenotype in human cancers .  
1.5.5 MOLECULAR MECHANISMS UNDERLYING THE WARBURG EFFECT 
The exact reasons why tumour cells exhibit elevated glycolysis and use this less 
energy-efficient pathway to generate ATP are still unclear; however, the overall increase in 
aerobic glycolysis (or Warburg effect) has been attributed to several factors (Jang et al., 
2013) such as oncogenes, hypoxic microenvironment tumour suppressors, mitochondrial 
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DNA (mtDNA) deletions and mutations, nuclear DNA (nDNA) mutations or abnormal 
gene expression (Figure 1.11, Figure 1.12 and  Figure 1.13).  
1.5.5.1 Role of oncogenes 
Several mutations that activate oncogenes or inactivate tumour suppressers were 
shown to significantly affect the activities of metabolic enzymes and play a vital role in 
aerobic glycolysis of cancer (Elstrom et al., 2004; Levine and Puzio-Kuter, 2010; Bayley 
and Devilee 2012). Importantly, mutant RAS (in addition to the functions discussed in 
section 1.3.3) has been associated with the regulation of aerobic glycolysis in cancer (Blum 
et al., 2006; Mazurek et al., 2001a; Ramanathan et al., 2005). Pharmacologic inhibition of 
RAS was shown to result in the inhibition of RAS signalling to both the Raf, MEK, ERK 
and the PI3 pathways. As a consequence of this the glucose transporter, Glut-1 was 
substantially down regulated (Blum et al., 2005; Blum et al., 2006). Conversely, mutant H-
RAS has been reported to upregulate 6-phosphofructo-1-kinase (PFK-1) activity via 
induction of F26bP (Kole et al., 1991; Telang et al., 2006). Similarly, Mazurek et al., 
(2001b), reported high levels of PFK-1 activity in rat kidney cells transfected with mutant 
RAS together with the human papillomavirus type 16 E7 (HPV-16 E7) oncoprotein led to 
elevated levels of fructose-1,6-bisphosphate. It was also found that the HPV-16 E7 
oncoprotein, which cooperates with RAS in cell transformation, directly binds to M2-PK, 
induces its dimerization and thereby promotes cell proliferation. Other oncogenes 
including Src, P13K/Akt and Bcr-Abl have also been implicated in the promotion of 
glycolysis and the Warburg effect (Chapter 5 discussion and Figure 1.11). Little is known 
about RAS expressing leukaemias. 
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1.5.5.2 Role of mtDNA 
High rates of human mitochondrial DNA (mtDNA) mutations observed in 
cancer cells are believed to lead to mitochondrial malfunction and a reduction in the ability 
to generate ATP through oxidative phosphorylation (Figure 1.13) (Carew and Huang 2002; 
Brandon et al., 2006). ROS has also been implicated in this. In study by Carew et al., 
(2003), primary human leukaemia cells isolated from patients were used to examine 
mtDNA mutations and their correlation with alteration in cellular ROS and mitochondrial 
mass. In this study, mtDNA mutations in leukaemia cells were found to be closely 
associated with increased ROS generation and altered sensitivity to drug treatment. It 
should be noted however that mtDNA mutations are unlikely to cause the whole defect in 
mitochondrial oxidative phosphorylation. In support of this, certain fast growing tumours 
were shown to have active ATP generation through oxidative phosphorylation which 
supplies a large portion of the total cellular energy (Rodriguez-Enriquez et al., 2000). 
Therefore it is likely that the Warburg effect reflects a metabolic state in cancer cells where 
ATP generation through mitochondrial oxidative phosphorylation is compromised by 
factors such as the ones indicated in (Figure 1.13) hence insufficient to support active 
cellular activity. Consequently cells become more reliant but not solely dependent on 
increased glycolysis for ATP supply. In support of this, Chen et al.,(2007) also pointed out 
that it is important to recognise that elevated glycolysis in cancer cells does not necessarily 
suggest that cancer cells only use the glycolytic pathway for ATP generation. In addition to 
its possible contribution towards the overall increase in glycolysis in cancer cells, 
mitochondrial respiratory malfunction has been shown to result in a change in cellular 
NADH/NADPH ration leading to a redox-mediated activation of the Akt survival pathway 
(Pelicano et al., 2006b) (Figure 1.13). 
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1.5.5.3 Role of nuclear DNA mutations or abnormal gene expression 
Mutations in nuclear DNA (nDNA) or aberrant expression of certain nuclear 
genes may suppress mitochondrial respiratory function and/or the TCA cycle and possibly 
promote glycolysis (Figure 1.13). nDNA encodes for most of the mitochondrial protein 
components. For example, succinate dehydrogenase (SDH) and fumarate hydratase (FH) 
are encoded by nuclear genes and play crucial roles in the TCA cycle and mitochondrial 
complex II function. Germline mutations in SDH and FH are associated with tumours 
(Gottlieb and Tomlinson 2005) and a reduction in SDH activity may lead to increased ROS 
generation (Albayrak et al., 2003; Ishii et al., 2005). Accumulation of succinate due to 
SDH deficiency caused an inhibition of Hypoxia inducing factor (HIF)-1α prolyl 
hydroxylase leading to stabilization and nuclear translocation of HIF-1α (transcriptional 
factor that promotes the expression of glycolytic enzymes) in normoxic condition (Selak et 
al., 2005). Interestingly, overexpression of glycolytic enzymes including GAPDH, enolase 
1, PK, LDH, HK2 and aldolase has been observed in a variety of cancer cells ( for further 
details see chapter 5 discussion). 
1.5.5.4 Role of tumour microenvironment 
Hypoxia is frequently observed in human cancer and research has shown that 
that adaptation to the respiratory suppression owing to oxygen depletion possibly cause 
tumour cells to switch to glycolysis for ATP production, accompanied by increased 
generation of lactate and acidification of tumour microenvironment (Gatenby and Gillies 
2004). The authors of these study speculated that this adaptation and switch to the 
glycolytic pathway leads to a further selection of malignant cells. HIF-1α, a key molecule 
that mediates cellular response to hypoxia has been shown to activate a set of genes 
involved in angiogenesis, glucose uptake and glycolysis (Harris, 2002). Another study by 
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Kim et al., (2006) suggest that HIF-1α may mediate a metabolic switch from mitochondria 
respiration to glycolysis by trans-activating pyruvate dehydrogenase kinase 1, which in 
turn activates pyruvate dehydrogenase leading to suppression of the TCA cycle (Figure 
1.12). It should be noted that despite the fact that increased glycolysis in response to 
hypoxia does not exactly represent the classical Warburg effect (increased aerobic 
glycolysis), Chen et al., (2007) argued that pharmacological agents that inhibit glycolysis 
will not only impact cells exhibiting the Warburg effect but also cancer cells in hypoxic 
environment. It has also been suggested that aerobic glycolysis by proliferating cells may 
also be a protective mechanism against ROS (Brand and Hermfisse 1997). Although it is 
suggested the increased ROS generation within the cancer cells may also inhibit the 
respiratory chain and suppress oxidative phosphorylation forcing cells to adapt active 
glycolysis for ATP generation (Chen et al.,2007), the exact role and contribution of ROS 
to the Warburg effect is not well understood and still remain to be explored. Interestingly, 
some researchers speculate that ROS are involved in signalling to GLUT1 contributing to 
glucose transport activation in leukaemic cells (Maraldi et al., 2007); however such 
speculations remain inconclusive and warrant further investigation. 
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Figure 1.11  Cancer cell metabolism and signalling pathways related to oncogenes 
and tumour-suppressor genes. 
Oncogenes and tumour suppressor genes play an important role in the signalling 
pathways that regulate metabolism in cancer cells. PI3K activates Akt which stimulates 
glucose uptake and flux by directly controlling glycolytic enzymes and activating mTOR 
which indirectly causes metabolic changes by activating HIF.  HIF then activates PDK 
which inactivates the mitochondrial pyruvate dehydrogenase complex hence inhibiting the 
entry of pyruvate into the TCA cycle. p53 supresses glycolysis by increasing the 
expression of TIGAR, supporting the expression of PTEN and promoting oxidative 
phosphorylation via SCO2. Myc augments glycolysis by increasing transcription of 
glycolytic enzymes and its involvement in glutamine metabolism. Adapted from :(Jang et 
al., 2013). 
GLUT
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Figure 1.12  Glucose metabolism in cancer cells: Regulation 
The regulation of glucose metabolism in cancer cells is via several ways.  
Following the entry of glucose into the cell via a glucose transporter (GLUT), it is 
phosphorylated by HK to glucose-6-phosphate which is further metabolized by glycolysis 
to pyruvate in the cytosol. Under aerobic conditions, normal cells use PDH to convert 
majority of pyruvate to acetyl-CoA which is then oxidised via TCA cycle, providing 
sources for ATP synthesis. Conversely, the metabolic pathways of glucose utilization in 
cancer are changed from ATP generation by oxidative phosphorylation to ATP generation 
via glycolysis. In addition, for cell proliferation to occur, cancer cells require the synthesis 
of new macromolecules such as lipids, proteins and nucleic acids. Some of the TCA cycle 
enzymes (purple coloured) are known to be mutated in cancer and others (highlighted in 
red) are potential targets for cancer therapy. Adapted from: (Jang et al., 2013). 
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Figure 1.13  Summary of the mechanistic perspective of the Warburg  
Potential mechanisms contributing to elevated glycolysis and decreased 
mitochondrial respiration in cancer cells. Abbreviations: mtDNA = mitochondrial DNA; 
nDNA = nuclear DNA; I-V = respiratory chain complexes I-V respectively. Adapted from: 
(Chen et al., 2007) 
Mitochondria dysfunction  
ATP  ROS    
Glycolysis  
Activation of survival pathways: Akt, HIF‐1 
Redox‐re‐balance 
Selection of more malignant cells 
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1.5.5.5 Glycolysis and cell death 
In addition to the promotion of cancer cell proliferation, glycolytic metabolism has been 
shown to protect these cells from death. Research has shown that increased glycolytic rate 
renders cancer cells more resistant to apoptosis induced by growth factor withdrawal. For 
instance, it was shown in leukaemic cells that the overexpression of GLUT1 and 
hexokinase 1 was sufficient for Akt to protect against IL-3 withdrawal (Rathmell et al., 
2003). Under normal glucose conditions, IL-3 targets the anti-apoptotic protein Mcl-1 for 
proteasome degradation leading to cell death (Maurer et al., 2006) but when glucose levels 
are elevated, Mcl-1 is more stable (Zhao et al., 2007) (Figure 1.14). Moreover, when 
glycolysis is inhibited, the AMPK/mTOR axis inhibits translation of Mcl-1 rendering cells 
more prone to death ligands (Pradelli et al., 2009). In addition, increased glycolytic 
metabolism was shown to inhibit expression or activity of the pro-apoptotic BH3-only 
proteins which mediate death induced by chemotherapeutic drugs and physiological agents 
(EI Mjiyad et al., 2010) (Figure 1.14). For example, overexpression of GLUT1 was shown 
to inhibit Puma and p53 induction upon growth factor withdrawal (Zhao et al., 2008). 
Further, hexokinase 1/GLUT1 overexpression inhibited sensitivity of cells to transfection 
of DNA encoding Bim (Zhao et al., 2007). Elevated glucose levels have been shown to 
promote CDK5-mediated phosphorylation and inactivation of Noxa in human leukaemic 
cells (Lowman et al., 2010) and under low glucose conditions, Bad has been shown to be 
dephosphorylated and induces apoptosis. These findings provide evidence that metabolic 
stress regulates the BH3-only proteins and that cancer cells also use glycolysis to escape 
cell death. In support of this, overexpression of the glycolytic enzyme GAPDH was shown 
to promote survival of cancer cells (Colell et al.,2007) and stimulation of glucose uptake 
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was shown to play a crucial role in the suppression of apoptosis in normal haematopoietic 
cells (Barnes et al., 2005) (for further discussion see Chapter 5). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.14  Cell death regulation by glucose metabolism 
The availability of nutrients regulates cell death induced by death receptors and 
stimuli that kill through the mitochondrial pathway by regulating the anti-apoptotic Bcl-2 
family member Mcl-1, pro-apoptotic BH3-only proteins (Bim, Noxa, Puma and Bad) and 
c-FLIP. Adapted from: (Munoz-Pinedo et al., 2012).  
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1.5.6 METABOLIC TARGETING FOR CANCER THERAPY 
Overall, it is clear that glycolysis can indeed be blocked by inhibition of 
glycolytic enzymes such as HK, PFK and PK which all regulate irreversible and rate-
limiting steps in glycolysis, a feature that has potential application for the metabolic 
targeting of cancer. Inhibition of glycolysis has also been shown to prevent cancer 
development, highlighting the necessity of glycolysis in proliferation, invasion and 
metastasis of cancer (López-Lázaro 2007; 2008 Gatenby et al., 2006). These findings have 
stimulated the search for small molecules that might specifically inhibit the key metabolic 
steps in glycolysis. Jang et al., (2013) pointed out that targeting enzymes such as lactate 
dehydrogenase, phosphofructokinase, pyruvate kinase and hexokinase and others indicated 
in (Figure 1.15) may yield therapeutic advantage and could help eradicate resistance to 
chemotherapy or radiotherapy. Several compounds are currently being investigated as 
potential therapeutic targets in glycolysis (summarised in Table 1.5) 
 Inhibitors of hexokinase such as 2-deoxyglucose, (2-DG) (3-bromopyruvate (3-
BrPA) and lonidamine (LON, 1-[(2, 4-dichlorophenyl) methyl]-1H-indazole-3-carboxylic 
acid) are currently in pre-clinical and early phase clinical trials. Hexokinase mediates the 
first rate limiting step of glycolysis where glucose is phosphorylated with the use of ATP 
(Figure 1.15) hence 2-DG serves as a competitive inhibitor of hexokinase by blocking 
access of glucose to this enzyme. Although 2-DG showed the promising anticancer effects 
in preclinical models (Maher et al., 2004), however later studies revealed that the principal 
mechanisms underlying 2-DG`s anti-cancer effects vary (Kurtoglu et al., 2007; Zhong et 
al., 2008). Furthermore, contrary to its widely believed anticancer effects, 2-DG was 
shown to activate multiple pro-survival pathways in cancer cells (Zhong et al., 2009) and 
hypoxic cells were shown to be resistant to this inhibitor (Maher et al., 2007). Despite the 
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fact that the success of 2-DG as a single agent for anti-glycolytic therapy has been 
challenged, encouraging outcomes of its use in combination treatments were reported 
(Maschek et al., 2004; Dwarakanath et al., 2009). 
LON, another inhibitor for hexokinase has been shown to induce apoptosis and 
treat multidrug resistance in several cell lines including HepG2 (Del Bufalo et al.,1996; Li 
et al., 2002; Ravagnan et al., 1999). However its clinical success has so far been impaired 
by significant pancreatic and hepatic toxicities reported (Price et al., 1996). Moreover, 
Phase II clinical trials of LON as a treatment for benign prostatic hyperplasia have been 
suspended due to its liver toxicity (Brawer, 2005; Ditonno et al., 2005). Despite this 
inhibitor is now undergoing investigation in combination treatments trials (Pelicano et al., 
2006a; Gatenby and Gillies, 2007). 
3-BrPA is a potent inhibitor of hexokinase and has been demonstrated to also 
affect mitochondrial respiration, leading to ATP depletion and death of cancer cells (Ko et 
al., 2001; Geschwind et al., 2004; Xu et al., 2005b). This inhibitor possesses promising 
anticancer property in that it is effective against hypoxic cancer and may overcome multi-
drug resistance. In support of this, 3-BrPA induced severe depletion of cellular ATP and 
cell death in cancer cells with mitochondrial defects or under hypoxia, which normally 
causes a decrease in cellular sensitivity to the majority of anti-cancer agents (Xu et al., 
2005b). Importantly, the same study showed that ATP depletion induced by 3-BrPA may 
disable the ATP-dependent multi-drug exporting pumps, thereby killing cells with the 
multi-drug resistant phenotype. It should be noted however that some researchers have 
pointed out that this inhibitor is unstable in solution and requires 100 µM to be effective in 
vitro (Chen et al.,2007), warranting further development of new analogues. Interestingly, it 
was previously reported that increased glycolysis is directly associated with glucocorticoid 
resistance that is associated with treatment failure in childhood acute lymphoblastic 
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leukaemia and inhibition of glycolysis by 2-DG, 3-BrPA or LON increases prednisolone-
induced toxicity in leukaemia cells (Hulleman et al., 2009).  
Phloretin and WZB117 (Table 1.5 and Figure 1.15) are other compounds that 
have demonstrated anticancer effects in preclinical models (Macheda et al., 2005; Liu et 
al., 2012). These compounds are believed to block the GLUTs (known to be overexpressed 
in most of cancer types), which would prevent glucose entry into the cancer cell and lead 
to the complete disruption of the glycolytic pathway. It should be noted that GLUTs are 
ubiquitously expressed in mammalian cells, posing a critical challenge to the selective 
blockade of GLUTs in tumour cells. FX11 an inhibitor of LDH diminishes intracellular 
ATP levels which increase oxidative stress resulting in tumour cell death (Le et al., 2010). 
Likewise, another inhibitor of LDH, oxamate (Table 1.5) sensitizes resistant cancer cells to 
chemotherapeutic agents such as taxol (Zhou et al., 2010). Both inhibitors are still in pre-
clinical stages and their fate will be determined by the outcome of clinical trials. 
PFK catalyses one of the rate limiting steps in glycolysis which involves the 
phosphorylation of fructose-6-phosphate to fructose 1,6-bisphosphate. This step is 
regulated by allosteric effectors involving ATP as a negative regulator and fructose-2,6-
bisphosphate as a positive regulator. Strategies were previously proposed involving 
targeting this regulatory mechanism by suppression of PFKB3 isozyme which controls the 
cellular levels of fructose-2,6-bisphosphate and the glycolytic flow to preferentially kill 
RAS-transformed cells (Chesney, 2006). Specific inhibitors of PFKB3 are being developed 
and preliminary studies revealed promising anti-cancer effects (Clem et al., 2008) even 
though further research is essential to assess whether this approach could potentially be 
successful in clinic.  
PKM2, which is highly expressed in cancer cells (Christofk et al.,2008; Mazurek 
et al., 2005), has been shown to be a potential therapeutic target (Chen et al.,2011; 
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Goldberg and Sharp, 2012). As a result, strategies to develop small molecule inhibitors 
specific for this enzyme are now in progress and their success will depend on the outcome 
of clinical trials.   
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Figure 1.15 Targeting glycolysis in cancer 
The enzymes that may be considered as potential targets for anti-cancer agents 
are indicated along with the relevant chemical inhibitors (red). Abbreviations: Glut1 = 
glucose transporter 1; HXK = hexokinase. Adapted from: (Chen et al., 2007).  
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Compound Target Mode of action 
2-Deoxyglucose Hexokinase Inhibits glycolytic flux 
3-BrPA Hexokinase Inhibits glycolytic flux 
WZB117 GLUT1 Inhibits glucose uptake 
Oxamate Lactate dehydrogenase Inhibits pyruvate 
metabolism 
Phloretin GLUT1 Inhibits glucose uptake 
LON Hexokinase Inhibits glycolytic flux 
FX11 Lactate dehydrogenase Inhibits pyruvate 
metabolism 
 
Table 1.5 Summary of compounds used for targeting glycolysis in cancer 
The above figure shows the compounds used for targeting glycolysis in cancer, 
their target enzymes and their mode of action. Abbreviations: 2-DG = 2-Deoxyglucose; 3-
BrPA = 3-bromopyruvate; GLUT = Glucose transporter; LON = Lonidamine. Adapted 
from Jang et al., (2013).  
 
Further studies of cancer metabolic profiles are still needed together with a clear 
understanding of the complex metabolic alterations in cancer and mechanisms of cell death 
induced by the glycolysis inhibitors (Figure 1.14). So far there are no studies of how RAS 
and ROS induced changes impact glycolytic enzymes in haematopoietic cells. However, it 
has been recently demonstrated that modulating aerobic glycolysis (AG) via inhibition of 
either PKM2 or LDHA negatively impacted leukaemic growth, whereas normal 
haematopoiesis was less dependent on these enzymes (Wang et al., 2014). The authors of 
this study concluded that the differential sensitivity of normal and malignant cells to 
modulation of AG suggests a potential therapeutic opportunity for leukaemia intervention.  
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1.6 MICROARRAY ANALYSIS 
1.6.1 OVERVIEW OF MICROARRAYS 
A microarray is defined as a 2D array on a solid substrate such as silicon thin-
film cell or glass slide that assays large amounts of biological material by the use of high- 
throughput screening, miniaturized, multiplexed, parallel processing and detection 
methods. Several types of microarrays have been invented following the initial 
introduction of the concept and methodology of microarray by Chang in (1983) via 
antibody microarray. These includes; DNA microarrays (cDNA, oligonucleotide, SNP 
microarrays), protein, tissue, cellular and peptide microarrays. Many companies such as 
Affymetrix, Illumina and Agilent have now been established and are involved in the design 
of the different types of microarrays.  
DNA arrays are the most widely used type of microarrays. These are a collection 
of microscopic DNA spots attached to a solid surface which simultaneously measure the 
expression levels of large numbers of genes. They can be used to genotype multiple 
regions of a genome. Each DNA spot consists of specific DNA sequence (termed probes) 
which can either be a short section of a gene or other DNA element that are used to 
hybridize cDNA or cRNA (antisense RNA) sample (termed target). Probe-target 
hybridization is normally detected and quantified by the detection of fluorophore-, silver- 
or chemiluminescence-labelled targets for the determination of relative abundance of 
nucleic acid sequence in the target. In summary, the main principle behind microarray 
analysis is the hybridization between two DNA strands, a feature of complimentary nucleic 
acid sequences to specifically pair with each other via hydrogen bonds formation between 
complimentary nucleotide base pairs.  
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1.6.2 USES OF MICROARRAYS FOR GENE EXPRESSION PROFILING 
DNA microarrays can be used to detect DNA (as in comparative genomic 
hybridization) or to detect RNA (most commonly as cDNA after reverse transcription) that 
may or may not be translated to proteins. The process of measuring gene expression via 
cDNA is called expression analysis or expression profiling. The use of miniaturized 
microarrays for gene expression profiling (GEP) was first reported in 1995 (Schena et al., 
1995) and this was followed by the first publication of a complete eukaryotic genome on a 
microarray (Lashkari et al., 1997) and the emergence of the advanced different designs of 
microarray platforms such as Gene chip® Human Exon 1.0 ST arrays (discussed below). 
1.6.3 AFFYMETRIX GENECHIP® HUMAN EXON 1.0 ST ARRAYS  
The widely used Genechips® are quarts chips made by Affymetrix for the 
analysis of DNA microarrays. These Genechips play a vital role in research since they 
enable fast scanning for the presence of particular genes in a biological sample by the 
detection of specific pieces of mRNA. The main advantage of Affymetrix chips is that a 
single chip can be used to do thousands of experiments in parallel although a chip can only 
be used once.  
Genechip® Human Exon 1.0 sense target (ST) arrays (also known as Human 
Exon Arrays) are a powerful new array design which are not only novel, but also have high 
density array manufacturing capability, offering for the first time, exon-level expression 
profiling at the whole-genome scale on a single array. The design of these arrays has 
facilitated the most comprehensive and informative coverage of the genome compared to 
other types that are widely used such as Genechip® Human Genome (HG) U133 Plus 2.0 
arrays which measure expression only at gene level (Figure 1.16 and Table 1.6). 
Furthermore, Human Exon Arrays are more accurate than HG U133 Plus 2.0 arrays for 
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gene expression measurement (Kapur et al., 2007; Abdueva et al., 2007; Affymetrix: 
Online) due to a higher coverage and more evenly distributed probes (Figure 1.16 and 
Table 1.6). This is due to the differences in the methods used to generate the targets for 
amplification. In contrast to HG U133 Plus 2.0 arrays which use primers targeting the 
poly-A tail of mRNAs focusing on the 3’ end probe selection region (PSR) the GeneChip 
Whole Transcript (WT) Sense Target Labelling Assay (Affymetrix :Online) applied for the 
Human Exon Arrays uses randomly attaching primers. Therefore bias towards the 3’ end of 
the transcript is avoided.  
 Human Exon Arrays provides additional alternative splicing and transcript 
termination information which is beyond classical gene expression results from 
microarrays (Bemmo et al., 2008). The knowledge of changes in splicing patterns is 
critical to a comprehensive understanding of biological regulation and disease 
mechanisms. The relevance to health related studies is given by the fact that approximately 
30 % of all alternatively spliced transcripts are disease related (Xi et al., 2008). Therefore 
these arrays have the ability to treat individual exons as independent objects making it 
possible to observe differential skipping or inclusion of exons which is impossible on 
arrays that focus on the transcription activities at the 3’ end such as Genechip® Human 
Genome U133 Plus 2.0 arrays (Figure 1.16 and Table 1.6).  
Furthermore Human Exon Arrays consists of sequences from cDNA-based 
content including the more established RefSeq and GenBank® mRNAs. Therefore each 
probe on this array is designed from the genomic sequence and annotated with its genome 
coordinates (Affymetrix: Online). Anchoring the design onto the genome enables the 
dynamic update of the design reflecting the new knowledge of the genomic sequence and 
annotations in addition to the more convenient correlation of the expression data with 
DNA sequence information. This is an advantage over other arrays which are typically 
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designed against only observed or annotated junctions. It is therefore clear that Human 
Exon Arrays are more advanced and greatly differ from other array types in terms of their 
design, coverage and density. For more detail on principles and advantages of Human 
Exon Arrays (Chapter 4). 
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Figure 1.16 Probe coverage and distribution in Genechip® Human Exon 1.0 ST versus 
HG U133 Plus 2.0 arrays 
Coloured regions represent exons (yellow); introns that are removed during 
splicing (black). The short dashes underneath the exon regions for the Human Exon Array 
(pink) and the 3’ (HG U133 Plus 2.0) (blue) array probe selection region (PSR) indicate 
the individual probes representing that PSR. While the conventional HG U133 Plus 2.0 
feature a probe set consisting of ~ 11 probes selected from the 3’ end of the mRNA 
sequence, the new Human Exon Array, in contrast, has 4 probes selected from putative 
exon region. Abbreviations: UTR=Untranslated region. Adapted from Affymetrix: online 
(http://www.affymetrix.com/). 
 
  
Genomic 
locus 
mRNA 
transcripts 
Human  Exon 
array PSR 
3’array PSR 
5’
Exon Intron
UTR
PSR: Along the entire length of the transcripts
PSR: Mostly 3’ end
polyA  3’
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Table 1.6 Comparison of array design principles between Genechip® Human Exon 
1.0 ST and Human Genome U133 Plus 2.0 arrays  
 Summary of the main differences in the design and performance of the Human 
Exon and HG U133 Plus 2.0 arrays. Abbreviations: ST = sense target; mRNA = messenger 
RNA.  Adapted from Affymetrix: online (http://www.affymetrix.com/). 
 
Summary of  Array Statistics Human Exon 1.0 ST Array Human Genome 
U133 Plus 2.0 Array 
Probe sets 1.4 million 54,000 
Exon clusters > 1 million N/A 
Supported by putative full-
length mRNA 
289,961 probe sets N/A 
# of perfect match probes for 
each probe selection region 
4 11 
Background subtraction 
strategy 
Median intensity of up to 1,000 
background probes with the same GC 
content 
One mismatch probe 
for every PM probe 
Probe selection region 
location 
Along the entire length of the 
transcripts 
Mostly 3' end 
Probe selection region length Median 123 bp 600 bp 
Number of probes for each 
RefSeq Sequence 
Median 30 - 40 11 
Interrogated strand Sense Antisense 
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1.6.4 ADVANTAGES AND LIMITATIONS OF MICROARRAY TECHNOLOGY IN CANCER 
Several GEP methods have been used in cancer research, however microarrays 
have become more advantageous because they are: easier to use, do not require large DNA 
sequencing and they allow parallel quantification of thousands of genes from multi- 
samples hence saving time.  
Gene expression profiling of cancers using microarrays represents the largest 
category of research using microarray technology and seem to be the most comprehensive 
approach to characterize cancer at a molecular level. The importance of this approach has 
been demonstrated and highlighted in a number of studies performed on several 
malignancies such as breast, head, neck, stomach cancers and AML (for further details see 
Chapter 4 discussion) 
Furthermore, gene expression microarrays provides a snapshot of all the 
transcriptional activity in a biological sample thus enable the discovery of totally novel and 
unexpected functional roles of genes whereas the majority of traditional molecular biology 
tools and techniques generally allow the study of single gene or a small set of genes. 
Therefore microarrays have been applied in many aspects such as the discovery of novel 
disease subtypes, identification of underlying mechanisms of disease or drug response and 
development of new diagnostic tools. In support of the above, microarrays have been 
referred to as a relatively new powerful tool for studying the molecular basis of 
interactions on a scale that is impossible using conventional analysis (Russo et al., 2003).  
It is important to note that there are challenges and limitations to the use of 
microarrays that have been previously highlighted by other researchers (Murphy, 2002). 
These include the processing and interpretation of data generated by microarrays. However 
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statistical and computational tools which aid in the analysis of microarray data have now 
been invented and improved making microarrays more attractive in research.   
Taking into consideration the emerging better designs (such as Affymetrix 
human exon 1.0ST arrays)  and advantages of microarrays, it is reasonable to conclude that 
microarrays will enable further improvements in diagnosis, therapy approaches and 
prognosis of cancer and other diseases via gene expression studies and the discovery of 
genes that can be targeted in the treatment of disease.  
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1.7 AIMS OF THE STUDY 
Production of ROS in AML is frequently observed and has been shown to 
promote proliferation of these cells; however the mechanism through which ROS 
influences growth is not understood.  This study will investigate how ROS influence gene 
expression in haematopoietic cells.  A previously characterised model system based on 
normal human HPC will be utilised to address this.  Expression of mutant RAS in these 
cells promotes ROS production and also drives their proliferation. The hypothesis that will 
be tested in this thesis is whether ROS promotes the proliferation of these cells through a 
transcription mechanism. The overall approach will be to identify ROS-mediated gene 
expression changes in RAS-transduced HPC by using a potent inhibitor of ROS production 
and then to analyse the functional consequences of key changes in the transcriptome 
induced by ROS. 
 
Specifically the study aims to: 
1) Optimise the conditions for analysis of gene expression changes attributable to 
ROS 
2) Carry out GEP analysis using optimised conditions and validate key gene 
changes mediated by ROS; 
3)  Determine the functional consequences of key ROS-mediated changes in gene 
expression using knock-in and knock-down approaches.  
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2 General Materials and Methods 
 
2.1 MATERIALS AND REAGENTS FORMULATIONS 
2.1.1 MATERIALS 
Materials used in the study and the corresponding manufacturer/supplier are 
listed in alphabetical order (Table 2.1, Table 2.2 and Table 2.3).  
 
2 
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Table 2.1 General materials used in the study 
 
Material/chemical Manufacturer/supplier 
Ampicillin Sigma-Aldrich, Poole, UK 
Bovine serum albumin fraction V (BSA) Sigma-Aldrich, Poole, UK 
Bradford’s Reagent Sigma-Aldrich, Poole, UK 
Calcium chloride (CaCl2) Sigma-Aldrich, Poole, UK 
Catalase Sigma-Aldrich, Poole, UK 
Chloroquine Sigma-Aldrich, Poole, UK 
Deoxyribonuclease I (DNase I) Sigma-Aldrich, Poole, UK 
Diphenyleneiodonium (DPI) Sigma-Aldrich, Poole, UK 
Dulbecco’s Modified Eagle’s Medium 
(DMEM) 
Sigma-Aldrich, Poole, UK 
Ethanoic acid Sigma-Aldrich, Poole, UK 
Ethanol Sigma-Aldrich, Poole, UK 
Ethylenediamine-tetraacetic acid (EDTA) Sigma-Aldrich, Poole, UK 
Foetal calf serum (FCS) BioSera, Ringmer, UK 
Ficoll-Paque® BD Biosciences, Oxford, UK 
Gentamycin Sanofi-Aventis, Guildford, UK 
Glucose oxidase (GOX) Sigma-Aldrich, Poole, UK 
Glycerol Sigma-Aldrich, Poole, UK 
Hank’s Balanced Salt Solution (HBSS) Invitrogen, Paisley, UK 
Heparin Leo Laboratories Ltd, UK 
Hydrochloric acid (HCl) Sigma-Aldrich, Poole, UK 
Hypoxanthine (6-hydroxypurine) Sigma-Aldrich, Poole, UK 
Iscove’s Modified Dulbecco’s Medium 
(IMDM) 
Sigma-Aldrich, Poole, UK 
L-glutamine Sigma-Aldrich, Poole, UK 
Liquid nitrogen (LN2) BOC, Guildford, UK 
Magnesium chloride (MgCl2) Sigma-Aldrich, Poole, UK 
Magnesium sulphate (MgSO4) Sigma-Aldrich, Poole, UK 
Methanol Sigma-Aldrich, Poole, UK 
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Mini EDTA-free protease inhibitor 
tablets 
Roche, Welwyn Garden City, UK 
Penicillin Invitrogen, Paisley, UK 
Phosphate Buffered Saline (PBS) Invitrogen, Paisley, UK 
Polybrene Sigma-Aldrich, Poole, UK 
Ponceau S Reagent Sigma-Aldrich, Poole, UK 
Potassium chloride (KCl) Sigma-Aldrich, Poole, UK 
Potassium dihydrogen phosphate 
(KH2PO4) 
Sigma-Aldrich, Poole, UK 
Roswell Park Memorial Institute 1640 
Culture medium (RPMI 1640) 
Sigma-Aldrich, Poole, UK 
Sodium chloride (NaCl) Sigma-Aldrich, Poole, UK 
Sodium hydroxide (NaOH) Sigma-Aldrich, Poole, UK 
Sodium orthovanadate (Na3VO4) Sigma-Aldrich, Poole, UK 
Sodium phosphate (Na2HPO4) Sigma-Aldrich, Poole, UK 
Super-Optimal medium (Catabolite-
Repressing) (SOC medium) 
Invitrogen, Paisley, UK 
Tissue culture grade H2O Hameln Pharmaceuticals, Gloucester, UK 
Tissue culture plastic ware Nunc, Roskilde, Denmark and Iwaki 
Biosciences, Iwaki, Japan 
TPA (12-O-tetradecanoylphorbol-13-
acetate) 
Sigma-Aldrich, Poole, UK 
Tris (tris(hydroxymethyl)aminomethane) Sigma-Aldrich, Poole, UK 
Triton X-100 (4-(1,1,3,3-
tetramethylbutyl)phenyl-polyethylene 
glycol) 
Sigma-Aldrich, Poole, UK a-Aldrich, Poole, 
UK 
Tween-20 (polyethylene glycol sorbitan 
monolaurate) 
Sigma-Aldrich, Poole, UK 
Xanthine oxidase Sigma-Aldrich, Poole, UK 
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Table 2.2 Growth factors 
Growth factor Manufacturer/supplier 
Human Granulocyte(G) colony-stimulating 
factor(CSF) 
Peprotech, London, UK 
Human Granulocyte-Macrophage(GM)–
CSF 
Peprotech, London, UK 
Human interleukin(IL)-3 Peprotech, London, UK 
Human IL-6 Peprotech, London, UK 
Human stem cell factor (SCF) Peprotech, London, UK 
Human Fms-like tyrosine kinase-3 
ligand(FLT3L) 
Peprotech, London, UK 
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Table 2.3 Antibodies  
 
Antibody Use Dilution Catalogue 
No. 
Manufacturer/supplier 
Aldolase C 
(ALDOC) 
Western 
Blotting 
1/1K Ab115212 Abcam, UK 
Anti-mouse HRP Western 
Blotting 
1/5K NA931 DAKO A/S, Denmark 
Anti-rabbit HRP Western 
Blotting 
1/5K NA934 GE Healthcare, UK 
Cannabinoid 
receptor 2 (CNRII) 
Western 
Blotting 
1/500 Ab3561 Abcam, UK 
Cbp/p300-
interacting 
transactivator,with 
Glu/Asp carbox 
(Cited-1) 
Western 
Blotting 
1/50K Ab92550 Abcam,UK 
CD117 Flow 
cytometry 
1/5 323408 Invitrogen ,Paisley, UK 
CD32-PE Flow 
cytometry 
1/5 MCA1075 Serotec Oxford, UK 
CD34- perCpCy5.5 Flow 
cytometry 
1/5 X0928 Biolegend, California, 
USA 
CD34-PE Flow 
cytometry 
1/5 345802 BD Biosciences, Oxford, 
UK 
Enolase 2 (ENO2) Western 
Blotting 
1/5K Ab79757 Abcam, UK 
GAPDH Western 
Blotting 
1/10K sc 32233 Santa Cruz, California 
Glycine 
amidinotransferase 
(GATM) 
Western 
Blotting 
1/500 Ab107500 Abcam, UK 
IgG1-PE Flow 
cytometry 
1/5 400148 BD Biosciences, Oxford, 
UK 
IgG1-perCpCy5.5 Flow 
cytometry 
1/5 409311 Biolegend California, 
USA 
Protein tyrosine 
phosphatase 
receptor type D 
(PTPRD)  
Western 
Blotting 
1/500 Ab103013 Abcam, UK 
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2.1.2 REAGENTS FORMULATIONS 
Table 2.4 Formulations of reagents, buffers and solutions  
 
Reagent Formulation 
Diogenes buffer (Chapter 3) 4.6 mM KH2PO48.0 mM Na2HPO4, 130.0 
mM NaCl, 4.4 mM KCl, 5.5 mM glucose, 
0.5 mM MgCl2, 0.5 mM CaCl2, 0.1% BSA, 
dissolved in dH2O, pH 7.4 
Loading buffer (section 2.2.4) 62.5 mg 0.25% Bromophenol blue, 62.5 mg 
0.25% xylene cyanol , 7.5 ml 30% glycerol, 
dissolved in H2O  
Lysis byffer (section 2.9.1) 10 mM HEPES-KOH, 10 mM 
betamercaptoethanol, 1mM magnesium 
acetate, 0.5 mM EDTA, 0.5 mM EGTA, 
0.25 M sucrose, 1 mM Na3VO4, 1 complete 
protease inhibitor tablet per 10 ml, dissolved 
in dH2O, pH 7.2. 
Magnetic activated cell sorting (MACS) 
buffer (section 2.4.2) 
PBS consisting of 0.5% BSA, 5 mM MgCl2, 
dissolved in dH2O, 0.45µm filtered, 
degassed under negative pressure for 30 
minutes.  
Media mix(Table 2.6 and Chapter 5) IMDM containing 1 % BSA fraction V, 20 
% FCS, 45 µM beta-mercaptoethanol, 360 
µg/ml 30% iron-saturated human transferrin 
Ponceau S (section 2.9.3) 1.3 mM Ponceau S dissolved in 0.83 M 
ethanoic acid 
Staining buffer for flow 
cytometry(section 2.10) 
PBS consisting of 1% BSA, 3.1 mM NaN3, 
dissolved in dH2O 
Selective Luria-Bertani (LB) 
broth(section 2.2.1) 
10g Tryptone, 5g yeast extract 5g NaCl 
dissolved in 1 L dH2O, pH 7. 100 µg/ml 
ampicillin added just before use. Selective 
LB agar: 35g of LB agar dissolved in 1L of 
dH2O. 100 µg/ml ampicillin added just 
before use 
TBS-Tween-20 (TBS-T) (section 2.9.3) TBS consisting of 0.1% Tween-20. Tris-
EDTA (TE) buffer: 10 mM Tris-HCl, 1 mM 
EDTA, pH 7.5 
Tris-buffered saline (TBS) (section 2.9.1) 1 M Tris-HCl, 130.0 mM NaCl, dissolved in 
dH2O, pH 7.6 
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2.2 RECOMBINANT DNA TECHNIQUES 
2.2.1 BACTERIAL TRANSFORMATION  
The generation of plasmid DNA for subsequent transfection of virus-packaging 
cells was achieved by DNA amplification in chemically competent Escherichia coli 
(E.coli). Recombinant plasmid DNA was added directly into one freshly thawed vial of 
competent E.coli (One Shot ®Stbl3™  Invitrogen) followed by gentle tapping. The 
mixture was incubated on ice for 30 minutes, heat shocked for 30 seconds at 42°C in a 
water bath, and then placed on a rotary shaker at 225 rpm for 1 hour at 37°C in pre-
warmed SOC medium. During this time, selective Luria-Bertani (LB) agar plates were 
prepared by melting LB agar which was allowed to cool to 42-48°C before adding the 
appropriate antibiotic (Table 2.5). LB agar (30 ml) was poured into 90 mm petri dishes and 
was allowed to cool.  
Following incubation, transformed E. coli suspension (150 µl) was spread over 
selective LB agar plates using a sterile spreader and incubated for 16 h at 37°C. Single 
isolated colonies were picked and used to inoculate 5 ml selective LB broth cultures 
containing 100 µg/ml of antibiotic. The inoculated broths were incubated for 8 h at 37°C 
on a rotary shaker and then diluted in selective LB broth at 1:500 (300 µl of culture in 150 
ml LB broth (section 2.1.2) and incubated for 16 h at 37°C on a rotary shaker. The 
following day DNA was purified from these bacterial cultures as described in section 2.2.3. 
Bacterial glycerol stocks were also prepared (section 2.2.2) and plasmid identity was 
verified (section 2.2.4). Purified DNA was used for transfection of Phoenix or 293T cells 
(section 2.5 for the method and Table 2.7 for cell line information). 
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Table 2.5 Plasmid DNA constructs  
Plasmid DNA 
construct 
Vector Antibiotic 
resistance 
Other details/source 
PINCO retroviral  Ampicillin  
pHIV ALDOC 
EGFP 
Lentiviral Ampicillin 2.2.5 and Chapter 5 
pEXK-ALDOC Cloning vector Kanamycin Eurofins, Germany 
pHIV-EGFP Lentiviral Ampicillin Addgene 
pLJM1-EGFP Lentiviral Ampicillin Addgene 
pMD2 Packaging(envelope) Ampicillin Addgene 
psPAX2  Packaging (gag/pol) Ampicillin Addgene 
 
 
CHAPTER 2: GENERAL MATERIALS AND METHODS 
79 
 
 
2.2.2 CRYOPRESERVATION OF TRANSFORMED BACTERIA 
 LB broth (850 µl) containing transformed E. coli cell suspension was mixed 
with 150 µl glycerol and transferred to -80°C freezer for long term storage. Cryopreserved 
E.coli was recovered from storage by scrapping the glycerol stock with a sterile loop and 
then streaking selective LB agar plates. Agar plates were incubated for 16 h at 37°C in a 
dry incubator. Single colonies were harvested and expanded in selective LB broth as 
described above (section 2.2.1). 
2.2.3 ISOLATION AND QUANTITATION OF AMPLIFIED RECOMBINANT PLASMID 
DNA 
Transformed E.coli which had been incubated in 150 ml selective LB broth for 
16 h at 37°C on a rotary shaker were collected by centrifugation at 6,000 g for 15 min, and 
high-purity plasmid DNA was obtained using the HiSpeed MiniPrep and/or Maxiprep 
DNA isolation kit (Qiagen, Crawley, UK) as in accordance to the manufacturer’s 
instructions. Purified DNA was quantitated using a NanoDrop spectrophotometer (Thermo 
Fisher Scientific, Loughborough, UK) as in accordance to the manufacturer’s instructions. 
The purity of DNA was confirmed by A260/A280 which was in the range of 1.8-2 in all 
the experiments carried out in this study. The integrity of the insert and other recombinant 
plasmids were checked and verified by restriction enzyme digestion (section 2.2.4) and 
sequencing (2.2.5). 
2.2.4 RESTRICTION ENZYME DIGESTION 
In order to support the verification of the cDNAs insertion into the plasmid of 
choice and the successful transformation of E. coli, plasmid DNA was isolated as above 
(section 2.2.3) and incubated with the suitable restriction enzymes in a water bath (specific 
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details are in the individual chapters). An agarose gel (0.8%) was prepared by dissolving 
agarose powder in 1X (Tris-borate EDTA (TBE) buffer. The gel bed was cast and allowed 
to solidify in an electrophoresis tank. DNA samples for loading consisted of 100-500 ng 
DNA, in 20 l of loading buffer) of which 12 µl was loaded per lane. Electrophoresis of 
the samples was carried out in 1X TBE buffer at 80V for 1 hour and DNA was visualised 
using peqgreen DNA dye and UV transillumination by a LAS-3000 digital imaging device 
(Fujifilm UK Ltd., Bedford, UK). The size of DNA plasmids or fragments was estimated 
using a 1 Kb DNA Ladder (New England Biolabs, NEB, UK), which was run in parallel 
with samples. The product of DNA restriction enzyme digestion was compared to the 
predicted restriction pattern obtained from pDRAW32 
(http://www.acasoft.dk/acaclone/download/install.htm). Specific details are in the 
individual chapters. 
2.2.5 GENERATION OF LENTIVIRAL EXPRESSION CONSTRUCT FOR ALDOC  
ALDOC coding sequence DNA was excised from pEXK-ALDOC plasmid 
(Table 2.5) using both Sma1 and Xba1 double restriction digests (Chapter 5 for results). 
Plasmid DNA (pEXK-ALDOC) (7 µg) was incubated with Sma1 (70 U) at 25°C for 1 hour 
followed by addition of Xba1 (70 U) and further 1 hour incubation at 37 °C in a water 
bath. The recipient pHIV EGFP lentiviral vector (Table 2.5) (already available in our lab) 
was linearized using the same restriction digest. Following digestion, the insert (ALDOC) 
was purified using preparative electrophoresis coupled with low melting point agarose gels 
(1X Tris-acetate gel with Seakem GTG (1.0%)) (Section 2.2.4). Following electrophoresis, 
the smallest gel slice containing the insert was visualized using peqgreen DNA dye and 
excised from the gel. The DNA insert was extracted from the gel and purified by passing 
DNA sample through a QIAquick Gel extraction Spin kit (Qiagen) according to the 
manufacturer’s instructions (section 2.2.4). DNA was finally eluted in 50 µl elution buffer 
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(EB). The insert (ALDOC) and vector (pHIV-EGFP) were ligated by incubation with 
ligase and ligase buffer at 16 °C for 4 hours in order to generate recombinant plasmid 
DNA, pHIV ALDOC EGFP which was used in subsequent experiments. The ligation 
mixture was then transformed as described in section 2.2.1.  
The final construct was verified by both test digests and direct sequencing. Test 
digests were performed using a similar protocol to the one described in 2.2.4 and 
sequencing was performed using the Eurofins sequencing service, (Eurofins, Germany). 
The results and specific details are in the individual chapters. 
2.3 CELL CULTURE  
2.3.1 CRYOPRESERVATION AND THAWING OF CELL SAMPLES 
Cell suspension, 500 µl in suitable growth medium was mixed with 500 µl of 
Iscove’s Modified Dulbecco’s Medium (IMDM) (Table 2.1) consisting of 30% FCS and 
20% DMSO (freeze mix). Samples were transferred to 1.8 centrifuge vials and placed in 
controlled refrigeration containers (Mr. Frosty) where 100% isopropanol is used as the 
thermal interface. These controlled refrigeration containers were then placed in a -80°C 
freezer overnight. The following day, samples were transferred to liquid nitrogen N2 for 
long term storage. 
The recovery of cryopreserved CD34+ cells and cord blood was achieved by 
rapid defrosting in a water bath at 37°C in the presence of 900 µl 0.45µm-filtered FCS and 
200 µg sterile DNase I. The cells were then diluted by dropwise addition of equal volumes 
of MACS buffer over 3 min twice, followed by centrifugation of cells at 180 g for 10 
minutes. The recovered cells were resuspended in a suitable growth medium (section 2.3.3) 
and allowed to recuperate for 16-24 h at 37°C in a 5% CO2 humidified atmosphere prior to 
use for experimental endpoints (Chapters 3-5). 
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Cryopreserved cell lines, were recovered by rapid defrosting them in a 37°C 
water bath followed by dropwise addition of 5 ml suitable growth medium, centrifugation 
of cell lines at 180 g for 5 min and resuspension in growth medium (section 2.3.3). Cell 
lines were also allowed to recuperate for 16-24 h at 37°C in a 5% CO2 humidified 
atmosphere. 
2.3.2 DETERMINATION OF CELL DENSITY 
Cells were counted before each passage by the use of haemocytometer 
(Hawksley, Brighton, UK) in order to estimate cell density (number of cells per volume of 
medium) before sub-culturing or for use in the experiments. The haemocytometer chamber 
was filled with 8 µl of cells from a known total volume of the cell suspension and placed 
into a counting chamber with the coverslip in place. Cell count was performed under the 
microscope using a hand held counter. The haemocytometer is etched with ruled lines 
marking a counting space which has a known volume (0.9 µl). This volume is subdivided 
by ruled lines into 9 cuboids equivalent to 100 nl each. The cellularity (density) of cells/ml 
is given by the average number of cells per cuboid multiplied by 1 × 104.   
2.3.3 CULTURE OF PRIMARY CELLS AND CELL LINES 
Cell lines (Table 2.6 and Table 2.7) were obtained from ATCC (Teddington, UK) unless 
otherwise stated, and cultured at 37°C in a humidified 5% CO2 atmosphere in RPMI 1640 
containing 10% FCS and 20 µg/ml gentamycin, unless otherwise stated. For primary cell 
cultures, the age of the culture is indicated in days since isolation. 
2.3.3.1 Non-adherent cells 
Cell lines were cultured (Table 2.6) and cell density was determined as described (section 
2.3.2).  
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Table 2.6 Culture details for non-adherent cells 
Cells Description Density 
(cells/ml)
Usual culture conditions 
CD34+ Primary cells from 
human cord blood 
2-4x105  Media mix (section 2.1) supplemented 
with 5 ng/ml human(hu) IL-3, huG-CSF, 
huGM-CSF, 20 ng/ml huSCF 
HL60 promyelocytic cell line 2-5x105  RPMI 1640 
Sub-culturing ratio 1:2 with fresh medium 
as necessary or every 24-36 hours. 
KG-1 Human acute 
myelocytic leukaemia 
2-5x105  IMDM 
With 20% FCS and 4mM L-Glutamine 
MV4-
11 
Human acute 
myelocytic leukaemia 
2-5x105  IMDM 
With 10% FCS and 2mM L-Glutamine 
K562 Human Chronic 
Myeloid Leukaemia 
2-5x105  RPMI1640 
THP-1 Human Monocytic 
Leukaemia 
2-5x105  RPMI1640 
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2.3.3.2 Adherent cells 
Adherent cells (Table 2.7) were cultured in DMEM with 10% FCS and 20 µg/ml 
gentamycin. Confluent cultures were detached from cell culture plastic ware by incubation 
with 1 ml 500 µg/ml trypsin solution containing 0.53 mM EDTA for 3 min. Trypsin was 
neutralised with 5 ml warm growth medium. Cells were disaggregated by pipetting, 
centrifuged for 180 g for 5 min and resuspended in fresh growth medium. The sub-
culturing of cells was performed as described in the table for each type of cells. 
Table 2.7 Culture details for adherent cells 
Cells Description Source  Sub-culture 
details 
Phoenix virus –
packaging cells 
retroviral-packaging 
cells 
Garry Nolan (Stanford 
University) 
Ratio 1:3 as 
necessary or every 
36 hours. 
HeLa cell line derived from 
cervical cancer cells 
 Ratio 1:4 as 
necessary or every 
72 hours. 
293T Isolated from human 
embryonic kidneys 
(HEK) and transformed 
with large T antigen 
 Ratio 1:6 as 
necessary or every 
72 hours. 
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2.4 ISOLATION OF NORMAL HUMAN CD34+ HAEMATOPOIETIC 
PROGENITOR CELLS FROM CORD BLOOD 
2.4.1 ISOLATION OF HUMAN MONONUCLEAR CELLS FROM CORD BLOOD 
Human cord blood was obtained from full-term pregnancies at the Maternity 
Unit, (University Hospital Wales, UK) with informed consent and approval from the South 
East Wales Research Ethics Committee. Cord blood samples were collected into tubes 
containing heparin (500 µl) and followed by the immediate isolation of mononuclear cells 
by density centrifugation using Ficoll-Paque®. Cord blood was diluted with an equal 
volume of Hank’s balanced salt solution (HBSS) consisting of 25 mM HEPES, 100 µg/ml 
gentamycin and 1 U/ml heparin and 7 ml of the diluted blood was layered onto 5 ml of 
Ficoll-Paque® and centrifuged at 400 g for 40 min. A separate layer of mononuclear cells 
was formed at the plasma-Ficoll interface and was recovered, washed with RPMI 1640 
containing 5% FCS and 1 U/ml heparin. These mononuclear cells were then recovered by 
centrifugation at 200 g for 10 min and were washed again in RPMI 1640 containing 10% 
FCS until there was no platelet contamination. Cells were finally counted using a 
haemocytometer (section 2.3.2) and stored in liquid nitrogen until when they are needed 
(section 2.3.1). 
2.4.2 ISOLATION OF HUMAN CD34+ HAEMATOPOIETIC CELLS FROM 
MONONUCLEAR CELLS 
Human CD34+ haematopoietic progenitor cells were isolated from mononuclear 
cells using the miniMACS® CD34+ Progenitor Cell Isolation Kit (Miltenyi Biotec, Bisley, 
UK) by positive selection. This was performed according to the manufacturer’s 
instructions. Previously prepared, cryopreserved mononuclear cells were thawed and 
resuspended in MACS buffer (section2.1.2) at 6.5x108 cells/ml and then incubated at 4°C 
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for 15 min with 50 µl anti-CD34 antibody (Table 2.3) per 108 cells in the presence of an 
FcR blocking agent. Cells were subsequently washed with 5 ml MACS buffer by 
centrifugation at 180 g for 5 min. These mononuclear cells were then incubated at 4°C with 
magnetic anti-Fc microbeads followed by washing as above. Magnetically-labelled CD34+ 
cells were passed through an MS+ separation column and hence were isolated from total 
mononuclear cells. CD34+ cells were therefore eluted from the column in the absence of a 
magnetic field by rinsing the column with 1 ml MACS buffer.  
In order to check for the  purity of CD34+ cells, 1x104 of isolated CD34+ cells 
were stained with anti-human CD34 antibody conjugated to R-phycoerythrin (PE) (BD 
Biosciences), and analysed by flow cytometry (section 2.10). Isolated CD34+ cells were 
cultured in IMDM containing 1% BSA, 20% FCS, 45 µM beta-mercaptoethanol, 360 
µg/ml 30% iron-saturated human transferrin, penicillin, 100 µg/ml streptomycin,  50 ng/ml 
huIL-3, huSCF, huFLT3L and 25 ng/ml huIL-6, huG-CSF and huGM-CSF (Table 2.2). 
These were then used in Chapter 3-Chapter 5. 
2.5 GENERATION OF RETROVIRUS 
The transfection of Phoenix virus-packaging cell line (Table 2.7) was achieved 
by the use of the previously prepared PINCO plasmid DNA (non-translated DNA stuffer 
fragment/GFP control or N-RASG12D) from transformed E.coli in order to generate 
recombinant retrovirus. A total of 6 million phoenix cells were seeded in F75 flasks for 
each of the DNA constructs on day 0. The following day, cell confluence was checked (~ 
95 %) and the media refreshed. For transfection an aqueous solution (450 µl) containing 
10-45 µg plasmid DNA and 250 mM CaCl2 was added slowly-dropwise to 2 HEPES-
Buffered Saline (HBS) which was bubbled at the same time using a pipette boy with 1ml 
pipette tip attached .The mixture was vortexted for 2-4 seconds and the precipitate was 
kept undisturbed for 20 minutes during which time 25 µM chloroquine was added to the 
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cell cultures. At the end of 20 minutes, the precipitate was added to each of the flasks and 
incubated overnight in a humidified CO2 atmosphere. The next day the medium was 
replaced with 8ml of fresh medium in preparation for harvest the following day and 
incubated overnight at 33 °C. On day 3, retrovirus was harvested and the media was 
replaced with the fresh one for a second harvest. Medium (8 ml) was removed, transferred 
to a UC, centrifuged at 200 g for 10 minutes to remove residual cells, aliquoted into 
cryotubes, snap frozen in liquid nitrogen and then stored in a freezer at -80°C. The virus 
was harvested for the second time the following day as for day 3.  
2.6 RETROVIRAL TRANSDUCTION OF HUMAN CD34+ 
HAEMATOPOIETIC PROGENITOR CELLS 
In order to generate human haematopoietic progenitor cells expressing mutant 
N- RAS (N-RASG12D), CD34+ cells were isolated as above (section 2.4) from neonatal cord 
blood and transduced with the retroviral vector PINCO encoding full-length N-RASG12D 
and GFP or empty vector control (GFP alone) generated in section 2.5. Firstly, 24 well 
untreated tissue culture plates were coated with 150 µl retronectin (Takara, Shiga, Japan) 
overnight. On the first day of infection, the plates were ‘blocked’ with 200 µl 1% BSA 
solution for 30 minutes, 1ml of virus was added per coated well and centrifuged at 1400 g 
for 90 minutes at room temperature. At the end of the spin, the supernatant was removed, 
replaced with the appropriate volume of cells, centrifuged briefly at 180 g for 3 minutes 
and incubated at 37°C in a humidified 5% CO2 atmosphere. The following day the 
infection process was repeated as above using fresh retroviruses. It is important to note that 
a mock control (CD34+ cells treated with 1 ml of medium) was included for comparisons. 
Finally cell transduction frequency was assessed by flow cytometry to detect GFP 
expression (section 2.10) and cells were either cryopreserved (section 2.3.1) or continued 
in culture (Table 2.6) for determination of other experimental endpoints.  
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2.7 GENERATION OF LENTIVIRUS 
Recombinant lentivirus was generated by the transfection of 293T cell line 
(Table 2.7 ) using previously prepared plasmid DNA (Table 2.5) from transformed E.coli. 
A total of 8.5 million 293T cells were set up in the appropriate poly-L-lysine coated F75 
flasks which helped to stabilize the cell monolayer. The following day, cell confluence was 
checked (above 50 %) and the overnight media (15ml) was refreshed (15 ml). For 
transfections a mixture of appropriate volumes of water, DNA transfer vector, packaging 
vectors-pMD.2G (envelope plasmid) and psPAX2 (packaging plasmid) (Table 2.5) was 
prepared. Transfection of these DNAs was carried out as described in (section 2.5). The 
next day the medium was replaced with 7.5 ml of fresh medium in preparation for harvest 
and incubated overnight 37°C in a humidified CO2 atmosphere. Lentivirus was harvested 
the following day and the medium was replaced for a second harvest the next day and 
cells. On the final harvest day, medium (7.5 ml) was removed, transferred to a UC, 
centrifuged at 200 g for 10 minutes to remove residual cells, supernatant (virus) was 
carefully aliquot into cryotubes, snap frozen in liquid nitrogen and then stored in a freezer 
at -80°C.  
 
2.8 LENTIVIRAL TRANSDUCTION OF CELL LINES 
Untreated 24 well tissue culture plates were coated with 150 µl retronectin 
overnight. On the first day of infection, the plates were blocked with 200 µl 1% BSA 
solution for a minimum of 30 minutes and 1ml of virus was added per coated well and 
centrifuged at 1400 g for 90 minutes at room temperature. At the end of the spin, the 
supernatant was removed and replaced with the appropriate number and volume of cells (4 
x105 cells in 1ml) and incubated at 37°C in a humidified 5% CO2 atmosphere. For cells 
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transduced with GFP, transduction frequency was assessed the following day cell by flow 
cytometry (section 2.10). It is noteworthy that appropriate controls (parental cell lines) 
were included for comparison and the determination of the thresholds (results in the 
individual chapters). For cells transduced with the puromycin resistance marker, see 
Chapter 5 section 5.2.1.3 for more detail.   Cells were either cryopreserved (section 2.3.1) 
or continued in culture (Table 2.6) for determination of other experimental endpoints.  
2.9 WESTERN BLOTTING 
2.9.1 PREPARATION OF PROTEIN EXTRACTS FROM WHOLE CELLS 
Cells were harvested, counted, washed twice in 20 ml of TBS then centrifuged at 
180 g for 10 min and the supernatant was removed. The cell pellet was then flash frozen in 
liquid N2 to enable full cell fragmentation and stored at -80°C until ready for processing. 
Volumes of protein extracts were recorded during extraction for use in total protein 
quantitation.  
Whole cell protein extracts were prepared by thawing flash frozen cell pellets 
(prepared as described above) on ice in the presence of 10 µg DNase I per 1x106 cells. 
Thawed cells were resuspended in a minimum of 50 µl lysis buffer containing 1% Triton 
X-100 per 1x106 cells (section 2.1.2) and incubated on ice for 30 min with occasional 
vortexing to encourage protein solubilisation. Detergent-insoluble material was sedimented 
by centrifugation at 16,000 g for 5 min at 4°C and supernatants were transferred to pre-
chilled Eppendorf tubes. Protein concentration was determined as described in (section 
2.9.2) and protein extracts were stored at -80°C until when needed. 
2.9.2 PROTEIN QUANTITATION 
The concentration of protein in the extracts prepared above was determined 
using Bradford’s reagent (Sigma-Aldrich, UK). Bradford’s stock reagent was diluted with 
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an equal volume of ultra-pure water (ratio 1:1) to create enough working solution for the 
test (190 µl per test well).  Protein extracts were diluted a minimum of 10 fold. The diluted 
extract (10 µl) was mixed with 190 µl diluted Bradford’s reagent in a 96-well plate and 
samples were tested in duplicate. BSA standard solutions were assayed in duplicate as well 
alongside protein extract samples to create a standard curve, which allowed calculation of 
protein extract concentration. Absorbance was measured at 590 nm using an ASYS Hitech 
Expert plus spectrophotometer (Biochrom, Cambridge, UK).  
2.9.3 PROTEIN ELECTROPHORESIS AND ELECTROBLOTTING 
XCell SureLockTM electrophoresis and electroblotting system (Invitrogen, UK) 
was used for protein electrophoresis and electroblotting. All the reagents, buffers and gels 
used in this process were purchased from Invitrogen. All protein extracts were incubated at 
70°C for 10 min in the presence of 1X LDS sample buffer and reducing agent to facilitate 
denaturation of proteins just before  electrophoresis. Denatured protein samples (0.7-10 µg 
protein per lane) were loaded onto a 4-12% Bis-Tris HCl polyacrylamide gel and 
electrophoresis was performed at 200 V for 50 min in the XCell SureLockTM Mini-Cell in 
the presence of MOPS-SDS running buffer. Proteins were then electroblotted from the 
electrophoresis gel onto nitrocellulose membranes using the XCell SureLockTM Mini-Cell 
blot module. Gels were removed from their cassettes and placed into layers containing 2 
blotting pads on top, the gel and membrane sandwiched between blotting filter paper and 3 
additional blotting pads at the bottom. The module was placed in XCell SureLockTM Mini-
Cell and with transfer buffer (1X NuPAGE® Transfer buffer, 1 ml NuPAGE® and 10% 
methanol). Electroblotting of proteins was carried out at 30 V for 1 hour.  
At the end of electroblotting, membranes were washed twice with 20 ml of 
dH2O for 5 min on a shaker to remove gel and other transfer buffer components. These 
membranes were then incubated with Ponceau S solution (section 2.1.2) for 30 sec to 
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visualise transferred protein, equal loading, and in some cases to facilitate membrane 
cutting between lanes.  Two further washes with dH2O were done as above, membranes 
were incubated with 10 ml TBS-T containing 2.5 % membrane blocking agent (Marvel) for 
1 h at room temperature on a rotary shaker. Blocked membranes were rinsed twice with 10 
ml TBS-T followed by one 15 min wash and three 5 min washes (with 10 ml TBS-T) on a 
rotary shaker.  
2.9.4 IMMUNOPROBING OF ELECTROBLOTTED PROTEINS 
Membranes previously blocked and rinsed above (section 2.9.3) were incubated 
at 4°C for 16 h (overnight) in the presence of primary antibody diluted in TBS-T 
containing 2.5 % blocking agent. Optimum dilutions of previously untested primary 
antibodies were determined. Details of specific antibodies used are in Table 2.3 and will 
further be given in the appropriate results sections. Outer lanes of gels were loaded with 
10-20 µl of 1X LDS buffer containing a 20 fold dilution of MagicMark XP® Protein 
Standard (Invitrogen) for the estimation of molecular weight of proteins. To verify equal 
loading, membranes were incubated overnight at 4°C on a rotary shaker with one of the 
following antibodies: 20 ng/ml anti-GAPDH (Santa Cruz) or 10 ng/ml anti-β-actin 
(Abcam, Cambridge, UK) (Table 2.3).  
Membranes were rinsed two times, washed once for 15 min and three times for 5 
min in a rotary shaker as above after incubation with the primary antibody.  Membranes 
were then incubated with diluted (5x104 fold) HRP-conjugated anti-mouse or anti-rabbit 
secondary antibody (GE Healthcare) in TBS-T containing 1% membrane blocking agent 
for 1 h on a rotary shaker. Membranes were finally rinsed two times, washed once for 15 
min and three times for 5 min in a rotary shaker as above. 
Electroblotted proteins labelled with primary and secondary antibodies were 
visualised using ECL Prime Advance® Western Blotting Detection Kit (GE Healthcare). 
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Excess wash buffer was drained from immunolabelled membranes and then incubated 
under low light for 5 min at room temperature with reconstituted ECL Advance®. ECL 
Advance® solution was then decanted, excess solution was removed using blotting paper, 
membranes were placed between two sheets of clean acetate and ECL Advance® 
chemiluminescence was detected using a LAS-3000 digital imaging device (Fujifilm UK). 
Digital images were processed and analysed using AIDA Image Analyzer v4.19 (Fujifilm 
UK) and Photoshop (Adobe Photoshop CS6 extended, UK). 
2.10  FLOW CYTOMETRIC ANALYSIS 
Cells were recovered from growth medium by centrifugation at 180 g for 5 min 
and then washed by resuspension in 1 ml staining buffer (section 2.1.2) per 1x106 cells 
unless otherwise stated for flow cytometric data acquisition and analysis using a C6 flow 
cytometer (BD Bioscieces, UK). Cells were then resuspended in 25 µl staining buffer 
(unless otherwise stated) and incubated with primary stage antibodies or other reagents 
according to the experimental protocols described in the appropriate results sections.  
Successive staining stages such as incubation with secondary antibodies were 
separated by a wash step involving resuspension in 200 µl staining buffer, centrifugation 
and resuspension in 25 µl of staining buffer unless otherwise stated. Background 
fluorescence was determined by isotype and manufacturer-matched control antibodies 
conjugated to the same fluorochromes for conjugated antibodies. For flow cytometric 
measurement of reporter gene expression, the autofluorescence of mock-infected cultures 
defined the threshold for GFP positivity and the threshold for positive staining was set to 
95% of background fluorescence (specific details are in the individual chapters). Samples 
were resuspended in a maximum of 100 µl FACS flow prior to data acquisition.  A C6 
flow cytometer was used for data acquisition, a minimum of 10,000 events were collected 
and analysed using FCS Express v3 (De Novo Software, Los Angeles, CA).  
CHAPTER 2: GENERAL MATERIALS AND METHODS 
93 
 
2.11 STATISTICAL ANALYSES 
Significance of difference was determined using Student’s t-test using Minitab 
v17.0 (Minitab Ltd., Coventry, UK) or as indicated in the results chapters. Other statistical 
tests used are described in the results chapters. 
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3 Examination of ROS production 
by human CD34+ haematopoietic 
cells and preparation of 
microarrays 
It has previously been shown that mutational activation of RAS in human 
primary haematopoietic stem/progenitor cells gives rise to deregulated development 
characteristic of preleukaemia (Darley et al., 1997; Darley et al., 2002; Pearn et al., 2007). 
Further, mutant RAS expression has been shown to disrupt the differentiation of normal 
CD34+ haematopoietic cells (Darley and Burnett, 1999). More recently it has been shown 
that both H-RAS and N-RAS promote the production of reactive oxygen species (ROS), 
including superoxide by these cells via increased NADPH oxidase (NOX) activity (Hole et 
al., 2010). Growing evidence suggests that ROS are at least partly responsible for the 
mutant RAS phenotype observed in several cell models (Irani et al., 1997; Liu et al., 2001; 
Cho et al., 2002; Lee et al., 1999). ROS have the potential to modulate cell signalling; 
however the direct effects of ROS on gene transcription are unknown. It is also noteworthy 
that transcriptional dysregulation is a key element in leukaemogenesis (Chapter 1). 
Therefore this study was undertaken to determine the contribution of ROS production to 
the changes in gene expression arising from expression of mutant RAS. This chapter 
investigates the effects of activated RAS expression on ROS production by primary human 
CD34+ haematopoietic cells and optimises conditions for microarray analysis. 
 
 
 
 
 
3 
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3.1 AIMS 
 Optimise and validate assays for the measurement of ROS using Diogenes and 
its inhibiton by DPI (a NOX oxidase inhibitor). 
 Determine whether mutant N-RASG12D can induce ROS production in human 
CD34+ haematopoietic progenitor cells and to confirm ROS inhibition in 
samples prepared for Gene Expression Profiling (GEP). 
 RNA isolation and quantification from all samples prepared GEP. 
 Generate GEP data using GeneChip® Human Exon 1.0ST arrays (Affymetrix UK 
Limited) to investigate the effect of mutant N-RASG12D and ROS on gene 
expression. 
3.1.1 EXPERIMENTAL DESIGN 
To achieve the above aims four treatment conditions: CD34+ cells transduced 
with N-RAS (test) or GFP vector (control) incubated in the presence and absence of DPI to 
determine the ROS-specific GEP (Figure 3.1). DPI is a NOX-inhibitor which has been 
previously shown to block superoxide production by NOX enzymes (Hole et al., 2010; 
O’Donnell et al., 1993). N-RAS cultures without DPI would detect ROS+RAS related 
changes, while N-RAS with DPI would detect only RAS related changes (Figure 3.1). For 
detailed strategy and experiments performed see Figure 3.2 and Chapter 4 for data 
analysis. 
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Figure 3.1  Strategy for the identification of the N-RASG12D genes changes that are 
mediated by ROS. 
Summary flow diagram showing the simplified strategy and four treatment 
conditions employed for the examination of the effect of RAS and ROS on gene expression 
and the determination of the ROS specific gene expression profile. For detailed strategy 
and experiments performed see Figure 3.2 and Chapter 4 for data analysis. 
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3.2 MATERIALS AND METHODS 
3.2.1 DETECTION OF SUPEROXIDE USING DIOGENESTM 
Firstly, mutant RAS expressing CD34+ cells were generated and analysed for 
GFP positivity as outlined in Chapter 2 and summarised in Figure 3.2. In order to establish 
whether human CD34+ haematopoietic progenitor cells over-expressing mutant N-RAS 
showed increased superoxide production compared to controls, chemiluminescent assays 
using the superoxide specific probe Diogenes (National Diagnostics, Atlanta, GA) was 
used (Hole et al., 2010). Transduced CD34+  cells were washed in phosphate-buffered 
saline (PBS) (Gibco, Paisley, UK) and resuspended in Standard Buffer (SB) (KH2PO4 
4.6mM, Na2HPO4 8.0mM, NaCl 13mM, KCl 0.44mM, Glucose 5.5mM, BSA (low LPS) 
0.1%, MgCl2 0.5mM, CaCl2 0.45mM dissolved in pure water, pH 7.3) at 1x106 cells/ml. 
Cell suspension (150µl) was deposited in triplicate into FluoroNunc Maxisorp 96 well 
plate (Thermo-Fisher Scientific) and 50 µl Diogenes (prepared according to the 
manufacturer’s instructions) was added immediately to the wells. Chemiluminescence 
traces were recorded using a Hidex Chameleon (Lablogic, Sheffield, UK). 
Variations on the method above are outlined below and the details are in the 
results section. 
 In order to determine if ROS mediates oxidative stress in mutant N-RAS cells, it 
was necessary to block superoxide production in these cells using the NOX 
inhibitor DPI (Sigma, UK). Initial experiments focused on optimising the 
conditions of use for this inhibitor. First, the effect of DPI on superoxide 
production was assayed. HL60 cells were incubated for 10 seconds in the 
presence of 0-1000 nM DPI prior to stimulation with 1 M 12-0-
tetradecanoylphorbol-13-acetate (TPA). Diogenes chemiluminescence was 
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detected as outlined above. HL60 is a promyelomonocytic cell line (Table 2.6) 
with an NRAS mutation and was previously shown in our lab to be responsive to 
TPA-induced superoxide production arising from NOX oxidase activity and 
hence suitable for the current study.  
 Determined the effect of 100 nM DPI on survival of mutant N-RAS transduced 
CD34+ cells over time. 
 Determined the effect of mutant N-RAS expression on ROS production in 
human haematopoietic progenitor cells, 
Below is a summary of the main experimental design strategy prior to 
microarray experiments (Figure 3.2).  
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Figure 3.2 Overall experimental design and strategy prior to microarray experiments 
(A) Summary flow diagram showing the experiments performed prior to the 
microarray experiments for the examination of the effect of the effect of N-RAS and ROS 
on gene expression. Human CD34+ haematopoietic progenitor cells (HPCs) were isolated 
from whole cord blood using the MiniMACS system. CD34+ cells were transduced using 
the PINCO retroviral vector to generate control (GFP only) and GFP + N-RASG12D 
expressing cells. (B) PINCO retroviral vector DNA constructs. Top panel = N- RASG12D + 
GFP; Bottom = GFP control; LTR = retroviral Long Terminal Repeat; SS = Stuffer 
sequence; CMV = cytomegalovirus promoter; RAS = N-RASG12D gene. Transduced cells 
were assessed for transduction efficiency and used for experimental end points described in 
the text. 
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3.2.2 PREPARATION OF RNA FOR MICROARRAY/GEP EXPERIMENTS 
RNA was extracted and isolated from the cell cultures described in 3.2.1 using 
Trizol reagent (Life Technologies, California) with MaXtract high density tubes 
(QIAGEN, UK) as per kit method, purified using RNeasy Kit (QIAGEN, UK) and then 
finally quantified and checked for quality/integrity using the Agilent RNA 6000 Nano Kit 
(Agilent Technologies, Germany) method and Agilent 2100 bioanalyser as per 
manufacturer’s instructions.    
3.2.3 GENERATION OF GEP DATA USING HUMAN EXON 1.0ST ARRAYS 
3.2.3.1 GEP experiments using Human exon 1.0 Sense Target (ST) arrays 
 The effect of RAS and ROS on gene expression was investigated using 
GeneChip® Human Exon 1.0ST arrays as per manufacturer’s instructions. High quality 
RNA (in 3.2.2) was sent to the university service, CBS where microarray hybridisations 
were carried out. Briefly, RNA samples were processed for Affymetrix whole 
transcriptome microarray analysis using The Ambion WT Expression Kit protocol 
(Applied Biosystems, USA) by generation of cDNA from 100 ng of total RNA which was 
then fragmented, labelled, hybridized, washed and scanned using the Affymetrix GeneChip 
WT Terminal Labelling, Hybridization, wash, stain and scan kits (Affymetrix, UK) as in 
accordance to the manufacturer’s instructions.  Results obtained were imported in to Partek 
Genomics Suite Software (Version 6.6; Partek Inc., MO, USA) for analysis (Chapter 4).  
3.2.4 DATA AND STATISTICAL ANALYSIS 
All flow cytometric data were acquired using C6 flow cytometer (Accuri,UK) 
and analysed using FCS Express v3 (De Novo Software, Los Angeles, CA). Significance 
CHAPTER 3: EXAMINATION OF ROS PRODUCTION 
101 
 
of difference was analysed using the Student’s t-test calculated in Minitabv.15 (Minitab 
Ltd, Coventry, UK). For the GEP data analysis please refer to Chapter 4. 
CHAPTER 3: EXAMINATION OF ROS PRODUCTION 
102 
 
3.3 RESULTS 
3.3.1 MUTANT N-RASG12D EXPRESSED IN NORMAL HUMAN CD34+ 
HAEMATOPOIETIC PROGENITOR CELLS 
In this study, a primary human CD34+ haematopoietic cell model was used to 
investigate the effect of mutant RAS expression on ROS production. In order to generate 
mutant N-RAS expressing CD34+ cells, a retroviral vector co-expressing N-RAS and GFP 
was used as previously described (Hole et al., 2010) (Figure 3.2). CD34+ cells were 
isolated from normal human cord blood, transduced with mutant RAS and analysed by 
flow cytometry (as described in Chapter 2) for GFP expression on day 3 of culture. Figure 
3.3A shows that following retroviral transduction approximately 70% of cells were CD34+. 
GFP positivity range for the control and N-RAS samples prepared for the microarray 
experiments was (54-84%) and (64-82%) respectively. Figure 3.3B shows example data 
for the samples used in the microarray experiments.   
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Figure 3.3 Analysis of normal human CD34+ haematopoietic progenitor cells  
Transduced human CD34+ haematopoietic progenitor cells were analysed for 
CD34+ and GFP expression on day 3 of development. Representative bivariate plots of 
transduced cells for (A) CD34+ and (B) GFP expression. GFP positive threshold was 
defined by autofluorescence of mock-transduced cells (Mock). CD34+ threshold was 
determined by isotype controls. Typical percentages of CD34+ and GFP positive cells are 
shown for each culture.  
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3.3.2 OPTIMISATION OF ROS INHIBITION CONDITIONS 
3.3.2.1 Optimisation of DPI concentration required to inhibit superoxide production in 
HL60 cells  
To establish the lowest effective concentration of DPI needed to inhibit 
superoxide production, the inhibition of superoxide production in HL60 cells was 
investigated using the superoxide specific chemiluminecent probe Diogenes. The results 
showed that DPI markedly reduced superoxide production in HL60 cells at all 
concentrations tested compared to the control (Figure 3.4). At 100 nM DPI >90% 
inhibition was observed. 
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Figure 3.4  Inhibition of superoxide production in HL60 cells using DPI 
HL60 cells were treated with 0 -1000 nM DPI, prior to stimulation with TPA (1000 
nM), and superoxide production was assayed using Diogenes. Data represents mean± 1 
SD (n=3).  
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3.3.2.2 Determination of the effect of 100 nM DPI on survival of mutant N-RAS 
transduced CD34+ cells over time 
In order to check that DPI at 100 nM did not affect cell viability and was not 
toxic to cells, cell survival assays were performed. Mutant N-RAS infected cells were 
incubated with 100 nM DPI for 0 - 72h followed by cell viability analysis using Annexin V 
and 7AAD by flow cytometry which are markers for early and late apoptosis respectively. 
As shown in Figure 3.5, the survival of CD34+ cells was not significantly affected at any 
time point tested though at later time-points there was a trend to decreased cell survival 
compared to untreated controls. Taken together, the above data suggests that 100 nM of 
DPI is capable of inhibiting superoxide production in haematopoietic cells with no loss in 
viability up to a period of 24 hours. 
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 Figure 3.5 The effect of 100nM DPI on survival of mutant N-RAS transduced CD34+ 
cells over 72 hours  
N-RAS expressing cells or control cells expressing GFP alone (day 3 of culture) 
were incubated with 100 nM DPI for 0-72 hours followed by cell viability analysis using 
Annexin V and 7AAD by flow cytometry: (A) representative data and (B) summary of the 
overall results for both control and N-RAS.  No error bars generated since n=1. 
 
A
B
No DPI + DPI 
Control
N-RAS
0
10
20
30
40
50
60
70
80
90
100
0 h
24 h
34 h
72 h
Control N-RAS
C
el
l v
ia
bi
lit
y 
(%
)
0 h 
24 h
48 h 
72 h
CHAPTER 3: EXAMINATION OF ROS PRODUCTION 
108 
 
 
3.3.3 OPTIMISATION OF CULTURE MEDIA CONDITIONS FOR THE MEASUREMENT OF 
ROS DIRECTLY IN CULTURE IN PREPARATION FOR GEP  
To check whether the optimum dose of DPI in the Diogenes assay was effective 
in the context where the cells were harvested for microarrays it was necessary to measure 
ROS production directly in the cell culture medium. Three different phenol red free media 
formulations were investigated. As shown in Figure 3.6, medium 3 (phenol-red free media 
with 10% FCS and without transferrin and BME) was found to be the best medium for 
ROS measurement directly in culture using Diogenes probe since this showed a marked 3 
fold increase in ROS production in N-RAS compared to the control whilst other media 
showed lower but also marked increase (2 fold and 2.5 fold for media 1 and 2 
respectively).  
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Figure 3.6 Assessment of different media for the measurement of ROS directly in 
culture 
Diogenes chemiluminescence was measured using a luminometer directly in 
culture media. The graph is a representative of superoxide release by N-RASG12D 
expressors or control cells in 3 different phenol red free media mix (Chapter 2): Medium 1 
=  with transferrin, BME and 20% FCS, Medium 2 = without transferrin and BME but with 
20% FCS, Medium 3 = as 2 but with 10% FCS. No error bars generated since n=1. 
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3.3.4 CHARACTERISATION OF CULTURES USED FOR MICROARRAY ANALYSIS  
In order to confirm that human haematopoietic progenitor cells overexpressing 
mutant N-RAS produced elevated ROS compared to controls, chemiluminescent studies 
were performed using the superoxide specific probe Diogenes in the presence and absence 
of the 100 nM DPI. Optimised media conditions (see above) were used (medium 3).  
Significant 8 fold increase in superoxide production by N-RAS mutants was observed as 
compared to the controls (Figure 3.7). ROS (superoxide) levels were successfully and 
significantly inhibited by DPI (indicated by 90 % inhibition P < 0.05). Because DPI 
inhibits NOX oxidase activity, these results suggest that nearly all of the superoxide 
produced is derived from oxidase activity.  
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Figure 3.7 Expression of mutant N-RAS increases superoxide (ROS) production in 
normal human haematopoietic cells 
Superoxide production was measured using Diogenes in the presence or absence 
of NOX family inhibitor (DPI) on day 7 of culture in medium 3. Cells were exposed to 100 
nM DPI for 18 h prior to these measurements. (A) Representative chemiluminescence trace 
of superoxide production. (B) Summary of the overall results for both Control and N-RAS.  
Data represents mean ± 1SD (n=5). Statistical significance was determined by Student’s t-
test.  * denotes statistically significant P<0.05. 
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3.3.5 RNA QUALITY AND INTEGRITY DATA 
Using Trizol reagent, RNA was extracted from cell cultures described in 3.3.4 
and Figure 3.7 on day 7 of culture. The quality and integrity of the RNA was assessed 
using the Agilent RNA 6000 Nano Kit protocol.  High RNA quality and integrity (free 
from DNA, contaminating proteins, ethanol, phenol and salts) are required for the best 
microarray results. RNA sample integrity is a crucial aspect of RNA quality which is the 
proportion that it is full length. The mRNA is likely to be full length if the 28S and 18S 
rRNA bands are resolved into two descrete bands and the 28S rRNA band intensity is 
approximately twice the size of the 18S rRNA band which was clearly the case for all the 
samples tested, Figure 3.8A and B. Analysis of rRNA ratio [28S/18S] and RNA integrity 
number (RIN) from the bioanalyser output showed acceptable quality RNA ratio in the 
range 1.8-2.2 and 8.4-10 for integrity (Figure 3.8C). Therefore, the overall results 
suggested that all the RNA was successfully extracted and isolated with high quality and 
integrity for GEP and validation experiments. 
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Figure 3.8 RNA quality and integrity check  
(A) Electropherogram example representing the results from the Agilent bioanalyser 
showing high RIN (RNA Integrity Number) indicating high integrity RNA. (B) 
Electrophoresis file run summary of successful RNA isolation from all samples tested 
showing the two discrete bands of 28S and 18S rRNA with former band intensity being 
approximately twice the size of the latter. (C) Summary of all RIN values which are in the 
range of 8.4-10 and rRNA ratios [28S/18S] range = 1.8-2.2.  # indicates experimental 
replicate number; nt = nucleotide and L = Ladder. 
C
Sample 
no 
Details  rRNA 
ratio 
[28S/18S] 
RIN 
1 #1 Control, 2.0 10 
2 #1 Control+DPI  1.8 10 
3 #1 N-Ras 1.9 9.9 
4 #1 N-Ras+DPI 2.0 9.9 
5 #2 Control 2.1 9.5 
6 #2 Control+DPI 1.9 9.6 
7 #2 N-Ras 1.5 8.4 
8 #2 N-Ras+DPI 2.2 8.9 
9 #3 Control 2.2 9.4 
10 #3 Control +DPI 2.0 9.8 
11 #3 N-Ras 1.8 9.5 
12 #3 N-Ras +DPI 2.2 9.9 
13 #4 Control 1.9 9.7 
14 #4 Control +DPI 1.8 9.8 
15 #4 N-Ras 1.9 9.8 
16 #4 N-Ras +DPI 1.8 9.8 
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3.4 DISCUSSION 
A common molecular abnormality in AML and other cancers is the mutational 
activation of RAS observed in many AML cases (Chapter 1) and this has been linked to 
overproduction of ROS in several cancer models (Sallmyr et al., 2008). Recent studies 
have shown that both N-RAS and H-RAS promote ROS production via NOX and it has 
been shown to also promote growth factor independent proliferation by an unknown 
mechanism (Hole et al., 2010). The overall objective of this study was to determine how 
ROS production arising from mutationally activated RAS affects gene expression and 
whether this contributes to the pro-proliferative phenotype which could help in the 
elucidation of the mechanisms underlying ROS’s contribution to leukaemogenesis. Even 
though both N-RAS and H-RAS have been previously shown to result in high ROS 
production, N-RASG12D was chosen for this study since it is the most clinically relevant. 
Therefore this chapter aimed to examine and confirm ROS production by human CD34+ 
haematopoietic cells expressing mutant RAS (N-RASG12D) and to optimise conditions and 
prepare samples for GEP microarray experiment to test whether RAS induced ROS could 
affect gene expression. 
In this study, a model system based on normal human haematopoietic progenitor 
(CD34+) cells was used. This model was chosen because it is well established in our lab 
and it is the most appropriate model to determine the effects of RAS and ROS on a normal 
background. To generate  mutant RAS expressing cells, CD34+ cells were isolated from 
neonatal cord blood and transduced with the retroviral vector PINCO encoding full-length 
N-RASG12D and GFP or an empty vector control (GFP alone) as previously described 
(Chapter 2). Percentage GFP positivity range for the control and N-RAS samples prepared 
for the microarray experiments were in the range of (54-84%) and (64-82%) respectively 
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suggesting efficient and successful transduction. It should be noted that the overexpression 
of mutant RAS in this cells has previously been confirmed under the same conditions using 
western blotting in our lab (Hole et al., 2010) hence this was not done for this study. 
In order to confirm that mutant RAS induced ROS production in human CD34+ 
haematopoietic progenitor cells, chemiluminescence assays were used which had been 
previously optimised and validated in our lab. The inhibition of ROS production in these 
cells was achieved by the use of DPI, a NOX inhibitor which has also been previously 
shown to block superoxide production by NOX2 (Hole et al., 2010; O`Donnel et al., 
1993). 
Microarrays are very expensive and could be time consuming and therefore it 
was crucial that the optimal conditions were established prior to commencing these 
experiments. Firstly assays for the measurement of ROS and its inhibition by DPI were 
optimised and validated. The effect of different concentrations of DPI on superoxide 
production was investigated using HL60 cells to establish the lowest effective 
concentration of DPI needed to inhibit superoxide production using chemilluminescent 
probe, Diogenes. It was necessary to optimise DPI concentration due to its known off 
target effects in the cells. A concentration of 100 nM was the minimum concentration 
required to inhibit >90% of superoxide from mutant N-RAS infected CD34+ cells.  To 
check that this concentration of DPI did not adversely affect cell viability, DPI-treated 
cultures were labelled with annexin V and 7AAD. The detection of apoptosis in these cells 
using this assay has been previously established (Hole et al., 2010). Annexin V is a 
member of the annexin protein family which have been shown to have high avidity for a 
plasma-membrane phospholipid; phosphatidylserine (PS), (Van Engeland et al., 1998). In 
viable cells PS is maintained in the inner leaflet of the plasma membrane by enzymatic 
action of flippases. The appearance of PS on the outer leaflet however is a marker of early-
intermediate stages of apoptosis (Boersma et al., 2005). Late stage apoptosis is 
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characterised by loss of membrane integrity (Wyllie, 1997) and in these cells the 
membrane impermeable dye, 7AAD, is able to enter cells and intercalate with DNA 
(Schmid et al., 1992), thus forming fluorescent DNA complexes (DNA/7AAD) that can be 
detected by flow cytometry. Therefore the incorporation of both methods enabled 
discrimination of early-intermediate and late stage apoptosis. 
 This assay confirmed that the viability of CD34+ cells was not significantly 
affected by 100 nM DPI for 24 hours. Since longer exposure (34-72 h), showed a slight 
decrease in survival, an 18 hour exposure to 100 nM DPI was used as the final condition 
for the gene expression profiling studies. 
In previous studies, ROS was measured in buffer, since culture medium 
components can interfere with the measurements. However, in this study it was necessary 
to measure ROS directly in the medium to exclude this interference and mis-interpretation 
of the results discussed below. Therefore this study optimised culture media conditions to 
measure ROS directly in culture at time of harvesting for GEP. Phenol red free media was 
used since this dye was interfering with the luminescence measurements. The effects of 
BME, transferrin and different concentrations of serum in media were checked in relation 
to ROS measurement sine these components might affect ROS measurements. For 
instance: transferrin contains iron which is likely to interfere with ROS measurement via 
Fenton chemistry (Chapter 1) resulting in misinterpretation of the results. In the presence 
of iron, superoxide and H2O2 react to generate hydroxyl radicals which could lead to the 
reduction of superoxide detectable by the chemiluminescent probe, Diogenes. This could 
explain lower levels (2 fold increase) of N-RAS induced ROS detected by Hole et al., 
(2010) in CD34+ cells compared to higher levels detected in the current study (discussed 
below).  
In the final optimised conditions at the time of harvest for GEP mutant, N-RAS 
generated a significant 8 fold increase in superoxide compared to the GFP controls 
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confirming the overproduction of ROS in these cells. In agreement with previous research, 
(Piccoli et al., 2007; Hole et al., 2010), normal human CD34+ cells produced low levels of 
ROS (superoxide) while expression of N-RAS strongly augmented its production.  
Interestingly, higher levels of N-RAS induced ROS (superoxide) were observed in the 
current study compared to the levels reported in Hole et al., (2010) where ROS was 
measured indirectly suggesting that the indirect measurement of ROS might have 
underestimated the level of ROS production by these cells. DPI, a NOX inhibitor, ablated 
ROS production (90% inhibition) in N-RAS expressing cells suggesting the successful 
inhibition of ROS in these cells and that it was NOX-derived superoxide. ROS can be 
produced via oxidase activity (such as NOX family) or via the mitochondrial ETC (Berdad 
and Krausel 2007, discussed in Chapter 1). Hole et al., (2010) previously demonstrated 
that excess ROS production in these cells was derived from NOX oxidases via Diogenes 
probe and DPI. This is in agreement with this study and consistent with other reports of 
RAS-induced ROS production in a variety of cell types (Rassool et al., 2007; Serù et al., 
2004; Santillo et al.,2001; Yang et al., 1999) (Chapter 1 for detail).  
It was therefore concluded that ROS production in this cells was confirmed 
together with its inhibition making them acceptable for RNA extraction in preparation for 
GEP using microarrays. 
RNA was extracted and isolated from cell culture models created above using 
Trizol reagent, purified and quantified using the optimised methods. Importantly, the 
quality and integrity of RNA was assessed to ensure high RNA quality and integrity for the 
best GEP microarray results. RNA quality and integrity is evaluated by the determination 
of the RNA ratio [28s/18s] and the RIN. The intensity size of 28s rRNA band was double 
the size of the 18 rRNA suggesting that the mRNA in all samples used in this study was 
full length. The RIN and rRNA ratios for all samples were found to be within the 
acceptable quality range of 8.4-10 and 1.8-2.2 respectively hence these results suggested 
CHAPTER 3: EXAMINATION OF ROS PRODUCTION 
119 
 
that RNA was successfully isolated and extracted. It was therefore concluded that all 
RNAs were of high quality and integrity thus used for GEP experiments. In addition, 
excess sample pellets and RNA were stored and used for the validation experiments 
(Chapter 4). 
The experiments in this chapter have confirmed ROS overproduction and its 
inhibition in mutant N-RAS expressing human CD34+ haematopoietic cells by direct 
measurement of ROS in cell culture. GEP data was also generated and analysis of this data 
is discussed in the next chapter. 
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4 Transcriptional dysregulation 
mediated by ROS in normal 
human haematopoietic progenitor 
cells expressing mutant N-
RASG12D 
The previous chapter confirmed ROS overproduction and its inhibition in mutant 
N-RAS expressing human CD34+ haematopoietic cells by direct measurement of ROS in 
cell culture. The main purpose of this chapter is to identify the transcriptional targets of 
mutant RAS and determine the contribution of RAS-induced ROS production on gene 
expression. This study expressed N-RASG12D in normal human haematopoietic CD34+ cells 
(Chapter 3). Using this model, cells were also treated with DPI, an inhibitor to NOX2, to 
determine the ROS related gene expression changes.  Affymetrix microarray GEP was 
used to quantitate changes in mRNA gene expression. GeneChip® Human Exon 1.0ST array 
data were imported into and analysed using Partek Genomics Suite Software (Version 6.6; 
Partek Inc., MO, USA). Genego Metacore ™ software was used for the pathway and 
network functional analysis. A summary of the data import, processing and analysis 
strategy is outlined in the method section (Figure 4.1A and B).  
4.1 AIMS 
 Analyze microarray GEP data obtained from Chapter 3 using Partek Genomic 
Suite software and determine N-RAS and ROS related gene changes; 
 Validate gene changes observed from microarray results using flow cytometry, 
and western blot methods. 
4 
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4.2 METHODS 
All equipment and reagents used were purchased from Affymetrix, UK Limited 
unless otherwise stated.  GEP is a technique that measures multiple gene expression in 
cells, using a number of genes arrayed onto glass slides or membranes (GeneChips®) and 
probed with fluorescent-labelled cDNAs (Affymetrix: online) (discussed in Chapter 1).  In 
this study, the Affymetrix Genechip whole transcriptome (WT) microarray approach was 
used.  GeneChip® Human Exon 1.0ST arrays were used where the probes on the arrays have 
been selected and distributed throughout the entire length of each transcript (full 
description, principles and illustrative figures are in 1.6). In summary, probes on different 
exons are summarized into an expression value of all transcripts from the same gene 
enabling gene level expression analysis.  
4.2.1 MICROARRAY DATA IMPORT, NORMALISATION AND QUALITY CONTROL 
4.2.1.1 Microarray data import and normalisation 
RNA from transduced cultures were extracted and processed for hybridisation to 
GeneChip® Human Exon 1.0ST Array for whole-transcript expression analysis and GEP 
data was generated as previously described (Chapter 3). All GEP data were analysed using 
Partek Genomics Suite (GS) Software (Version 6.6; Partek Inc., MO, USA) (See Figure 
4.1A and B for summary of the analysis strategy).  For Partek analysis CEL files were 
imported using Affymetrix annotation files (NetAffx, Version hg16, build 34, July 2003). 
GEP Exon-level data were filtered to include only those probe sets that are in the “core” 
meta-probe list which refers to probe sets that are supported by the most reliable evidence 
from RefSeq and full-length mRNA GenBank records containing complete CDS 
information.  The core data include target-sequence, perfect-match, unique probe sets.  The 
Robust Multi-Array Analysis (RMA) algorithm was used for Exon-level expression 
CHAPTER 4: TRANSCRIPTIONAL DE-REGULATION MEDIATED BY ROS  
122 
 
analysis.  Adjustments were made for GC content and probe sequence on pre-background-
subtracted values.  Background correction, quantile normalization, log2 transformation, and 
median polishing were used for summarization.  
4.2.1.2 Quality controls 
Several quality controls spikes were included during the microarray experiments 
in order to facilitate data quality assessment at different stages of the microarray 
experiments. This was done as in accordance to the manufacturer’s instructions and 
recommendations. These included the hybridization controls such as bac_spike which is a 
set of probesets which hybridize to the pre-labelled bacterial spike controls (BioB, BioC, 
BioD and Cre) and are useful in identifying problems with the hybridization and chip, 
polya_spike which is the set of polyadenylated RNA spikes (Lys, Phe,Thr and Dap) which 
are helpful in identifying problems with the target preparation phase of the experiment.  
All these spikes were added at different concentrations as recommended by the 
manufacturer. 
Following the successful completion of the import of CEL files, post import 
quality control (QC) spreadsheet which summarized the intensity values of the Affymetrix 
control probesets was generated together with the graphical representations of the probe-
sets values. This was done using the QC metrics of the QA/QC section of the Partek 
workflow which provides quality control information from control and experimental 
probes on the Genechips® in order to provide confidence in the quality of the microarray 
data and to identify samples that do not meet the QC criteria as detailed by the 
manufacturer.  All the image plots generated were inspected visually for any artefacts. 
4.2.2 MICROARRAY DATA ANALYSIS 
The Affymetrix GEP data is available as supplemental material on the attached CD.  
A two-arm approach was applied in order to identify statistically differentially regulated 
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genes.  Firstly, statistically significant changing genes were identified using a 2-way 
ANOVA based on the following model; Yijk = μ + Conditioni+Cord blood replicatej+ εijk. 
Where Yijk represents the kth observation on the ith Condition jth Cord blood replicate; μ is 
the common effect for the whole experiment; εijk represents the random error present in the 
kth observation on the ith Condition jth Cord blood replicate.  The errors εijk are assumed to 
be normally and independently distributed with mean 0 and standard deviation δ for all 
measurements.  Cord blood replicate is a random effect and Condition represents 
experimental treatment e.g. mutant N-RASG12D.  Fisher's Least Significant Difference 
(LSD) was performed for the following contrasts i) mutant N-RASG12D vs controls (GFP 
alone) or (ii) N-RASG12D vs N-RASG12D+DPI or iii) GFP alone vs GFP alone +DPI (Figure 
4.1B).  Where possible the Benjamini-Hochberg multiple testing correction was applied to 
both these strategies, otherwise the level of significance was reduced to P<0.01.  Secondly, 
statistically significant genes were filtered to remove all genes that changed by less than 
1.2-fold in each of the contrasts above.   To identify mutant N-RASG12D gene changes that 
are mediated via ROS, the gene lists generated above were combined in a Venn diagram 
(Figure 4.6) to identify biological and statistically significant gene changes according to 
Figure 4.1B. No significant gene changes were observed for the control+DPI vs control 
hence was excluded from the Venn diagram. 
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Figure 4.1  Strategy for the identification of the N-RASG12D genes changes that are 
mediated by ROS. 
(A) is the summary of the overall experimental strategy used in this chapter and 
(B) is an outline of the specific comparisons made between treatment conditions for the 
determination of ROS specific genes.  
 Pathway analysis 
Generation of GEP data from total RNA 
(Comparison of N-RAS +/- DPI vs Control) 
Data import and normalization 
 Validation of protein expression 
ANOVA statistical analysis and detection of sources of variation and 
identification of dysregulated genes using strategy outlined in B 
A
N-RAS+DPI     N-RAS Control+DPI 
ROS 
dependant 
target 
genes 
To 
exclude 
any DPI 
induced 
All RAS 
dependant 
target 
genes 
		 Control B
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4.2.3 GENEGO METACORE PATHWAY ANALYSIS  
Partek GS ANOVA output (microarray gene list B) was imported into Genego 
Metacore ™ software (GeneGo Inc) for pathway analysis and the establishment of both 
direct and indirect interactions/networks between significant differentially expressed ROS 
target genes. This analysis also facilitates the identification and ranking of pathways and 
information/knowledge (including the subcellular localization) relating to the target genes. 
Metacore is an integrated software suite based on high-quality, manually-curated database 
of transcription factors, receptors, ligands, kinases, species-specific directional interactions 
between protein-protein-DNA, protein-RNA interactions, drug targeting, bioactive 
molecules and their effects with wide literature support for validity and ease reference 
(Metacore data-mining and pathway analysis: online). This software is therefore industry 
leading in reliability, accuracy and comprehensiveness hence suitable for the analysis of 
microarray data obtained in this study.  
4.2.4 VALIDATION OF GENE CHANGES /PROTEIN EXPRESSION 
4.2.4.1 Validation of protein expression using flow cytometry 
The general method performed is described in Chapter 2, variations and specific 
details can be found in the results section (4.3.4.1). 
4.2.4.2 Validation of protein expression using Western Blotting 
The general method performed is described in chapter 2, variations and specific 
details can be found in the results section (4.3.4.2). 
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4.2.5 INVESTIGATION OF THE EFFECT OF GOX ON THE EXPRESSION OF ROS TARGET 
GENES 
The general method performed is described in Hole et al., (2013) and Chapter 2 
for treatment of cells with Glucose oxidase (GOX) and western blotting respectively. 
Variations and specific details can be found in the results section (4.3.5). This was done to 
further validate whether ROS related genes identified above (Table 4.1) were ROS 
responsive since ROS (in the form of H2O2) was generated in cultures of these cells by the 
addition of glucose oxidase (GOX).  
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4.3 RESULTS 
4.3.1 MICROARRAY DATA, QC, IMPORT AND NORMALIZATION 
4.3.1.1 QC assessment and Microarray Data 
Prior to data analysis, a number of QC checks were performed.  Only ‘high 
quality’ data (defined as data showing no indication of features that could skew or 
otherwise lead to data misinterpretation) were allowed to be used in subsequent analysis. In 
order to do this, a number of quality controls spikes (bac_and polyadenylated RNA spikes) 
were previously included during the microarray experiments as described in 4.2.1.2. This 
was also done to identify outlier arrays within the data set before the data analysis. Firstly, 
the raw GEP data of each sample/chip was inspected visually.  As shown in Figure 4.2, the 
raw data were uniformly distributed with no artefacts suggesting that the GEP chip 
processed was of good quality and this applied to all images of all samples tested.   
Secondly, to validate adequate hybridization of labelled cDNA to the 
GeneChip®, each GEP was analysed for increasing signal intensity of the control spikes as 
described in 4.2.1.2. The results of the QC data indicated that hybridization controls had 
signal increases following the order BioB< BioC<BioD < Cre (Figure 4.3A) and the 
labelling controls (RNA spikes) signal strengths followed the order Lys< Phe<Thr a< Dap 
(Figure 4.3 B) as expected. Signal box plots were examined for both pre and post RMA 
normalization and the results showed no outliers in all the 16 samples tested (Figure 4.3 C) 
and these data also suggested effective normalization.  
The overall observations suggested successful hybridization and all the 16 
samples had met the QC criteria. Thus at this stage the microarray data from all the 
Genechips were considered of high quality. 
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Figure 4.2 Example images of microarray data 
Microarray experiments were performed using GeneChip® Human Exon 1.0ST 
arrays and the raw data images were generated and visualized using Partek GS software. 
Four independent replicate experiments were performed for both N-RAS and control with 
and without (+/-) DPI.  Example data for visualisation from one replicate of the N-RAS 
and control samples +/- DPI are shown. All images were of excellent quality with no 
artefacts.   
 
 
Control
N-RAS 
- DPI        + DPI        
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Figure 4.3 Post import QC and microarray data for quality assessment of the Exon 
arrays 
QC graphs showing: (A) Log expression signal from all the samples tested for the 
hybridization control spikes which showed signal increases following the order BioB< 
BioC<BioD < Cre; (B) Labelling control (RNA spikes) signal strengths followed the order 
Lys < Phe < Thr < Dap (C) box plot of log expression signal from each of the 16 samples/ 
Genechips before and after RMA normalization indicating effective normalization. 
A B
C
Before normalization After normalization 
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4.3.1.2 Exploratory data analysis using Principal Components Analysis (PCA) 
In order to visualize data, preliminary data analysis was performed using PCA 
(Figure 4.4). This was useful in identifying any outliers and major effects of samples, 
replicates and treatment conditions in the data and thus allowing the establishment of 
factors that are important in subsequent statistical analysis. As shown in Figure 4.4, the 
GEP of a chip groups with other data according to replicate (individual cord blood) than it 
does due to the sample treatment condition. These results suggested that the variation in 
expression of genes within individual cord bloods is driving the grouping of the samples. 
Therefore replicate (cord blood source) and sample treatment condition were included in 
the model of ANOVA selected for statistical analysis. 
4.3.1.3 Generation of the statistical model used for data analysis 
In order to generate the appropriate statistical model for the data analysis, 
sources of variation plots were generated using Partek GS to detect and visualize the 
factors relevant to the data obtained. The results indicated that the main sources of 
variation in this study were replicate (individual cord blood) and the sample treatment 
condition, (Figure 4.5). It is important to note that batch was not a factor tested since all 
samples were arrayed at once. In conclusion, replicate and sample were the two important 
factors relevant to the statistical data analysis in order to determine differences based on 
sample treatment. ANOVA 2 way analysis was therefore selected and used as a statistical 
model for results analysis. This model took into account both sources of variation 
established, replicate and sample treatment to control for the biological variation. 
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Figure 4.4 Microarray data was visualized using PCA scatter plots  
Gene expression data from each sample/GeneChip are represented by coloured 
dots according to the legend. The coloured ellipsoids represent individual cord blood 
samples (or replicates) transduced with retroviral vectors and treated with or without DPI. 
For each replicate of the experiment, different cord blood was used and four replicates 
were performed per treatment condition (i.e. n=4). 
 
Control + DPI
Control 
N-RAS
N-RAS+DPI 
Sample and treatment Replicate
1 
2 
3 
4 
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Figure 4.5 Main sources of variation 
Bar graph generated from the microarray data showing that the main factors 
influencing the results were sample treatment condition (sample) and replicate (individual 
cord blood) indicated by mean F ratios.  
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4.3.1.4 Visualization of the direction of gene changes due to ROS using dot plots  
Dot plots were generated for each of the mutant N-RASG12D gene changes that 
are mediated via ROS (from gene list B generated in Figure 4.6) using Partek GS for the 
determination and visualization of gene changes due to ROS (Figure 4.7 ). The results of 
all the dot plots were examined and the summary of the direction of gene change due to 
ROS was tabulated (Table 4.1). The patterns of gene expression levels in different 
treatment conditions were as expected with the highest expression levels in the presence of 
ROS and lowest leves in the absence of ROS in N-RAS cells compared to the control 
confirming that these genes were indeed up-regulated by ROS. 
4.3.2 DETERMINATION OF GENES DYSREGULATED BY N-RASG12D AND ROS 
ANOVA 2 way analysis was used to determine the differentially expressed 
genes between the categories described in 4.2.2 and Figure 3.1B. Lists of genes that passed 
the specified criteria (4.2.2) were generated for each comparison in order to identify genes 
that are dysregulated by N-RASG12D and ROS. According to the results, 342 gene changes 
were found in the control alone relative to N-RASG12D alone with FDR<0.05 (gene list C), 
68 gene changes were found in the N-RASG12D alone relative to N-RASG12D + DPI with 
FDR<0.05 (gene list A) and no significant gene changes were found in the control + DPI 
relative to control alone with FDR<0.05 (Please refer to the CD for the gene lists). The lists 
of these differentially expressed genes were intersected using Venn diagrams as previously 
described (4.2.2) to identify mutant N-RASG12D significant gene changes mediated by ROS 
(Figure 4.6). The results showed that 25 genes (gene list B) were common between gene 
list A (N-RASG12D alone relative to N-RASG12D + DPI) and gene list C (control alone 
relative to N-RASG12D alone) suggesting that 25 mutant N-RASG12D significant gene 
changes were mediated via ROS (Figure 4.6 and Table 4.1). 
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Figure 4.6 Dysregulated gene changes in cells expressing mutant RAS 
The gene lists used in this figure were generated using the statistical model 
already described and the lists were intersected using Venn diagrams in Partek. This figure 
shows number of gene changes in gene list A (N-RASG12D alone relative to N-RASG12D + 
DPI) and gene list C (control alone relative to N-RASG12D alone). Gene lists A and C were 
intersected and N-RASG12D gene changes that are mediated via ROS (gene list B) are 
tabulated below (Table 4.1) No gene changes were detected in control alone relative to 
control + DPI hence no Venn diagram shown for this comparison. 
Genelist A (68)    Genelist B (25)   Genelist C (342) 
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Figure 4.7 Example dot plot of the mutant N-RASG12D gene changes that are mediated 
via ROS 
The Y-axis represents the normalised gene expression value (log2); the X-axis 
represents the different sample treatment conditions and replicate data for each condition. 
For each treatment condition n=4. This plot shows example data for one gene (ALDOC) 
found to be dysregulated by ROS. Other images are in appendix 1. The above results 
demonstrate the different gene expression values associated with the sample conditions 
tested. 
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4.3.2.1  Mutant N-RASG12D gene changes that are mediated via ROS. 
The number of mutant N-RASG12D gene changes that are mediated via ROS was 
found to be 25 (Figure 4.6). However one transcript did not have the gene assignment 
reducing the number to 24. Table 4.1 summarises all ROS target genes identified together 
with some important literature for the selection of target genes for further tests and 
validation experiments. The results indicated that the expression of 4 mutant N-RASG12D 
genes were significantly down regulated by the presence of ROS with a fold change range 
of 1.2-3.6 fold and 20 mutant N-RASG12D genes were significantly up-regulated by the 
presence of ROS with a fold change range of 1.2-4.3 fold. All the p-values of these genes 
were in the range of 2.26×10-7-1.32×10-4 indicating very strong significance. ROS 
significantly dysregulated the expression of genes involved in several pathways such as the 
glycolytic, metabolism and signal transduction.These results suggested that the presence of 
ROS can result in the significant down or up-regulation of genes.  
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Table 4.1 Mutant N-RASG12D gene changes that are mediated via ROS 
This table shows the ROS target genes identified (gene list B), Unique 
Affymetrix identifier (ID) and NM Reference sequence (RefSeq), fold and direction of 
gene change due to ROS (- = down regulated + = up regulated by ROS), p-value and 
important literature search outcomes for each gene including the description of their 
functions based on the Human Protein Reference database (Prasad et al., 2009). It was 
generated using the fold changes from the ANOVA microarray output results of gene list 
B. These genes were obtained by the intersection of the gene list A and C (Figure 4.6). The 
gene lists used to generate this list are provided in the CD. One transcript did not have a 
gene assignment.  It should be noted that further information about the roles of the genes is 
in the Discussion (Section 4.4). 
 
Gene Affymetrix 
ID 
 
RefSeq Gene 
expression 
(fold and 
direction 
of change) 
p-value Process 
ALDOC 3750767  NM−005165 +4.3 1×10−6 
Glycolysis 
ENO2 3403015 NM−001975  +2.6 1×10−4 
FBP1 3215570 NM−000507 +1.8 2×10−7 
GPI 3829687 NM−000175 +1.5 2×10−6 
PFKP 3232349 NM−002627 +1.4 9×10−6 
GATM 3622386 NM−001482 +2.8 3×10−5 
Metabolism 
 
SULF2 3908358 NM−018837 +2.1 2×10−5 
CKB 3580769 NM−001823 +2.1 7×10−5 
ASPH 3137530 NM−004318 +1.4 1×10−4 
PTPRD 3198346 NM−002839 +2.2 2×10−5 
Signal 
transduction 
KIT 2727587 NM−000222 -2.1 5×10−5 
CD32 2363808 NM−001190828 +1.5 7×10−5 
TNS1 2599153 NM−022648 +1.7 8×10−6 
REC8 3529725 NM−001048205 +1.4 6×10−5 
STARD8 3980078 NM−001142503 +1.4 3×10−5 
CMTM8 2615892 NM−178868 -1.2 1×10−4 
CNR2 4044363 NM−001841 -3.6 2×10−6 
CD34 2453307 NM−001773 +1.7 4×10−5 
Other 
CITED1 4012178 NM−001144885 +1.7 6×10−5 
CYTL1 2758870 NM−018659 -1.9 6×10−6 
CACNB1 3755580 NM−199247 +1.3 1×10−4 
SLC6A8 3995804 NM−0005629 +1.7 1×10−5 
JAKMIP2 2880361 NM−014790 +1.2 3×10−5 
WDR54 2489228 NM−032118 +1.8 5×10−6 
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4.3.3 GENEGO METACORE PATHWAY ANALYSIS 
The Partek GS ANOVA output (fold differences) of the data from gene list B 
Table 4.1 was imported into Genego Metacore™ software for pathway analysis and 
network visualization of significant mutant N-RASG12D gene changes that are mediated via 
ROS. As shown in Figure 4.8, a biological interaction network of the genes in question was 
determined. Many of the dysregulated ROS target genes identified are enzymes associated 
with metabolism, particularly the glycolytic pathway which confirmed the findings in 
Table 4.1. These include ALDOC, ENO2, FPBP1, GPI, and PFK-1. A common feature of 
these targets is that they seem to be linked to the transcription factors: SP1 and ESR 
(Figure 4.8). Other ROS target genes identified were associated with signal transduction 
and transcription. Taken together, these results and the findings in Table 4.1 suggest that 
N-RAS induced ROS changes gene expression of enzymes associated  with transcription, 
signal transduction and  metabolism; particularly glycolysis. 
4.3.4 CONFIRMATION OF DYSREGULATED GENE EXPRESSION IN HUMAN CD34+ 
HAEMATOPOIETIC CELLS EXPRESSING MUTANT RAS  
The above GEP data analysis identified 25 target genes that are mediated via 
ROS production.  In order to confirm the gene changes observed at protein level, western 
blotting or flow cytometry was performed in primary cells (detail in individual sections). 
The main factors considered for the selection of targets for validation experiments were: 
level of fold change due to ROS (high induction with ROS), availability of reagents and 
outcome of literature search (e.g.: novel or significant in terms of ROS or role in 
leukaemia).  Using these criteria CD117, CD34, CD32, CITED, ENO2, ALDOC, PTPRD, 
GATM and CNR2 were selected for validation. 
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Figure 4.8 Functional and network analysis of mutant N-RASG12D gene changes that 
are mediated via ROS 
Representation of the (A) direct and (B) indirect interactions/network between 
mutant N-RASG12D gene changes that are mediated via ROS. Data were generated using 
Genego Metacore TM as described in 4.2.3 and 4.3.3. 
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4.3.4.1 Flow cytometric results 
In order to establish whether the changes at RNA level observed from the 
microarray data were also seen at protein level, flow cytometric analysis of the ROS 
targets CD117, CD34 and CD32 was performed in control and N-RASG12D expressing cells 
in the presence and absence of the inhibitor, DPI (as described in Chapter 2 and Figure 
4.9). These ROS induced genes were selected for validation by flow cytometry because 
they showed high induction with ROS (with fold change range of 1.5-2.1 using microarray 
GEP), the reagents were readily available and were targets novel in terms of ROS and 
AML biology (Table 4.1).  
The results of the histograms indicated that there is enhanced protein expression 
and differences between the isotype control and the test flow cytometric signals for most of 
the proteins. However the expression of these proteins is not influenced by RAS or DPI 
except for CD117 which does conform to a similar pattern to the array data (Figure 4.9 and 
Figure 4.10). These fold changes were measured from a very low background expression 
of the protein so the interpretation of this data should be treated with caution thus difficult 
to be confident with these data.  Figure 4.10 compares the flow cytometric data and the 
previously obtained microarray results. It was concluded that the expression of these target 
genes at protein level was not validated.  
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Figure 4.9 Histograms of the flow cytometric signal for target genes CD32, CD34 and 
CD117  
N-RASG12D expressing or control CD34+cells expressing GFP alone (isolated 
and transduced as described in chapter 2) were incubated with and without 100 nM DPI on 
day 6 of culture, followed by flow cytometric analysis  and generation of histograms for 
(A) CD32; (B) CD34 and (C) CD117 protein expression on day 7. Appropriate antibodies 
and isotype controls were used (see Chapter 2 Table 2.3 for antibody details). n = 2  
(C)  CD117 
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Figure 4.10 Comparison between the flow cytometric data and microarray data  
The bar chats above are comparisons between (i) the flow cytometric data and 
(ii) microarray data for (A) CD32, (B) CD34 and (C) CD117 ROS target genes. Flow 
cytometric data = fold changes of targets levels in control and N-RAS +/-DPI calculated 
from the geometric means of GFP positive cells. Geometric means were obtained for each 
target gene from the above histograms (Figure 4.9) and the actual geometric mean signal 
was calculated using the formula, net geometric mean –background signal = actual signal 
for only GFP positive cells. Fold changes were calculated from the actual geometric signal. 
No error bars generated since n=1. Microarray data = fold changes for the ROS target 
genes obtained from the microarray data via Partek GS (Table 4.1).  
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4.3.4.2 Western blotting results for the validation of protein expression 
Protein changes were also investigated using western blotting and performed in 
control and N-RASG12D expressing CD34+ cells in the presence and absence of DPI (as 
described in Chapter 2 and Figure 4.11) in order to check whether the changes seen at 
RNA levels were present at protein level. Six ROS target genes showing a fold change 
range of 1.7-4.3 using microarray (Table 4.1) were assessed by western: CITED-1, ENO2, 
ALDOC, PTPRD, GATM and CNR2.  PKC phosphorylation is responsive to changes in 
the redox stress environment and was used as a control to show the effect of RAS-induced 
ROS and the effect of inhibition of ROS by DPI.   
The results indicate that ROS induced strong protein expression signals of 
ALDOC (2-3 fold) and PTPRD (2.5 Fold), CITED-1 (1.5-2 fold), ENO2 (1.2 fold) and 
GATM (2.5 fold) in N-RASG12D expressing CD34+ cells compared N-RAS + DPI (no 
ROS) (Figure 4.11). These results were in agreement with the microarray GEP.  Also 
consistent with the microarray data it was found that, N-RAS induced higher protein 
expression signals compared to the control while there was no difference in the expression 
signal intensities between the control and control + DPI (Figure 4.11). CNR2 was not 
validated since there were no bands observed with regards to its protein expression even 
though the control band was present (data not shown).  In summary, out of the 6 targets 
tested, 5 were validated at protein level.  
4.3.5 H2O2 PROMOTES THE EXPRESSION OF ROS TARGET GENES 
Expressions of CITED-1, ENO2, ALDOC, PTPRD were examined further to 
determine whether their expression was directly promoted by ROS.  These experiments 
employed KG-1 AML cell line as well as primary cells (CD34+).  ROS (in the form of 
H2O2) was generated in cultures of these cells by the addition of glucose oxidase (GOX).  
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The expression of these proteins was subsequently investigated using western blotting as 
described in Chapter 2.  As above, phosphorylation of PKC was included as a positive 
control for ROS exposure.  Phosphorylation of both these proteins was induced in KG-1 
and CD34+ cells treated with GOX (Figure 4.12).  Direct exposure to ROS induced both 
ALDOC, and PTPRD in both KG-1 and CD34+ cells.  ENO2 was induced in KG-1 cells 
only and CITED-1 in CD34+ cells only (Figure 4.12).  Removal of GOX-derived by 
addition of catalase lowered protein expression but only in samples harvested after 3h.  
This may indicate that the amount of catalase added was insufficient to remove all the 
H2O2 during overnight culture and the PKC and p38MAPK phosphorylation data support this 
interpretation. 
In conclusion all four ROS targets genes tested were directly ROS responsive in 
at least one context. 
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Figure 4.11 Assessment of ROS target protein expression  
N-RASG12D expressing or control CD34+cells expressing GFP alone (isolated 
and transduced as described in chapter 2) were incubated with and without 100 nM DPI on 
day 6 of culture. Whole cell protein extracts were prepared on day 7 of culture as described 
in chapter 2 and western blot analysis was performed as described in chapter 2 using (1 
µg/ml) anti-ALDOC, CITED-1, GATM, PTPRD, ENO2, CNR2 and (2.9 ng/ml) P-PKC 
antibodies. 20 ng/ml anti-GAPDH antibody was used as a loading control. Results are 
representative of at least 2 independent experiments (A) replicate 1 and (B) replicate 2 
including a different/alternative antibody for ALDOC and GATM.  
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Figure 4.12 Assessment of the effects of GOX on ROS target protein expression   
(A) KG-1 and (B) CD34+cells (isolated and transduced as described in chapter 2) 
were incubated with and without (10 U/ml) GOX for 3 hours (indicated) and overnight. 
Catalase, which breaks down H2O2, was also added to some of the GOX treated cells 
before incubation. Whole cell protein extracts were prepared and western blot analysis was 
performed as above using (i) (1 µg/ml) anti-ALDOC, PTPRD, P-p38 MAPK, (2.9 ng/ml) P-
PKC (ii) (1 µg/ml) ENO2 and Cited-1 antibodies. 20 ng/ml anti-GAPDH antibody was 
used as a loading control. Results are representative of at least 2 independent experiments. 
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4.4 DISCUSSION 
In Chapter 3, N-RASG12D was overexpressed in normal human haematopoietic 
CD34+ cells as a model to examine the effect of ROS on gene expression in haematopoietic 
cells. This model was validated in terms of ROS production and inhibition of ROS 
production using DPI.  Finally, 4 replicate samples used in the GEP studies.  
In this chapter data obtained from these experiments were imported and analysed 
using Partek GS software for gene expression changes. In addition, functional analysis and 
pathway networks between genes of interest were achieved using Metacore software. 
Finally gene changes observed were validated using flow cytometry or western blot 
methods. 
 Genechip® Human Exon 1.0ST arrays used in this study contains probes that 
have been selected and distributed throughout the entire length of each transcript. They 
consists of 4 probes per exon and 40 probes per gene which enables both gene expression 
and alternative splicing analysis (Abdueva et al., 2007) and have also been shown to be 
more accurate than other arrays due to a higher coverage and more evenly distributed 
probes (Affymetrix Online; Kapur et al., 2007) as previously discussed in detail. For the 
analysis used in this chapter multiple probes on different exons were summarized in to an 
expression value of all transcripts from the same gene.  
Partek GS software used in this study was also suitable for data import and GEP 
studies because it was already available in our department. The RMA algorithm used in 
this study for the exon level expression analysis includes the adjustment of GC content and 
probe sequence on pre-background-subtracted values. It works by estimating, for each 
probe set, values for the probe and chip effects that would result in the pattern of perfect 
matches (PM) values observed in the data (Okoniewski and Miller, 2008; Irizarry et 
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al.,2003). The fact that RMA only uses PM has made it very popular hence it has become 
the widest used normalization method as opposed to MAS5.0 (Hubbell et al., 2002).   
Quality controls (QCs) used in this study during microarray experiments 
facilitated data quality assessment at different stages of the microarray experiments. These 
are useful in the identification of problems associated with hybridization and target 
preparation phase of the experiments to ensure excellent interpretation and confidence in 
the data generated before analysis. The visual inspection of image plots was also 
performed and this revealed that all samples tested met the QC criteria indicated by the 
absence of artefacts. Therefore data from all the samples were taken further for gene 
expression analysis with confidence. 
Hierarchical clustering groups similar elements together hence can also be used 
as quality control. This is very helpful in the detection of bias potentially introduced for 
technical rather than biological reasons which should result in the exclusion of the sample 
in question before further analysis (Zimmermann and Leser 2010). However such bias is 
normally removed by normalization and taken in to account during the design of the 
statistical model. PCA (used in this study) on the other hand provides similar information 
to Hierarchical clustering apart from the fact that it preserves more information despite 
reports of it being computationally demanding (Zimmermann and Leser 2010).  According 
to the PCA, Hierarchical clustering and the sources of variation plots, cord blood 
(replicate) is driving factor of gene expression in addition to the sample treatment. 
Therefore in the current study, ANOVA 2 way analysis was used which took into account 
the two sources of variation established namely replicate and sample treatment in order to 
control for the biological variation.  
Gene expression analysis (Table 4.1), showed that 25 genes were significantly 
altered (either up or down-regulated) by ROS. However one transcript did not have gene 
assignment (for unknown reasons) reducing the number to 24. It was also found that of the 
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24 target genes identified, the expression of 4 genes was down-regulated by ROS with fold 
change range of 1.2-3.6 fold and 20 targets genes were up-regulated by ROS with the fold 
change range of 1.2-4.3 fold with ALDOC being the most strongly up-regulated. All the p-
values of these gene changes were found to be in the range of 2.26×10-7-1.32×10-4 
indicating very strong significance. These results suggested that ROS can independently 
induce significant alteration in gene expression. 
The Partek GS ANOVA output of the above 24 significant genes were then 
taken for pathway functional analysis using Metacore software to identify the pathways 
that were significantly altered and for network functional and interaction analysis. Taken 
together, the GEP data, manual literature searches and Metacore pathway analysis 
identified ROS-induced gene changes were most significantly associated with Glycolysis 
and Gluconeogenesis. These genes included ALDOC, PFK, GPI, FPBP1 and ENO2 and 
are discussed in detail in chapter 5.  
Validation of gene changes at the protein level was carried out for genes which 
showed the biggest fold change with ROS and for which suitable antibodies were 
available.  Of the 9 gene changes investigated 4 were not validated at the protein level 
suggesting that protein expression was additionally regulated at the post-transcriptional 
level.  Five gene changes (ENO2, CITED-1, GATM, ALDOC and PTPRD) were 
successfully validated at protein level using western blotting.  
 To confirm that these genes were indeed directly responsive to ROS, KG-1 cells 
and primary CD34+ cells were exposed to ROS (H2O2) through addition of GOX (as 
previously optimised for this purpose in a study by Hole et al., (2013). Each of these genes 
showed up-regulation at the protein level in at least one context.  Of the glycolytic 
enzymes analysed ALDOC gave the most consistent up-regulation in response to ROS. 
Increased glycolysis has been implicated in many cancer cells in several studies 
(1.5.4 and 5.4). It is now believed that cancer cells use the metabolic pathway for 
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generation of ATP as a main source of energy supply, “Warburg effect” (as discussed in 
1.5.4) which is used to increase biosynthetic precursors for proliferation or building blocks 
for cell function and growth. This is considered as one of the most significant metabolic 
alterations during cancer development leading to malignant transformation (Pelicano et al., 
2006a). Many researchers have shown that metabolic alterations may develop via 
oncogenic signalling, mitochondrial defects, adaptation to tumour microenvironment and 
most importantly expression of metabolic enzymes (1.5). This study supports these 
previous publications with regards to the significantly altered expression of most of the 
enzymes involved in metabolic pathways: glycolysis and gluconeogenesis, by ROS in 
mutant N-RAS expressing human CD34+ cells. (This is fully discussed in Chapter 5).  
Other ROS target genes identified in this study as significantly altered have also 
been previously linked to cancer including AML. For instance, it was previously shown 
that CNR2 (known as CB2) is frequently expressed in AML blasts and this gene either 
induces a neutrophilic differentiation block or confers abnormal migration properties in a 
ligand-dependent manner (Jorda et al., 2004). In the same study it was also demonstrated 
that CB2 receptor is aberrantly expressed in several human myeloid cell lines but not in 
normal bone marrow precursor cells. CB2 encodes a 7-transmembrane (7TM) protein and 
belongs to the family of Gαi protein-coupled receptors (Gαi  PCRs) (Munro et al., 1993).  It 
has been shown to be a proto oncogene involved in transformation (Valk et al., 1997; 
1998). It should be noted however that the expression of this ROS target gene was found to 
be significantly down-regulated by ROS in the current study making it unlikely that its 
expression in AML blasts is linked to ROS production.  
PTPRD, another gene which has been found to be significantly up-regulated by 
ROS in this study, is a tumour suppressor that has been previously reported to be mutated 
in glioblastoma (Veeriah et al., 2009) and other human cancers (Solomon et al., 2008; 
Stallings et al., 2006; Sato et al., 2005;Purdie et al., 2007; 2009). PTPRD was also shown 
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to predict poor prognosis in breast cancer and colon cancer (Chan et al., 2008). It is a 
member of the highly conserved family of the receptor protein tyrosine phosphatase (PTPs) 
and has not been previously linked to the pathogenesis of leukaemia.  
  ROS and antioxidants are known to influence the expression of a number of 
genes and signal transduction pathways, reviewed by Allen and Tresini (2000). For 
instance changes in the redox state were shown to modulate activation of transcription 
factors such as Myb (Myrset et al., 1993) and Egr-1 (Huang and Adamson 1993). In 
addition, numerous proto-oncogenes are known to be transcriptionally activated by 
increased cellular oxidation. For example, exposure of both normal and transformed cells 
to H2O2 stimulates increased expression of jun-B, jun-D, c-fos and fos-B (reviewed by 
Allen and Tresini (2000). However there is limited literature on the possible mechanisms 
through which ROS can influence gene expression. ROS was shown to regulate ERBB2 
and ERBB3 (genes linked with cancer development and poor prognosis) expression via 
miR-199a/125b repression and DNA hypermethylation through DNA methyltransferase 1 
(DNMT1) elevation in cancer cells and tumour tissues (He et al., 2012). Another study by 
Arnold et al., (2001) demonstrated that H2O2 mediates the cell growth and transformation 
caused by mitogenic oxidase NOX1 (Arnold et al., 2001). The same study showed that 
H2O2 triggers a genetic programme that results in altered gene expression including many 
genes previously associated with transformation and cancer as well as regulation of the cell 
cycle and signal transduction. According to the authors of this study the expression of 24 
metabolism genes were altered, making it the category with the biggest change. Though 
the identity of these genes was not revealed the current study is not inconsistent with this 
previous work.   
In conclusion, the results of this chapter have shown for the first time that 
mutant N-RAS induced ROS significantly dysregulated the expression of 24 genes in 
human CD34+  haematopoietic cells, many of which are involved in glycolysis and 
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gluconeogenesis. In addition, direct addition of H2O2 via GOX induced/promotes the 
expression of some of these genes confirming that they are ROS responsive. However, it is 
unknown whether the dysregulation of these genes have any functional effects on 
haematopoietic cells. This is dealt with in the next chapter (Chapter 5).   
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5 Functional analysis of ALDOC in 
haematopoietic cells 
 
It was previously demonstrated that endogenous ROS production has significant 
effects on the proliferation of human CD34+ haematopoietic progenitor cells expressing 
mutant RAS (Hole et al., 2010). However, the mechanism by which ROS promote 
proliferation still remains unclear. Chapter 4 demonstrated that ROS significantly up 
regulated the expression of ALDOC (a target involved in the glycolysis pathway) in human 
CD34+ haematopoietic progenitor cells expressing mutant RAS and also haematopoietic 
cell lines. It was therefore hypothesized that the pro-proliferative effect previously 
observed may be due to increased glycolysis via ALDOC over-expression. Therefore this 
chapter focused on the functional analysis of ALDOC on haematopoietic cells in order to 
establish whether this could be part of the mechanism through which ROS promotes 
proliferation in AML (Hole et al., 2013). This chapter also examines whether over-
expression of ALDOC influences survival of human haematopoietic cells/leukaemic cell 
lines. MV4-11, THP-1, and KG-1 are the human AML cell lines used in this study which 
were chosen because they were previously shown to be responsive to ROS induced 
proliferation (Hole et al., 2013). In addition, RAS mutations have been shown to be present 
in all these cell lines. It was therefore concluded that all these cell lines were suitable for 
testing the hypothesis stated above. 
In order to address these aims, ALDOC was ectopically expressed and in a 
complementary series of experiments ALDOC was knocked down to determine the role of 
ALDOC expression in proliferation and survival.  
 
5 
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5.1 AIMS 
In order to better understand the functional role of ALDOC in human leukaemic 
cell lines, this chapter aims: 
 
 To overexpress and  knock-down ALDOC in leukaemic cell lines using 
lentivirus and shRNAs for ALDOC. 
 To investigate whether ALDOC overexpression/knock-down affects 
proliferation of leukaemic cell lines. 
 To investigate the effects of ALDOC overexpression/knock-down on serum-
independent survival of leukaemic cell lines. 
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5.2 MATERIALS AND METHODS 
5.2.1 EXPRESSION AND KNOCKDOWN OF ALDOC IN LEUKAEMIC CELL LINES  
5.2.1.1 Generation of the ALDOC overexpressing leukaemic cell lines 
 Control pHIV-EGFP (empty vector) and pHIV ALDOC EGFP lentiviruses were 
generated as described in (section 2.7). Specific details of the vector construction are in the 
results section (5.3.1.1). K562, THP-1, MV-4-11 and KG-1 cell lines were lentivirally 
transduced with each virus as described in (section 2.8). Cells were assessed for GFP 
expression by flow cytometry analysis to determine the transduction efficiency.  
5.2.1.2 Fluorescence activated cell sorting of transduced cells 
Discrete subpopulations of GFP positive cells were isolated using cell sorting. A 
minimum of 2 x106 transduced cells were resuspended in PBS containing 1% BSA (sterile 
filtered) and passed through 40 µM cell strainer into BD FACS tubes. Cells were then 
sorted using fluorescence activated cell sorter (FACS) (BD Aria), harvested and cultured 
into fresh serum replete medium for recovery and used for the determination of the 
experimental end points. GFP positivity was analysed using flow cytometry before and 
after cell sorting in order to validate successful sorting.  
 
5.2.1.3 Generation of the ALDOC knock-down leukaemic cell lines 
 In order to suppress ALDOC protein expression in leukaemic cell lines and 
follow the effects of this loss on proliferation and survival, lentiviruses encoding shRNA 
control and ALDOC shRNA Table 5.1 (Sigma, UK) were generated as described in  
(section 2.7).  K562, THP-1, MV-4-11 and KG-1 cell lines were lentivirally transduced 
with each virus as described in (section 2.8). The vector utilised puromycin resistance as a 
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selectable marker of gene transduction. Two controls (pLKO.1-puro Non-Mammalian 
shRNA control cells (transduction control) and puromycin sensitive/parental cells 
(selection control) were employed in this transduction. Puromycin (1 µg/ml for K562 and 
MV-4-11, 0.7 µg/ml for THP-1 and 1.5 µg/ml for KG-1) was added in all the cultures 
accordingly.  Completion of the puromycin resistant cells selection was established by the 
absence of viable cells in parental cells (puromycin sensitive control). Once selection was 
complete, cells were harvested in to fresh medium and cultured as described in (section 
2.3.3.1 Table 2.6) for recovery before use for further experimental end points. 
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Table 5.1 Hairpins (shRNA) designed to target transcripts from ALDOC 
AS = ALDOC shRNA sequence ID number/name given in the current study; % Match = percent match of hairpin target sequence (21mer) to 
transcript RNA sequence; % SDR Match = percent match of the "Specificity-Defining Region" of the hairpin target sequence to transcript RNA 
sequence. SDR is the initial 19 bases of the (21mer) target sequence. 100 % = 19/19. 230 = Target gene reference number.   
Adapted from Broad institute: online (http://www.broadinstitute.org/rnai/public/gene/details?geneId=TRCG0000013892
Sequence 
no. 
Sequence ID Legacy Clone 
Name 
Target Seq Target 
Taxon 
Target 
Gene 
Target 
Gene 
Symbol 
Vector Match 
Position 
Match 
Region 
Match 
% 
SDR 
Match 
% 
AS2 TRCN0000052513 NM_005165.1-
1113s1c1 
GCAGCACAGTCACTCTACATT human 230 ALDOC pLKO.1 1113 CDS 100 100 
AS1 TRCN0000052514 NM_005165.1-
306s1c1 
CTCTACCAGAAAGATGATAAT human 230 ALDOC pLKO.1 306 CDS 100 100 
AS3 TRCN0000052515 NM_005165.1-
647s1c1 
CGACCTCAAACGTTGTCAGTA human 230 ALDOC pLKO.1 647 CDS 100 100 
AS4 TRCN0000052516 NM_005165.1-
880s1c1 
AGAGCGAAGAAGAGGCATCAT human 230 ALDOC pLKO.1 880 CDS 100 100 
AS5 TRCN0000052517 NM_005165.1-
610s1c1 
CTATTGTGGAACCTGAAATAT human 230 ALDOC pLKO.1 610 CDS 100 100 
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5.2.2 INVESTIGATION OF THE EFFECTS OF ALDOC KNOCK-IN AND KNOCK-DOWN ON 
LEUKAEMIC CELL LINES  
5.2.2.1 Preparation of cells for the analysis of proliferation and survival  
Transduced K562, THP-1, and MV-4-11 cells and their corresponding controls 
were harvested from growth medium by centrifugation at 180 g for 10 min. To reduce 
background effects of serum due to left over serum from the growth medium (which would 
interfere with the survival assay), all traces of serum containing medium were removed by 
washing the cells twice by centrifugation with 20 ml and 10 ml serum-free medium at 180g 
for 10 min. Washed cell pellets were resuspended and set to a final density 0.5x105 
cells/ml (for K562) and 1.0 x105 cells/ml (for THP-1 and MV-4-11) in either serum-free, 
supplemented (with glutamine and gentamycin) IMDM or RPMI or in media with 10% 
serum and supplements (normal growth condition) for comparison. These cells were used 
for the proliferation and survival assays.  
To determine whether ALDOC promotes proliferation in transduced K562, 
THP-1 and MV-4-11 (generated in 5.2.1.1 and 5.2.1.3) under normal growth conditions, 
cells were prepared as above and analysed as below. To determine whether ALDOC 
promotes serum-independent survival of ALDOC and shRNA transduced K562, THP-1, 
and MV-4-11 the detection of apoptosis in these cells deprived of serum was necessary. 
Cells (1 ml) (generated in 5.2.1.1 and 5.2.1.3 ) were incubated in a 24 well plate in a 5% 
CO2 humidified atmosphere at 37 oC in the presence or absence of serum (to induce 
apoptosis). The incubation time was 72 h to maximise any survival differential between the 
controls and ALDOC or ALDOC shRNA transduced cells (i.e. for both knock-in and 
knock-down experiments). These cells were analysed as below. Any modifications are 
indicated in the appropriate figure legend. At least 3 independent replicate experiments for 
both knock-in and knock-down were carried out for all the assays.  
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The above models were used to investigate whether ALDOC KI and KD 
affected the proliferation of leukaemic cell lines using 2 different methods; namely MTS 
(5.2.2.2) and Cellometer (5.2.2.3) assays under normal growth conditions (i.e. in the 
presence of serum). More than one assay was carried out in order to improve confidence in 
the results. The MTS assay is a colorimetric method for the determination of the metabolic 
activity of cells in culture via the reduction of a tetrazolium compound and hence is not 
necessarily directly related to cell number. Assay conditions which alter metabolic activity 
such as the presence of ALDOC, an enzyme involved in metabolism could possibly 
influence the results. The advantage of this assay is that multiple readings can be taken 
overtime. However the MTS assay requires a lot of optimisation for each cell lines used, 
including the number of cells needed as well as the incubation time for formazan 
formation. The Cellometer method on the other hand recognizes cells based on their light 
scattering properties. Cells are stained with trypan blue (a dye exclusion method that 
utilizes membrane integrity to identify dead cells) and the instrument can thereby 
distinguish viable cells giving both the concentration and percentage viability of the 
culture. The Cellometer reports actual cell number and the percentage viability. It is a rapid 
analysis method for accurate viability determination and a simple method for cell 
proliferation studies as compared to the MTS assay. It is more accurate than manual 
counting of cells using a haemocytometer.  
 
5.2.2.2 MTS assay 
To determine whether ALDOC promotes proliferation under normal growth 
conditions, transduced K562, THP-1, and MV-4-11 cells (100 µl) and their corresponding 
controls harvested and prepared as above, were incubated in a 96 well plate at 37oC in a 
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5% CO2 humidified atmosphere for 72 h to maximise any proliferation differential between 
the controls and ALDOC or ALDOC shRNA transduced cells.  
After incubation, MTS reagent (20 µl) (Promega, USA) was added to each well 
of the 96-well assay plate containing the samples in 100 µl of culture medium using a 
multi-channel pipette. Cells were incubated further for 4 h in a 5% CO2 humidified 
atmosphere at 37 oC and absorbance was measured after 4 h using a 96-well plate reader. 
Results were analysed using Microsoft Excel 2007.  
5.2.2.3 Cellometer 
To determine whether ALDOC promotes proliferation under normal growth 
conditions, transduced K562, THP-1, and MV-4-11 cells and their corresponding controls 
harvested and prepared as above were incubated in a 24 well plate at 37oC in a 5% CO2 
humidified atmosphere for 72 h. 
After incubation, 20 µl of the cells were harvested, stained with 20 µl of trypan 
blue (Sigma, UK) and the percentage and total number of viable cells was determined by 
Cellometer counter (Nexcelom Biosciences, USA). Results were analysed using Microsoft 
Excel 2010. 
5.2.2.4 DNA content analysis of transduced leukaemic cell lines 
To measure apoptosis, propidium iodide (PI) was used to label intracellular 
DNA and flow cytometry was used to analyse DNA content using a protocol similar to that 
described in section 5.2.2.3 with some slight modifications (indicated where appropriate). 
After incubation, cells were washed with 15 ml PBS by centrifugation at 180 g 
for 10 min and the pellet was resuspended in 300 µl PBS and left on ice for 5 min. Ice cold 
ethanol (700 µl) was added to the cell suspension and the mixture was incubated on ice for 
further 30 min followed by incubation overnight at -20 oC. Following incubation, 10 ml of 
PBS was added to the cell suspension and then centrifuged at 300 g for 10 min. The cell 
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pellet was resuspended in 75 µl PBS and 25 µl of staining solution consisting of PI at 40 
µg/ml and RNase at 0.1 µg/ml (Sigma, UK) was added and the mixture was incubated for 
30 min at 37 oC in a water bath. PI labelled cells were analysed by flow cytometry. The 
results were further analysed using multi-cycle on FCS express version 4 (De Novo 
Software, Los Angeles, CA) for the determination of the percentage of the cells that were 
apoptotic (sub G0/G1 events) which was determined by the subtraction of the background 
apoptotic frequency (from 10% serum growth condition) to correct for the low level of 
background apoptosis in normal growth condition. 
5.2.2.5 7-AAD method 
Given the fact that loss of homeostasis and membrane integrity are some of the 
indications of late stage apoptosis (Wyllie, 1997), and that 7-AAD, a known membrane – 
impermeable molecule can enter cells with defective plasma membranes and interpolates 
with DNA resulting in the fluorescent complexes (Schmid et al., 1992), this facilitated the 
use of this molecule (7-AAD) in conjunction with flow cytometry for the detection of 
apoptosis. In addition this assay was also previously validated in our lab for the detection 
of apoptosis in CD34+ cells.   
After incubation, 100 µl of the remaining cells were harvested, labelled with 1 
µg/ml 7-AAD (Sigma-Aldrich) for 30 min and analysed by flow cytometry and the results 
were further analysed using FCS Express version 4 (De Novo Software, Los Angeles, CA).  
7-AAD enabled the discrimination of apoptotic and viable cells.  
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5.3 RESULTS 
5.3.1 GENERATION OF ALDOC OVEREXPRESSING LEUKAEMIC CELL LINES  
5.3.1.1 Construction of ALDOC lentiviral expression vector 
ALDOC lentivirus vector (pHIV ALDOC EGFP) was generated as described in 
(section 2.2.5 and Figure 5.1 and Figure 5.2). In summary, ALDOC coding sequence DNA 
was excised from pEXK-ALDOC plasmid (Table 2.5) using SmaI and XbaI double 
restriction digest (Figure 5.1). The expected fragments sizes corresponding to the ALDOC 
sequence (1.2 kb) and pEXK sequence (2.5 kb) were generated. The ALDOC coding 
sequence was excised from a preparative agarose gel and purified as described in section 
2.2.5.  The recipient pHIV EGFP lentiviral vector (Table 2.5) was linearized using the 
same restriction digest (Figure 5.1).  The insert (ALDOC) and the vector (pHIV-EGFP) 
were ligated by incubation with ligase in ligase buffer in order to generate the recombinant 
plasmid, pHIV ALDOC EGFP (Figure 5.1). The ligation was transformed as described in 
section 2.2.1. Following ligation and transformation six clearly distinct ampicillin- 
resistant colonies were isolated, and cultured for DNA isolation. To identify colonies 
harbouring pHIV ALDOC EGFP DNA, NcoI restriction enzyme test digest was performed 
using a similar protocol to the one described in section 2.2.4, on all plasmid DNAs isolated 
from the above colonies. pHIV EGFP contains three NcoI enzyme recognition sites and 
ALDOC insert contains one NcoI recognition site. Therefore as shown in Figure 5.1 pHIV 
ALDOC EGFP contains four NcoI enzyme restriction sites hence four fragments are 
expected in the colonies containing pHIV ALDOC EGFP DNA whereas the parent vector 
would only generate 3 fragments (Figure 5.2). Four colonies (C1, C2, C4 and C5) were 
identified via test digest as potentially expressing the relevant pHIV ALDOC EGFP DNA 
(Figure 5.2) indicated by the expected fragment numbers and sizes. Finally one colony 
(C1) was taken as the definitive colony and DNA from this colony was used for sequence 
verification using Eurofins sequencing service (Eurofins Genomics, Germany). The results 
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were as predicted (data not shown) and hence DNA derived from this colony was used in 
subsequent experiments. 
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Figure 5.1 Generation of pHIV ALDOC EGFP 
The ALDOC lentivirus vector (pHIV ALDOC EGFP) was generated by excision 
of ALDOC coding sequence DNA from pEXK-ALDOC using double restriction digest, 
SmaI and XbaI. Locations of restriction enzyme recognition sequences and the insert 
sequence are shown. The recipient pHIV EGFP lentiviral vector was linearized using the 
same restriction digest. Ligation and transformation yielded the final pHIV ALDOC EGFP 
which was verified using NcoI restrictive enzyme digestion (Figure 5.2) and then used for 
the generation of lentivirus encoding ALDOC.  
NcoI 
pHIV ALDOC EGFP 
8852 bp
ALDOC 
ALDOC
SmaIXbaIXbaI SmaI
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Figure 5.2 Recombinant plasmid DNA verification by restriction enzyme digestion 
Six clearly distinct colonies generated as described above (5.3.2) were analysed 
for their plasmid DNA content. Test digests were carried out using NcoI and agarose gel 
electrophoresis as described in Chapter 2. The insert-derived band at 763bp indicated 
successful subcloning in 4/6 of the colonies. 300 ng DNA was loaded per lane. 
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5.3.1.2 The overexpression of ALDOC protein in leukaemic cell lines 
To establish whether ALDOC promotes proliferation in leukaemic cell lines, it 
was important to overexpress (knock-in) ALDOC in leukaemic cell lines. K562, THP-1, 
KG-1 and MV-4-11 cells were lentivirally transduced with either GFP control or ALDOC 
DNA constructs generated above (section 5.3.1.1). Transduced cells were analysed for 
GFP expression by flow cytometry (section 5.2.1.1). All cell lines with GFP positivity of 
less than 70% were enriched for GFP expression by cell sorting as described in 5.2.1.2. 
ALDOC and control MV-4-11 cells exhibited a pre-sort GFP positivity in the range (36-
75%) and a post-sort GFP positivity in the range (93-94 %) (Figure 5.3A). Since the GFP 
positivity of K562 and THP-1 cultures were in the range (70-99%) for both ALDOC and 
control these were not taken for cell sorting (Figure 5.3A). KG-1 cells showed a very low 
GFP expression (less than 1%) and demonstrated instability in GFP expression post-sort; 
hence these cells were not studied further. 
 Following gene transduction, confirmation of ALDOC overexpression was 
carried out via western blotting. The results of the western blots (Figure 5.3B) showed that 
ALDOC was overexpressed in THP-1, MV-4-11 and K562 cells indicated by 
approximately 2 fold increase of ALDOC protein levels in ALDOC transduced cultures as 
compared to the corresponding controls in each of the cell lines. These results should be 
interpreted with caution since the loading control used, GAPDH is an enzyme involved in 
the glycolytic pathway just like ALDOC. However, this was similar to the overexpression 
of ALDOC observed in CD34+ N-RAS cells, protein levels (2-3 fold) (Chapter 4). It was 
therefore concluded that the ALDOC DNA construct used in this study was effective. 
 
CHAPTER 5: FUNCTIONAL ANALYSIS OF ALDOC  IN  HAEMATOPOIETIC CELLS 
171 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A 
75.1% GFP+ 
93% GFP+
36.4% GFP+ 
94% GFP+
97% GFP+ 70% GFP+
ALDOC CONTROL
MV-4-11 
Pre-sort
MV-4-11 
Post-sort
K562
Thp-1 99% GFP+
i) ii)
96% GFP+
97% GFP+
70% GFP+
93% GFP+ 94% GFP+
75.1% 36.4% 
CHAPTER 5: FUNCTIONAL ANALYSIS OF ALDOC  IN  HAEMATOPOIETIC CELLS 
172 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3 The assessment of ALDOC overexpression  
(A) Analysis of GFP positivity; ALDOC and GFP control transduced cultures of 
K562, THP-1 and MV-4-11 were analysed for GFP positivity (filled histograms) post 
transduction. Threshold for positivity was determined by autofluoroscence (open 
histograms) of parental cells, and percentages of GFP+ are shown for i) control cells and ii) 
ALDOC cells. GFP was analysed pre and post-cell sorting for both the control and 
ALDOC MV-4-11 cells. (B) Assessment KI efficiency of ALDOC in K562, THP-1 and 
MV-4-11 cells; Whole cell protein extracts of ALDOC and GFP control transduced 
cultures of K562, THP-1 and MV-4-11 were prepared as described in section 2.9.1 and 
western blot analysis was performed as described in section 2.9 using (1000 ng/ml) anti-
ALDOC antibody (Abcam). 20 ng/ml anti-GAPDH (Santa Cruz) was used as a loading 
control.  
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       C     A     C     A     C    A      
C = Control 
A = ALDOC
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5.3.2 GENERATION OF ALDOC KNOCK-DOWN LEUKAEMIC CELL LINES 
In order to establish the functional role of ALDOC in leukaemic cell line observed above 
(section5.3.1.2 ) it was important to knock down the endogenous levels of ALDOC protein 
within the leukaemic cell lines and examine the consequences on the proliferation and 
survival of these cells. To optimise and validate this approach, K562 cells were used in the 
initial stage of this study because of their tractability and high endogenous levels of 
ALDOC. The western blot (Figure 5.4A) show that the knockdown (by approximately 3.5 
fold) was greatest in cells expressing ALDOC shRNA2 (AS2) (sequence ID 
TRCN0000052513). This construct was then also used to knock-down ALDOC in other 
cell lines (THP-1, MV-4-11 and KG-1). KG-1 cells grew very poorly after the infections 
with the ALDOC shRNA, hence were not studied further. Western Blot analysis (Figure 
5.4B) showed that ALDOC was also successfully knocked down in THP-1 and MV-4-11 
by approximately 1.5 fold. 
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Figure 5.4  Assessment of ALDOC shRNA knockdown  
(A) Assessment KD efficiency of ALDOC shRNA in K562 cells; K562 cell line 
was initially transduced with 5 clones of ALDOC shRNA, AS1, AS2, AS3, AS4 and AS5. 
(B) Assessment KD efficiency of successful ALDOC ShRNA in THP-1 and MV-4-11 
cells; 1 shRNA clone (AS2) was used to knock-down ALDOC in MV-4-11 and THP-1 
cells. Whole cell protein extracts of ALDOC shRNA and the corresponding control 
shRNA transduced cultures of K562, THP-1 and MV-4-11 were prepared and western blot 
analysis was performed under the same conditions described above (Figure 5.3).  
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5.3.3 THE ROLE OF ALDOC IN PROLIFERATION 
Given the previous findings of the ability of ROS to promote proliferation, this 
study investigated whether the overexpression of ALDOC that occurs in response to ROS 
(Chapters 3 and 4) could play any role in promoting proliferation of K562, THP-1 and 
MV-4-11 cell lines by studying the effect of both ALDOC overexpression (knock-in) and 
knock-down . 
5.3.3.1 ALDOC knock-in promotes proliferation of human leukaemic cell lines 
In order to establish whether ALDOC promotes proliferation of human 
leukaemic cells, MTS and Cellometer counts assays described in 5.2.2.2 and 5.2.2.3 were 
used. Under normal culture conditions THP-1 and MV-4-11 cells overexpressing ALDOC 
showed a significant increase in relative proliferation over 72 h compared to the 
corresponding controls. MV-4-11 showed significant ~2.4 and 1.4 fold increases with the 
Cellometer and MTS assays respectively while THP-1 showed significant ~2.7 and 1.5 
fold increases with the Cellometer and MTS assays respectively. ALDOC also modestly 
enhanced proliferation in K562 cells (<1.5 fold) which was not significant with regards to 
both the Cellometer and MTS assays. The trend of the results was consistent across all the 
cell lines with regards to both MTS and Cellometer data despite greater effects in 
proliferation with the Cellometer (Figure 5.5). Taken together these data demonstrates that 
ALDOC knock-in is sufficient to promote proliferation of these leukaemic cell lines. 
5.3.3.2 ALDOC knock-down impairs the proliferation of human leukaemic cell lines  
Considering the results obtained above (5.3.3.1), it was then tested whether 
ALDOC expression was also necessary for proliferation of these cells by examining the 
effects of ALDOC knock-down. To investigate this, a similar version of the protocol used 
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in 5.3.3.1 was used to establish whether ALDOC knock-down affected the proliferation of 
K562, THP-1 and MV-4-11 cells using ALDOC knock-down cell lines and shRNA control 
cell lines (generated as described in 5.2.1.3) and validated in (5.3.2) . 
Under the conditions of the experiments above, ALDOC knock-down in THP-1 
and MV-4-11 cells showed a significant decrease in relative proliferation over 72 h 
compared to the corresponding controls. MV-4-11 showed significant ~2 fold decrease 
with both the Cellometer and MTS assays while THP-1 showed significant ~5 fold 
decrease with both Cellometer and MTS assays. Finally K562 showed the modest effect on 
proliferation with less than 2 fold decrease with both assays and was not statistically 
significant (Figure 5.6) The results were consistent across all the cell lines with regards to 
both MTS and Cellometer data (Figure 5.6). Taken together these data demonstrate that 
ALDOC knock-down can impair proliferation of THP-1 and MV-4-11 cell lines. 
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Figure 5.5 The effect of ALDOC knock-in on proliferation of transduced leukaemic 
cells 
Leukaemic cell lines (MV-4-11, THP-1, K562) overexpressing ALDOC and 
their corresponding control were cultured in serum-replete (10%) media for 72 h and 
proliferation was measured using (A) Cellometer and (B) MTS assay (experiment was 
carried out in quadruplicate for each treatment condition). Data are normalised relative to 
control cells hence there are no error bars on controls. Statistical significance was 
calculated using the Student’s t-test.*P<0.05 n=3 for Cellometer and n=4 for MTS assay; 
error bars represent SD. 
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Figure 5.6 The effect of ALDOC knock-down on proliferation of transduced 
leukaemic cells 
ALDOC knock-down lines (MV-4-11, THP-1, and K562) and their 
corresponding control were cultured in the same conditions as above (Figure 5.5) and 
proliferation was measured using (A) Cellometer and (B) MTS assay. Data are normalised 
relative to control cells hence there are no error bars on controls.  Statistical significance 
was calculated using the Student’s t-test.*P<0.05 n=3 for each assay; error bars represent 
SD. 
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5.3.4 THE ROLE OF ALDOC IN CELL SURVIVAL 
5.3.4.1 ALDOC overexpression promotes serum-independent survival of human 
leukaemic cell lines 
Given the effects of ALDOC on proliferation (5.3.3.1 and 5.3.3.2) it was then 
examined whether ALDOC ectopic expression also influenced cell survival. To test this, 
cells were cultured in the absence of serum and apoptosis was determined using two 
different methods namely 7AAD assay (described in section 5.2.2.5) and the DNA content 
assay (section 5.2.2.4) for the determination of the frequency of cells with sub G0/G1 
DNA content (a well-established feature of apoptotic cells).   
Under culture conditions previously described (absence of serum), THP-1 cells 
overexpressing ALDOC showed a significant ~1.2 fold and marked ~2.5 fold  decrease in 
apoptosis over 72 h compared to the corresponding controls using the 7AAD and DNA 
content methods respectively. MV-4-11 showed non-significant ~1.2 and ~1.1 fold 
decreases using the 7AAD and DNA content methods respectively and finally K562 
showed significant ~1.5 and marked 2.5 fold decreases with the 7AAD and DNA content 
methods respectively (Figure 5.7A and Figure 5.8A). All ALDOC KI cell lines therefore 
showed some resistance to apoptosis with the highest significant effect in THP-1 cells 
(Figure 5.7A and Figure 5.8A). It was therefore concluded that ALDOC overexpression is 
able to promote serum-independent survival of human leukaemic cells. 
5.3.4.2 ALDOC protein knockdown inhibits the survival of human leukaemic cell lines  
Considering the results obtained (5.3.4.1), it was then examined whether 
ALDOC expression was also necessary for survival of these cells by examining the effects 
of ALDOC knock-down. To investigate this a similar version of the protocol used in 
5.3.4.1 was used to establish whether ALDOC knock-down affected the survival of K562, 
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THP-1 and MV-4-11 cells using ALDOC knocked-down cell lines and shRNA control cell 
lines (generated as described in 5.2.1.3 and validated in 5.3.2). 
Under the conditions of the experiments above, ALDOC knock-down showed a 
significant effect on apoptosis in THP-1 cells only. ALDOC KD THP-1 cells showed ~1.7 
fold increase in apoptosis over 72 h compared to the corresponding controls using 7AAD 
method (Figure 5.7B) and a ~2.5 fold increase in the sensitivity to apoptosis using DNA 
content method (Figure 5.8B) though this increase was not statistically significant. MV-4-
11 and K562 showed smaller changes in sensitivity to apoptosis but these were not 
significant. These results taken together with the results of the ALDOC knock-in (5.3.4.1) 
suggested that ALDOC exhibit pro-survival properties with the highest effects in THP-1 
cells since cells were able to survive under no serum condition and ALDOC enhanced the 
survival of these cells. Moreover these cells were more sensitive to apoptosis in the 
absence of ALDOC.  It was therefore concluded that ALDOC exhibit both the pro-survival 
and pro-proliferative effects which might help in understanding the role of ALDOC, ROS 
and RAS in leukaemogenesis. 
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Figure 5.7 Summary of the 7AAD flow cytometric data showing apoptotic transduced 
leukaemic cells after serum deprivation for 72 h 
(A) Effect of ALDOC knock-in on survival of MV-4-11, THP-1 and K562 cells i) 
Representative flow cytometric plots showing apoptotic cells in control, ii) ALDOC 
transduced cells and iii) A summary of the flow cytometric data. (B) Effect of ALDOC 
knock-down on survival of MV-4-11, THP-1 and K562 cells i) Representative flow 
cytometric plots showing apoptotic cells in shRNA control, ii) shRNA ALDOC transduced 
cells and iii) Summary data are expressed as mean percentage apoptotic cells. Statistical 
significance was calculated using the Student’s t-test.*P<0.05 n=4 for knock-in and n=3 
for knock-down; error bars represent SD. 
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Figure 5.8 Summary of the DNA content sub-G0/G1 data showing apoptotic 
transduced leukaemic cells after serum deprivation over 72 h 
 (A) Effect of ALDOC knock-in on survival of MV-4-11, THP-1 and K562 cells 
i) Representative histograms showing apoptotic cells (indicated by the sub G0/G1 DNA 
content data) in control, ii) ALDOC transduced cells and iii) A summary of the apoptosis 
DNA content data. (B) Effect of ALDOC knock-down on survival of MV-4-11, THP-1 and 
K562 cells. A summary of the apoptosis DNA content data showing apoptotic cells 
following serum deprivation and staining with PI. % apoptotic cells (sub G0/G1 events) 
were determined by the subtraction of the background apoptotic frequency (from 10% 
serum growth condition). Data are expressed as mean percentage apoptotic cells. Statistical 
significance was calculated using the Student’s t-test.*P<0.05 n=3 for each assay; error 
bars represent SD. 
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5.4 DISCUSSION 
It was previously shown that ROS production has significant effects on the 
proliferation of human CD34+ haematopoietic cells expressing mutant RAS (Hole et al., 
2010); however, the mechanism by which ROS promotes proliferation remained unclear. 
Data in Chapter 4 demonstrated that N-RAS-induced ROS significantly up regulated the 
expression of 24 genes in CD34+ haematopoietic cells many of which were associated with 
glycolysis and gluconeogenesis as revealed by Exon Microarray and Metacore pathway 
analysis; for example ALDOC (4.3 fold), GPI (1.5 fold), PFK-1 (1.4 fold), ENO2 (2.6 
fold), FBP1 (1.8 fold). Amongst the genes identified, five were validated using Western 
Blotting of which ALDOC and ENO2 were analysed in further experiments to test directly 
whether these genes were ROS responsive. Both of them were indeed ROS responsive and 
ALDOC was selected for further functional studies since it showed the strongest 
expression in the presence of GOX in both cell lines and CD34+ cells. This chapter aimed 
to test whether ALDOC could mediate some of the previously observed functional effects 
of ROS particularly the ability of ROS to promote proliferation.  
To understand the role of ALDOC in human leukaemic cell lines, an ALDOC 
lentiviral construct vector (pHIV ALDOC EGFP) was generated and this was used to 
knock-in ALDOC into KG-1, THP-1, K562 and MV-4-11 cells. On the other hand 
ALDOC knock-down in the same cell lines was achieved using shRNA for ALDOC. KG-1 
cells showed very low and unstable GFP expression in both the control and ALDOC 
cultures following infections. Moreover these cells did not grow well following infections 
with shRNA hence were not studied further. Though, these cells would have been the ideal 
ones to use for functional studies (since they were previously shown to be responsive to 
GOX (Chapter 4), their lack of stability of lentiviral expression following infections means 
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that they are not a useful model for these studies. On the other hand the KI and KD of 
ALDOC in THP-1, K562 and MV-4-11 cells were successful as confirmed by Western 
Blotting.  
5.4.1 EFFECTS ON PROLIFERATION 
The data generated from this study using the above models and methods have 
shown that ALDOC expression can influence proliferation. The overexpression of ALDOC 
resulted in the significant increase in proliferation of MV-4-11 (1.4-2.4 fold) and THP-1 
cells (1.5-2.7 fold). Conversely a significant decrease in proliferation was observed when 
ALDOC was knocked-down in MV-4-11 (2 fold) and THP-1 cells (5 fold) with both the 
MTS and Cellometer methods. There were no significant effects of ALDOC in the 
proliferation of K562 cells suggesting that ALDOC does not regulate the proliferation of 
these cells. The proliferation data for ALDOC KI were consistent across the MTS and the 
Cellometer assays in terms of the trend of effect despite a slightly bigger effect size 
observed with regards to the Cellometer. A possible cause of this variation could be the 
differences in end points measured by the two assays (discussed above); however, 
variation in assay results (between MTS and the Cellometer) were not observed in the KD 
proliferation assays suggesting that the former differences could be due to experimental 
variation rather than to differences in end points used. Interestingly MV-4-11 and THP-1 
cell lines were previously shown to respond to ROS induced proliferation in our lab and 
both contain RAS mutations.  Therefore it is possible that ALDOC, a ROS responsive 
gene, specifically promotes the proliferation in the context of mutant RAS.  This might 
then explain the failure of a pro-proliferative reponse in K562 cell lines (which do not 
contain mutant RAS).        
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Taken together the above data suggest that ALDOC expression could mediate 
the changes in proliferation observed as a consequence of ROS production and also 
highlight for the first time a potential role of ALDOC in leukaemic cell proliferation.  
The expression of the aldolase isozymes have been reported in cancer with 
ALDOA commonly overexpressed in pancreatic and digestive tract cancers demonstrated 
by elevated levels in patient’s serum (Asaka et al., 1983). Tissue ALDOC levels were 
found elevated in patients with lung cancer (Ojika et.al., 1991). A study by Hatakeyama et 
al., (2011), demonstrated that mRNA levels of ALDOC gene was 30-fold higher in the 
highly metastatic gastric cancer cell line MKN45P than in the lower metastatic cell line 
MKN45 (Hatakeyama et al., 2011).  Recently the up-regulation of ALDOB was reported in 
the bone marrow blasts from AML patients with low prognosis-risk score (PRS) which the 
authors of this study concluded that it verified the modified glucose metabolism of this 
patients (Chen et al., 2014). According to the authors of this study, a low PRS was able to 
predict patients with poor survival. In the same study, in vitro results demonstrated 
enhanced glycolysis contributed to decreased sensitivity to anti-leukaemic agent Ara-C, 
whereas inhibition of glycolysis suppressed AML cell proliferation and potential 
cytotoxicity of Ara-C. Therefore this study provides evidence for the use of metabolic 
pathways as novel prognostic markers and potential therapeutic targets for AML. Despite 
these reports of overexpression of aldolases, their specific role in cancer cell proliferation 
was not addressed; however, dysregulation of glycolysis generally has been widely 
reported in cancer.  
Glycolysis is a metabolic process that occurs in the cytoplasm which involves 
the production of energy from glucose. In normal cells the rate of glycolysis is low and the 
products of this process are further processed in the mitochondria via oxidative 
phosphorylation. However, cancer cells display a metabolic shift from oxidative 
phosphorylation in the mitochondria to glycolysis in the cytosol or lactate fermentation 
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even in the presence of oxygen, a phenomenon known as the “Warburg effect” (Warburg, 
1956a and b) (Chapter 1 section 1.5). This has been further shown to result in biosynthetic 
precursors from glycolytic intermediates thus supporting rapid tumour progression (Hu et 
al., 2011; Hanahan and Weinberg, 2011; Kroemer and Pousyssegur, 2008; Vander Heiden 
et al., 2009).  Cancer cells exhibiting increased aerobic glycolysis are dependent on both 
glucose and glutamine as a source of carbon and the up-regulation of GLUT1, GLUT3 
(glucose transporters) and hexokinase I and II (key enzymes for the regulation of the first 
rate limiting steps in glycolysis) have been implicated in this (Bos et al., 2002; Burt et al., 
2001). High rates of glycolysis and glucose uptake have been demonstrated and reported in 
many tumours including AML (Chapter 1). For instance, use of FdGPET imaging for the 
clinical diagnosis of cancer has demonstrated that the elevated glucose uptake is observed 
in the majority of human cancers (Mochiki et al., 2004; Kaira et al., 2011; Vergez et al., 
2010).  
There is evidence that oncogenic mutations (discussed below) promote the up-
regulation of glucose transporters thus facilitating increased glucose consumption by 
cancer cells, which in turn increases the rate of glycolysis. Several molecules such as 
mutant RAS, c-Myc, HIF-1α, Akt have been implicated in this (Vafa et al., 2002; Kim and 
Dang, 2006).  
MYC, an oncogene involved in the regulation of cellular proliferation, has also 
been shown to also contribute to the Warburg effect by increasing glycolysis and lactate 
production via enhancement of the overexpression of GLUT 1 and lactate dehydrogenase 
A (LDHA) in cancer (Dang and Gao 2009). Metabolic changes in c-Myc driven 
oncogenesis were reported to have preceded tumour formation and modulated by 
inactivation of c-myc (Hu et al., 2011). The same study also emphasised the additional 
importance of glucose metabolism or high rates of glycolysis as a source of biosynthetic 
precursors for cancer cells since modifications of glycolysis and alanine (amino acid 
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synthesized from glycolytic intermediates) synthesis pathways were identified in pre-
tumour stages.  
Mutant RAS has been shown to contribute to an increase in glycolysis and 
proliferation in cancer cells (Chapter 1). For example, mutant RAS transfection in Fisher 
rat 3T3 (FR3T3) fibroblasts stimulates glucose uptake, increases glycolysis, inhibits 
oxygen consumption and weakens mitochondrial respiration (Flier et al., 1987). Another 
study has demonstrated that BJ fibroblasts cell line expressing H-RAS exhibit increased 
glycolysis and become more sensitive to the glycolytic inhibitor, 2-deoxyglucose 
(Ramanathan et al., 2005). It was also demonstrated that K-RASG12V transformation leads 
to mitochondrial dysfunction and a metabolic switch from oxidative phosphorylation to 
elevated glycolysis and generation of ROS in human embryonic kidney (HEK 293) cells 
(Hu et al., 2012). Activated RAS has been reported to increase glycolysis in several ways. 
For example, activation of Akt by RAS has been shown to promote the increased 
expression and membrane localization of the glucose transporter GLUT 1, stimulation of 
phosphofructokinase activity and the association of hexokinases 1 and 2 with the 
mitochondria thus increasing glucose uptake and glycolysis in haematopoietic cell line 
FL5.12 (Rathmell et al., 2003), mouse hepatoma (Hepa1c1c7) cells (Barthel et al., 1999), 
and Rat 1a cells, (Gottlob et al., 2001).  
Although it is clear that oncogenes such as these contribute to the Warburg 
effect, the mechanisms involved in the transition from oxidative phosphorylation to aerobic 
glycolysis in cancer cells were not addressed in detail by any of these studies.  The current 
study suggests that increased glycolysis may arise from up-regulated glycolytic genes 
triggered by RAS-induced ROS. In accord with this subsequent work has demonstrated 
increased glycolysis in N-RAS cells (Hopkins et al., 2014) indicating that N-RAS also 
promotes the Warburg effect in the haematopoietic context. Increased rates of glycolysis 
have also been implicated in AML patients (Chen et al., 2014).  This coupled with the 
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observation that over-production of ROS occurs in 60% of AML patients due to NOX 
oxidase activation (Hole et al., 2013) suggests that this may also be a mechanism of 
increased glycolysis in AML. In support of analysis of a GEP database of 139 AML 
patients; this showed that those with high ROS (defined by high NOX2 oxidase 
expression; Hole et al., 2013) had a distinct profile of glycolytic enzyme overexpression, 
particularly ALDOC (r=0.4; p=2x10-25), GPI (r=0.4; p=2x10-8) and FBP1(r=0.7; p=5x10-8) 
(Hopkins et al., 2014).  These are amongst the most significant ROS-responsive genes in 
Table 4.1 and suggest that promotion of glycolysis through extracellular ROS production is 
also seen in AML blasts.   
5.4.2  EFFECTS ON SURVIVAL 
In addition to the proliferation, analysis of the influence of ALDOC on cell 
survival was carried out. The 7-AAD and DNA content methods were used for these 
studies. 7-AAD is a membrane-impermeable molecule that can enter cells with defective 
plasma membranes and interpolate with DNA resulting in the fluorescent complexes 
(Schmid et al., 1992) and hence is suitable for the measurement of late stage apoptosis 
(section 5.2.2.5). The DNA content method was used to determine sub G0/G1 events and is 
based on the univariate analysis of cellular DNA content following cell staining with PI 
and analysis using flow cytometry. This approach enables the detection of apoptotic cells 
with fractional DNA content (sub G0/G1 events) and is a complementary method for 
measuring apoptosis.  
The overexpression of ALDOC resulted in the significant decrease in apoptosis 
of THP-1 cells (1.2-2.5 fold) and K562 (1.5-2.5 fold) under serum-free conditions. 
Conversely a significant increase in apoptosis was observed when ALDOC was knocked-
down for THP-1 cells (1.7-2.5 fold) and to some extent for K562 cells (1.3 fold). No 
significant effects on MV-4-11 survival were seen for either KI or KD. The survival data 
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for ALDOC KI and KD were consistent across the 7AAD and the DNA content method in 
terms of the trend of effect despite the lack of significance/statistical power in data due to 
the low number of replicate samples.  
Overall, these results suggest that ALDOC overexpression can promote survival 
and that ALDOC expression was also necessary for survival of THP-1 cells. This is a novel 
finding and the mechanism underlying this is still yet to be elucidated; however, existing 
literature suggest that this might be related to glycolysis. Munoz-Pinedo (2012) pointed out 
that cancer cells may benefit from keeping an active metabolism not only for proliferation 
but also as a mechanism to escape cell death. Interestingly, stimulation of glucose uptake 
has been linked to the suppression of apoptosis in normal haematopoietic cells (Barnes et 
al., 2005) and increased tumour aggressiveness has been linked to elevated glucose uptake 
(Mochiki et al., 2004; Kunkel et al., 2003). Hypoxic tumours such as pancreatic cancer and 
melanoma are dependent upon raised glycolysis for survival (Postovit et al., 2002; He et 
al., 2004; Büchler et al., 2003; Postovit et al., 2004). In addition it has been previously 
demonstrated that increased glycolytic rate renders cancer cells more resistant to apoptosis 
induced by growth factor withdrawal. For instance, in leukaemic cells overexpression of 
hexokinase 1 and GLUT 1 was sufficient to protect against IL-3 withdrawal (Rathmell et 
al., 2003). IL-3 withdrawal targets the anti- apoptotic protein Mcl-1 for proteasome 
degradation leading to cell death (Maurer et al., 2006) but Mcl-1 has been shown to be 
stable when glucose levels are high (Zhao et al., 2007). Another study has demonstrated 
that AMPK/mTOR axis (Chapter 1) inhibits translation of Mcl-1 if glycolysis is inhibited, 
thus making cells more susceptible to death ligands (Pradelli et al., 2009). Increased 
glycolysis also inhibits expression and activity of many pro-apoptotic BH3-only proteins, 
which mediate death induced by physiological agents and chemotherapeutic drugs (El 
Mjiyad et al., 2010). For example over expression of GLUT 1 was shown to inhibit Puma 
induction in the early haematopoietic precursor (murine pro-lymphocytic) cell line, FL5.12 
CHAPTER 5: FUNCTIONAL ANALYSIS OF ALDOC  IN  HAEMATOPOIETIC CELLS 
190 
 
upon growth factor withdrawal (Zhao et al., 2008). Metabolic stress was shown to regulate 
the pro-apoptotic BH3-only proteins, Noxa and Bad. High glucose levels has been shown 
to promote CDK5-mediated phosphorylation and inactivation of Noxa in leukaemic cells 
(Lowman et al., 2010) and Bad was shown to be dephosphorylated and induced apoptosis 
under low glucose conditions (Danial et al.,2003). Besides the BH3-only proteins, it was 
also shown that glucose deprivation induced a drop in the cFLIP levels and sensitization to 
death receptors in HeLa cells (Munoz-Pinedo et al., 2003). Interestingly, it was shown that 
maintenance of ATP production or overexpression of the glycolytic enzyme GAPDH 
promotes survival of cancer cells (Colell et al., 2007; Ferraro et al., 2008; Ricci et al., 
2004).  
 Glycolytic rate has also been linked to chemotherapy resistance and poor 
prognosis Increased glycolysis has been shown to be associated with resistance to 
apoptosis induction by a combination of ATRA and ATO in AML cell lines (Herst et al., 
2008). The authors of this study suggested that the extent of myeloblast glycolysis may be 
an effective and easily applied method to determine the pre-treatment prognosis of AML. 
Elevated glycolysis and treatment resistance is also a feature of ALL (Beesley et al., 2009 
and Hulleman et al., 2009). The fact that most tumours are highly dependent on glucose 
have led to the development of inhibitors against almost every step of glycolysis some of 
which are currently being tested in vitro, in vivo and in clinical trials (see Chapter 1 and 6).  
5.4.3 CONCLUSION  
In conclusion data from this study show for the first time that a major target of 
ROS are enzymes of the glycolytic pathway. Evidence that ROS promotes glycolysis in 
both cell lines and in AML patients and that myeloid leukemia cells show dependency on 
ALDOC, for their growth and survival has also been shown. Thus results of this study also 
highlight the duality of ALDOC effects, concurrently enhancing proliferation while 
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hampering apoptosis. These data suggest a possible mechanism for the enhanced glycolysis 
seen in AML and also indicate that agents restoring the redox environment could be used 
to correct metabolic imbalances which contribute to treatment resistance in this disease. 
Further work would however be required to substantiate these conclusions and this is 
discussed in Chapter 6. 
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6 General Discussion and 
Further Work 
 
AML is characterised by accumulation of blasts with an unrestrained 
proliferative capacity and a block at various stages of myeloid differentiation (Löwenberg 
et al., 1999). Its development has been attributed to alterations in genes that confer 
proliferative advantage or differentiation arrest (Gilliland et al., 2004) and mutational 
activation of RAS, particularly N-RAS is one of the most common molecular 
abnormalities associated with AML (section 1.2.2).  Mutant RAS has also been linked to 
overproduction of ROS in several cancers including AML (Sallmyr et al., 2008; Kumar et 
al., 2008).  It was previously demonstrated that normal human CD34+ haematopoietic cells 
expressing mutant RAS overproduce ROS due to NOX activation and this has been shown 
to promote the proliferation of these cells (Hole et al., 2010).  More recently, NOX derived 
ROS was shown to promote proliferation in AML blasts (Hole et al., 2013).  The 
mechanisms by which ROS promote proliferation are unclear. Therefore the main aim of 
this study was to examine the effects of RAS induced ROS on gene expression and to 
determine the functional consequences of the key changes in gene expression.  
The results of this study have shown for the first time that extracellular ROS 
driven by N-RASG12D drives significant expression of several glycolytic enzymes in human 
CD34+ haematopoietic cells including ALDOC (Chapters 3 and 4)  and that ALDOC 
promotes both proliferation and survival of myeloid leukaemia cell lines (Chapter 5). 
Taken together, the results of this study and other findings in our lab (Hopkins et al., 2014) 
suggest that extracellular ROS promote glycolysis in CD34+ haematopoietic cells and 
AML blasts (discussed in Chapter 5).  
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The results of the current study raise a question as to whether ALDOC or other 
glycolytic enzymes found in this study and/or NOX induced ROS may be relevant 
therapeutic targets in AML. The extent of ALDOC expression and levels of glucose 
metabolism in AML particularly in leukaemias with mutant RAS or high NOX2 activity is 
currently unknown; however, analysis of our GEP database of 139 AML patient blasts has 
shown that those with high ROS (defined by high NOX2 oxidase expression; Hole et al., 
2013) had a distinct profile of glycolytic enzyme overexpression, particularly ALDOC, 
GPI and FBP1 (Hopkins et al., 2014) which are amongst the most significant ROS 
responsive genes identified in this current study. To strengthen the argument for targeting 
ALDOC in AML, future studies could involve the analysis of ALDOC protein expression 
in AML blasts and association with clinical outcome with the hope of discovering a 
prognostic association with ALDOC overexpression, especially given that (Chen et al., 
2014) recently showed that aldolase B enzyme (ALDOB) overexpression was associated 
with elevated glycolysis and poor prognosis in AML.  The effect of KI and KO of other 
glycolytic genes (such as GPI, FBP1 and PFK-1) found in this study on proliferation and 
survival is another area of interest. 
To substantiate the effect of ALDOC overexpression on glucose metabolism, 
measurement of glucose uptake, lactate production, oxygen consumption and cellular ATP 
production would need to be carried out. Other methods such as GC-TOF-MS, LC-MS and 
NMR may also be used for metabolic profiling to help in the identification and 
quantification of the metabolites which would provide information on multiple metabolic 
pathways.  Similarly, metabolic profiling of AML blasts would also establish whether the 
changes that have been observed in the model system are characteristic of patients’ disease.  
Further, the analysis of this material would not be influenced by the high nutrients and 
oxygen conditions which is a concern with the in vitro model described here.  
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The high levels of glycolysis that have been shown in many types of cancer has 
provided a biochemical basis for the design of therapeutic strategies to preferentially kill 
cancer cells by pharmacological inhibition of glycolysis (section 1.5.6). A variety of 
molecules now exist that have a potential anticancer activity in vitro and in vivo as a single 
agent or in combination with other therapeutic strategies. These data suggest that such 
approaches would also be applicable to AML, particularly those expressing high levels of 
ROS. Alternatively, given that ROS drives the expression of these glycolytic enzymes, 
targeting ROS or NOX2 for the purpose of restoring the metabolic imbalance in AML 
would be another potential therapeutic approach.  
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7 Appendices 
Appendix 1 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 TNS1 
  CMTM8 
G
en
e 
ex
pr
es
si
on
 v
al
ue
 (L
og
2)
  KIT 
 CYTL1 
G
en
e 
ex
pr
es
si
on
 v
al
ue
 (L
og
2)
    APPENDICES 
218 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 CNR2 
 CD34  WDR54 
G
en
e 
ex
pr
es
si
on
 v
al
ue
 (L
og
2)
G
en
e 
ex
pr
es
si
on
 v
al
ue
 (L
og
2)
 CD32 
    APPENDICES 
219 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 JAKMIP2 
 ASPH  FBP1 
G
en
e 
ex
pr
es
si
on
 v
al
ue
 (L
og
2)
 PTPRD 
G
en
e 
ex
pr
es
si
on
 v
al
ue
 (L
og
2)
    APPENDICES 
220 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 REC8 
 PFK-1 
 
 CKB 
G
en
e 
ex
pr
es
si
on
 v
al
ue
 (L
og
2)
 ENO2 
G
en
e 
ex
pr
es
si
on
 v
al
ue
 (L
og
2)
    APPENDICES 
221 
 
 
  
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
G
en
e 
ex
pr
es
si
on
 v
al
ue
 (L
og
2)
 GATM  GPI 
 CACNB1 Un-identified 
G
en
e 
ex
pr
es
si
on
 v
al
ue
 (L
og
2)
    
 
 
 
 
    APPENDICES 
222 
 
 
  
 
 
 
 
 
 
 
 
 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Dot plots of mutant N-RAS gene changes mediated by ROS 
The Y-axis represents the normalised gene expression value (log2); the X-axis 
represents the different sample treatment conditions and replicate data for each condition 
(coloured dots). For each treatment condition n=4. These plots are data for all genes found 
to be dysregulated by ROS (see chapter 4).  
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